



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

JAN -9 2008

Office of Regulatory Policy
HFD-7
5600 Fishers Lane (Rockwall II Rm 1101)
Rockville, MD 20857


Attention: Beverly Friedman

The attached application for patent term extension of U.S. Patent No. 7,109,205 was filed on August 7, 2007, under 35 U.S.C. § 156. It is noted that applicant also filed applications for patent term extension for NDA 22-081 in U.S. Patent Nos. 5,703,017, 5,840,722, and 5,932,730, pursuant to 37 CFR 1.785.

The assistance of your Office is requested in confirming that the product identified in the application, LETAIRIS™(ambrisentan), has been subject to a regulatory review period within the meaning of 35 U.S.C. § 156(g) before its first commercial marketing or use and that the application for patent term extension was filed within the sixty-day period after the product was approved. Since a determination has not been made whether the patent in question claims a product which has been subject to the Federal Food, Drug and Cosmetic Act, or a method of manufacturing or use of such a product, this communication is NOT to be considered as notice which may be made in the future pursuant to 35 U.S.C. § 156(d)(2)(A).

Our review of the application to date indicates that the subject patent would be eligible for extension of the patent term under 35 U.S.C. § 156.

Inquiries regarding this communication should be directed to Raul Tamayo at (571) 272-7728 (telephone) or (571) 273-7728 (facsimile).


Mary C. Till
Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: Martin L. Katz
Wood, Phillips, Katz, Clark & Mortimer
Citigroup Center, Suite 3800
500 West Madison Street
Chicago, IL 60661-2511

DATE 1-9-08

APPLICATION NUMBER 10/602275

DOC CODE TERM. REF

DOC DATE 8-7-07

DELIVER THE ATTACHED FILE/DOCUMENT TO THE TC
SCANNING CENTER

CONTRACTOR: THE ATTACHED FILE/DOCUMENT MUST BE
INDEXED AND SCANNED INTO IFW WITHIN 8 WORK HOURS;
UPLOADING OF THE SCANNED IMAGES SHOULD OCCUR NO
LATER THAN 16 WORK HOURS
FOLLOWING RECEIPT OF THIS REQUEST

AFTER SCANNING, ORIGINAL DOCUMENTS SHOULD BE BOXED IN
ACCORDANCE WITH INSTRUCTIONS

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**FEE TRANSMITTAL
for FY-2007**

Effective 2/8/2006. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$) 1,120**Complete if Known**

Application Number	Patent No. 7,109,205
Filing Date	June 24, 2003 (Issue Date: September 19, 2006)
First Named Inventor	Hartmut Riech
Examiner Name	
Art Unit	
Attorney Docket No.	

METHOD OF PAYMENT (check all that apply)
☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None
☒ Deposit Account:Deposit
Account
Number

01-0025

Deposit
Account
Name

Abbott Laboratories

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments
☒ Charge any additional fee(s) during the pendency of this application
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.
FEE CALCULATION**1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1011	300	2011	150	Utility filing fee	
1012	200	2012	100	Design filing fee	
1013	200	2013	100	Plant filing fee	
1014	300	2014	150	Reissue filing fee	
1005	200	2005	100	Provisional filing fee	
SUBTOTAL (1)					(\$ 0)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	-20 **	=	0	X		=	0
Independent Claims	-3 **	=	0	X		=	0
Multiple Dependent		=				=	0

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1202	50	2202	25	Claims in excess of 20	
1201	200	2201	100	Independent claims in excess of 3	
1203	360	2203	180	Multiple dependent claim, if not paid	
1204	200	2204	100	** Reissue independent claims over original patent	
1205	50	2205	25	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)					(\$ 0)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**


Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	120	2251	60	Extension for reply within first month	
1252	450	2252	225	Extension for reply within second month	
1253	1020	2253	510	Extension for reply within third month	
1254	1,590	2254	795	Extension for reply within fourth month	
1255	2,160	2255	1080	Extension for reply within fifth month	
1401	500	2401	250	Notice of Appeal	
1402	500	2402	250	Filing a brief in support of an appeal	
1403	1000	2403	500	Request for oral hearing	
1452	500	2452	250	Petition to revive - unavoidable	
1453	1500	2453	750	Petition to revive - unintentional	
1462	400	1462	400	Petition fee under 37 CFR 1.17(f)	
1463	200	1463	200	Petition fee under 37 CFR 1.17(g)	
1464	130	1464	130	Petition fee under 37 CFR 1.17(h)	
1807	50	1807	50	Processing fee under 37 CFR 1.17 (q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	790	2809	395	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	790	2810	395	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	790	2801	395	Request for Continued Examination (RCE)	
Other fee (specify) <u>Application of Extension of Patent Term</u>					1,120
*Reduced by Basic Filing Fee Paid					
SUBTOTAL (3)					(\$ 1,120)

4. SEARCH/EXAMINATION FEES

1111	500	2111	250	Utility Search Fee	
1112	100	2112	50	Design Search Fee	
1113	300	2113	150	Plant Search Fee	
1114	500	2114	250	Reissue Search Fee	
1311	200	2311	100	Utility Examination Fee	
1312	130	2312	65	Design Examination Fee	
1313	160	2313	80	Plant Examination Fee	
1314	600	2314	300	Reissue Examination Fee	
SUBTOTAL (4)					(\$ 0)

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	John D. Conway	Registration No. (Attorney/Agent)	39,150	Telephone	508-688-8046
Signature		Date	August 7, 2007		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: U.S. Patent No. 7,109,205
Title: CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION
AND USE
Issue Date: 19 September 2006
Inventors: Hartmut Riechers, Dagmar Klinge, Wilhem Amberg, Andreas
Kling, Stefan Müller, Ernst Baumann, Joachim Rheinheimer, Uwe
Josef Vogelbacher, Wolfgang Wernet, Liliane Unger, and Manfred
Raschack
Patent Owner: Abbott GmbH & Co. KG
Unit: OPLA
Attn: Mary C. Till

RECEIVED

7 August 2007

AUG 07 2007

Mail Stop Hatch-Waxman PTE
Office of Patent Legal Administration
Room MDW 7D55
600 Dulany Street (Madison Building)
Alexandria, VA 22314

**PATENT EXTENSION
A/C PATENTS**


APPLICATION FOR PATENT TERM EXTENSION UNDER 35 U.S.C. §156

In support of the Application for Patent Term Extension of U.S. Patent No. 7,109,205,
Applicant submits the following:

1. PTE Application (being submitted as one original and two additional copies thereof)
2. Exhibits A-L
3. Duplicate Fee Transmittal Sheet

Applicant certifies that the two additional copies are identical to the original being
submitted.

Respectfully submitted,



John D. Conway
Registration No. 39,150
Attorney for Applicant
Abbott Bioresearch Center
100 Research Drive
Worcester, MA 01605
Tel.: 508-688-8046
Fax: 508-688-8110

Enclosure

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: U.S. Patent No. 7,109,205
Title: CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION
AND USE
Issue Date: 19 September 2006
Inventors: Hartmut Riechers, Dagmar Klinge, Wilhem Amberg, Andreas
Kling, Stefan Müller, Ernst Baumann, Joachim Rheinheimer, Uwe
Josef Vogelbacher, Wolfgang Wernet, Liliane Unger, and Manfred
Raschack
Patent Owner: Abbott GmbH & Co. KG
Unit: OPLA
Attn: Mary C. Till

RECEIVED

AUG 6 7 2007

**PATENT EXTENSION
A/C PATENTS**

Mail Stop **Hatch-Waxman PTE**
Office of Patent Legal Administration
Room MDW 7D55
600 Dulany Street (Madison Building)
Alexandria, VA 22314

APPLICATION FOR PATENT TERM EXTENSION UNDER 35 U.S.C. §156

Abbott GmbH & Co. KG ("Applicant"), of Max-Planck-Ring 3, 65205 Wiesbaden, Germany, submits this application for extension of patent term of U.S. Patent No. 7,109,205 ("U.S.'205") under 35 U.S.C. §156. The relevant facts establishing the authority of Applicant to file this application for extension of patent term in accordance with 37 C.F.R. §1.730 are set forth below:

- Between 24 June 2003 and 12 October 2003, Hartmut Riechers, Dagmar Klinge, Wilhem Amberg, Andreas Kling, Stefan Müller, Ernst Baumann, Joachim Rheinheimer, Uwe Josef Vogelbacher, Wolfgang Wernet, Liliane Unger, and Manfred Raschack (the inventors of the subject matter claimed in U.S. Patent No. 7,109,205) assigned to Abbott GmbH & Co. KG all right, title and interest in their invention. This assignment was recorded in the

United States Patent and Trademark Office on 11 December 2003 at Reel 014778, Frame 0028. A copy of this assignment is attached as Exhibit A.

- The Investigational New Drug application (“INDA”) for ambrisentan was originally filed by Myogen, Inc. Effective on 17 November 2006, Myogen, Inc. was acquired by Gilead Sciences, Inc. (“Gilead”) and became a wholly owned subsidiary known as Gilead Colorado, Inc. A copy of the New Drug application (“NDA”) submission letter indicating this fact is attached as Exhibit B.
- Gilead is the exclusive licensee to U.S. ‘205.
- Gilead is the sponsor of the drug product, LETAIRIS™ (ambrisentan), for which the FDA granted regulatory approval and which forms the basis of this patent term extension. A copy of the approval letter is attached as Exhibit C.
- Applicant is authorized by Gilead to rely on its activities and the activities of its predecessor, Myogen, Inc., before the Food and Drug Administration (“FDA”) for regulatory review activities. Gilead has executed a statement authorizing reliance by Applicant on such activities of Gilead. A copy of this statement is attached as Exhibit D.

The following information is submitted in accordance with 35 U.S.C. §156(d) and 37 C.F.R. §§1.740 to 1.741. The formal requirements of 37 C.F.R. §1.740 are specifically set out below.

1. Identification of Approved Product [37 C.F.R. §1.740(a)(1)]

The approved product is LETAIRIS™ (ambrisentan) 5 and 10 mg tablets for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening. See the approved label for LETAIRIS™ tablets provided as Exhibit E. Ambrisentan is the active ingredient in LETAIRIS™ tablets. Ambrisentan is further identified as follows:

A. Chemical Name

The chemical name for ambrisentan is (+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid.

The CAS registry number for ambrisentan is 177036-94-1.

B. Generic Name

The generic name of the active ingredient in LETAIRIS™ tablets is ambrisentan. Ambrisentan is the U.S. Adopted Name (USAN) and International Nonproprietary Name (INN) for this compound.

C. Molecular Formula


The molecular formula of ambrisentan is C₂₂H₂₂N₂O₄.

D. Molecular Weight

The molecular weight of ambrisentan is 378.42.

E. Structural Formula

The structural formula of ambrisentan is:



F. Product Ingredients

Ambrisentan is the active ingredient in LETAIRIS[™] tablets, as provided in the approved label text attached as Exhibit E. As provided in Exhibit E, LETAIRIS[™] tablets further contain the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. As further provided in Exhibit E, LETAIRIS[™] tablets have a film coating containing FD&C Red #40 aluminum lake, lecithin, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.

2. **Federal Statute under which Regulatory Review Occurred [37 C.F.R. §1.740(a)(2)]**

The approved product, LETAIRIS[™] tablets, was subject to regulatory review under Section 505(b)(1) of the Federal Food, Drug and Cosmetic Act ("FFDCA"), 21 U.S.C. §355(b)(1), as amended.

3. **Date of Permission for Commercial Marketing [37 C.F.R. §1.740(a)(3)]**

LETAIRIS[™] product was approved by the FDA for commercial marketing pursuant to Section 505(b)(1) of the FFDCA on 15 June 2007. A copy of the letter from the FDA to Gilead, dated 15 June 2007, setting forth the approval of the product is attached as Exhibit C.

4. Identification of Active Ingredient and Certifications [37 C.F.R. §1.740(a)(4)]

- (a) The active ingredient of LETAIRIS™ is ambrisentan, (+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid, having the structure depicted in Section 1 above.
- (b) Ambrisentan has not been approved for commercial marketing or use under the FFDCA, the Public Health Service Act, or the Virus-Serum-Toxin Act, prior to the approval granted on 15 June 2007.
- (c) The use for which the product is approved is as follows: “LETAIRIS™ is indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening.” See the approved label for LETAIRIS™ tablets provided as Exhibit E.

5. Statement of Timely Filing [37 C.F.R. §1.740(a)(5)]

The present application for extension of patent term is being submitted within the sixty-day period permitted for submission under 37 C.F.R. §1.720(f). The FDA approved commercial marketing and use of the approved product, LETAIRIS™ tablets, on 15 June 2007. The sixty-day submission period ends on 13 August 2007. As demonstrated by the signed Certificate of Hand-Delivery, this application for extension of patent term is timely submitted.

6. Identification of Patent for which Extension is Sought [37 C.F.R. §1.740(a)(6)]

U.S. Patent No: 7,109,205

Title: CARBOXYLIC ACID DERIVATIVES, THEIR
PREPARATION AND USE

Issue Date: 19 September 2006

Expiration Date: 7 October 2015

Application No.: 10/602,275

Application Filing Date: 24 June 2003 (effective filing date 7 October 1995)

Inventors: Hartmut Riechers, Dagmar Klinge, Wilhem Amberg,
Andreas Kling, Stefan Müller, Ernst Baumann, Joachim
Rheinheimer, Uwe Josef Vogelbacher, Wolfgang
Wernet, Liliane Unger, and Manfred Raschack

Patent Owner: Abbott GmbH & Co. KG

7. Patent Copy [37 C.F.R. §1.740(a)(7)]

A copy of U.S. '205, the patent for which extension is being requested, is attached as Exhibit F. This copy contains the entire specification (including claims) for U.S. '205. There are no drawings in U.S. '205.

8. Disclaimer and Post-Issuance Activity Statement [37 C.F.R. §1.740(a)(8)]

- (a) Terminal Disclaimers were filed on 24 August 2005 disclaiming any term of the U.S. '205 which would extend beyond the expiration date of the full statutory term of U.S. Patent No. 5,932,730; U.S. Patent No. 6,197,958; or U.S. Patent No. 6,600,043. A copy of each Terminal Disclaimer is attached as Exhibits G-1 to G-3.
- (b) A patent term adjustment, under 35 U.S.C. 154(b), of 261 days was recorded. Under 35 U.S.C. 154(b)(2)(B), no patent term of which has been disclaimed

beyond a specified date may be adjusted under this section beyond the expiration date specified in this disclaimer.

- (c) A Certificate of Correction was requested, but the Certificate has not been issued as of yet for U.S. '205.
- (d) U.S. '205 has not been subject to a Reexamination Proceeding.
- (e) Maintenance fees for U.S. '205 patent are not yet due and have not yet been paid.


**9. Statement Showing How the Claims of the Patent Cover the Approved Product
[37 C.F.R. §1.740(a)(9)]**

The statements in this section are provided solely to comply with the requirements of 37 C.F.R. § 1.740(a)(9). These comments are not an assertion or an admission by the applicant as to the scope of the listed claims, or as to whether or how any of the listed claims would be infringed, literally or under the doctrine of equivalents, by the manufacture, use, sale, offer for sale or the importation of any product.

U.S. '205 has compound-per-se claims and pharmaceutical composition claims related to the approved product. Each applicable patent claim is set forth below together with a showing of the manner in which each applicable patent claim reads on the approved product. The elements of the claims which embrace LETAIRIS™ product are shown in bold for convenience.

Claim 1

A compound having the formula:
wherein:



X is CH;

Y is oxygen;

Z is oxygen;

R is CO₂H;

R² is methyl;


R³ is methyl;

R⁴ is phenyl;

R⁵ is phenyl;

R⁶ is methyl;

or a pharmaceutically acceptable salt thereof.

Ambrisentan

X is CH

Y is oxygen

Z is oxygen

R is carboxyl (COOH, which is the same as CO₂H)

R² is methyl

R³ is methyl

R⁴ is phenyl

R⁵ is phenyl

R⁶ is methyl

Claim 1 embraces the active ingredient, ambrisentan, of the approved product,
LETAIRIS™ tablets.

Claim 2

The compound of claim 1, wherein said compound is an optically active enantiomer.

Claim 2 embraces the active ingredient, ambrisentan, of the approved product, LETAIRIS™ tablets. As illustrated in the approved label provided as Exhibit E, ambrisentan contains a single chiral center determined to be in the (S) configuration.

Claim 3

The compound of claim 2, wherein the enantiomer is the S enantiomer.

Claim 3 embraces the active ingredient, ambrisentan, of the approved product, LETAIRIS™ tablets. As illustrated in the approved label provided as Exhibit E, ambrisentan contains a single chiral center determined to be in the (S) configuration.


Claim 4

The compound of claim 3, wherein the enantiomer is the pure form of the S enantiomer.

Claim 4 embraces the active ingredient, ambrisentan, of the approved product, LETAIRIS™ tablets. As illustrated in the approved label provided as Exhibit E, ambrisentan contains a single chiral center determined to be in the (S) configuration.

Claim 7

A pharmaceutical composition comprising a compound having the formula:



wherein:

X is CH;

Y is oxygen;

Z is oxygen;

R is CO₂H;

R² is methyl;


R³ is methyl;

R⁴ is phenyl;

R⁵ is phenyl;

R⁶ is methyl;

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Ambrisentan

X is CH

Y is oxygen

Z is oxygen

R is carboxyl ($COOH$, which is the same as CO_2H)

R² is methyl

R³ is methyl

R⁴ is phenyl

R⁵ is phenyl

R⁶ is methyl

Claim 7 embraces a pharmaceutical composition comprising the active ingredient, ambrisentan, of the approved product, LETAIRIS™ tablets. See attached Exhibit E. (A Certificate of Correction is pending related to the superscript denominations of R²-R⁶.)

Claim 8

The composition of claim 7, wherein said composition is suitable for oral, parenteral, or nasopharyngeal delivery.

Claim 8 embraces a pharmaceutical composition comprising the active ingredient, ambrisentan, of the approved product, LETAIRIS™ tablets. As illustrated by the approved label provided as Exhibit E, LETAIRIS™ tablets are to be administered orally.

Claim 9

The composition of claim 7, wherein the composition is in a solid form.

Claim 9 embraces a pharmaceutical composition comprising the active ingredient, ambrisentan, of the approved product, LETAIRIS™ tablets. As illustrated by the approved label provided as Exhibit E, LETAIRIS™ tablets are film-coated tablets.

Claim 11

The composition of claim 7, wherein the composition is in the form of a tablet, capsule, powder, granule, suppository, solution, colloid, ointment, cream, vapor or spray.

Claim 11 embraces a pharmaceutical composition comprising the active ingredient, ambrisentan, of the approved product, LETAIRIS™ tablets. As illustrated by the approved label provided as Exhibit E, LETAIRIS™ tablets are film-coated tablets.

Claim 12

The composition of claim 7, wherein the carrier comprises a tablet binder, filler, preservative, tablet disintegrant, flow regulator, plasticizer, wetting agent, dispersant, emulsifier, solvent, release-slowing agent, antioxidant, or propellant gas.

Claim 12 embraces a pharmaceutical composition comprising the active ingredient, ambrisentan, of the approved product, LETAIRIS™ tablets. As illustrated by the approved label provided as Exhibit E, LETAIRIS™ tablets contain croscarmellose sodium, lactose monohydrate, magnesium stearate and microcrystalline cellulose.

Claim 13

The composition of claim 7, wherein the compound is an optically active enantiomer.

Claim 13 embraces a pharmaceutical composition comprising the active ingredient, ambrisentan, of the approved product, LETAIRIS™ tablets. As illustrated in the approved label provided as Exhibit E, ambrisentan contains a single chiral center determined to be in the (S) configuration.

Claim 14

The composition of claim 13, wherein the enantiomer is the S enantiomer.

Claim 14 embraces a pharmaceutical composition comprising the active ingredient, ambrisentan, of the approved product, LETAIRIS™ tablets. LETAIRIS™ tablets contain ambrisentan. As illustrated in the approved label provided as Exhibit E, ambrisentan is an optically active enantiomer and contains a single chiral center determined to be in the (S) configuration.


Claim 15

The composition of claim 14, wherein the enantiomer is the pure form of the S enantiomer.

Claim 15 embraces the active ingredient, ambrisentan, of the approved product, LETAIRIS™ tablets. As illustrated in the approved label provided as Exhibit E, ambrisentan contains a single chiral center determined to be in the (S) configuration.

Claim 18

The compound



Claim 18 embraces the active ingredient, ambrisentan, approved product LETAIRIS[™] tablets, which contain ambrisentan. The structural formula depicted in Claim 18 embraces ambrisentan, (+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid.

Therefore, as demonstrated above, Claims 1-4, 7-9, 11-15 and 18 of U.S. '205 read on the approved product, LETAIRIS[™] tablets.

**10. Statement of Relevant Dates to Determine the Regulatory Review Period
[37 C.F.R. §1.740(a)(10)]**

The relevant dates and information pursuant to 35 U.S.C. §156(g) in order to enable the Secretary of Health and Human Services to determine the applicable regulatory review period are as follows:

(a) *Patent Issue Date*

U.S. '205 was issued on **19 September 2006**.

(b) *IND Effective Date [§ 1.740(a)(10)(i)(A)]*

The IND for the approved product, LETAIRIS™ tablets, was submitted to the FDA on 3 June 2002. A copy of the letter transmitting the IND to the FDA is attached as Exhibit H. The FDA accorded the IND a date of receipt of 4 June 2002, and the IND was assigned number 64,915 ("IND 64,915"). A copy of the letter from the FDA acknowledging receipt of IND 64,915 is attached as Exhibit I. Accordingly, IND 64,915 became effective on **4 July 2002**.

(c) *NDA Submission Date [§ 1.740(a)(10)(i)(B)]*

The NDA for the approved product, LETAIRIS™ tablets, was submitted to the FDA on 13 December 2006. A copy of the letter transmitting the NDA to the FDA is attached as Exhibit B. The FDA accorded the NDA a date of receipt of 18 December 2006, and the NDA was assigned number 22-081 ("NDA 22-081"). A copy of the letter from the FDA acknowledging receipt of NDA 22-081 is attached as Exhibit J. Accordingly, NDA 22-081 became effective on **18 December 2006**.

(d) *NDA Approval Date [§ 1.740(a)(10)(i)(C)]*

NDA 22-081 was approved by the FDA on **15 June 2007**. A copy of the approval letter from the FDA to Gilead is attached as Exhibit C.

**11. Brief Description of Activities Undertaken During the Regulatory Review Period
[37 C.F.R. §1.740(a)(11)]**

A description of significant activities undertaken by the marketing applicant, Gilead through Myogen, Inc. (now Gilead Colorado, Inc. a wholly owned subsidiary of Gilead), during the applicable regulatory review period with respect to the approved product and the significant dates applicable to such activities are set forth in Exhibit K. Exhibit K is divided into two parts as follows: (K-1) IND 64,915 Chronology and (K-2) NDA 22-081 Chronology.

12. Opinion of Eligibility for Extension [37 C.F.R. §1.740(a)(12)]

In the opinion of Applicant, U.S. '205 is eligible for patent term extension under the provisions of 35 U.S.C. §156. Specifically, Applicant believes that the requirements of 35 U.S.C. §156 for an extension of patent term are satisfied as follows:

(1) Patent with Eligible Subject Matter [35 U.S.C. §156(a)]

The patent has claims which embrace the active ingredient of LETAIRIS™ tablets.

(2) Non-expiration of Patent Term [35 U.S.C. §156(a)(1)]

The term of U.S. '205 expires 7 October 2015, which is 20 years from the filing date of the priority patent application. Although a patent term adjustment under 154(b) was recorded, the 7 October 2015 expiration date is maintained in order to comply with the Terminal Disclaimers provided as Exhibits G-1 to G-3. Therefore, this application has been submitted before the expiration of the patent term.

(3) No Prior Patent Term Extension [35 U.S.C. §156(a)(2)]

The term of U.S. '205 has never been extended.

(4) Owner or Agent [35 U.S.C. §156(a)(3)]

The present application for extension is submitted by the owner of record, Abbott GmbH & Co. KG in accordance with the requirements of 35 U.S.C. §156(d).

(5) Regulatory Review [35 U.S.C. §156(a)(4)]

The approved product was subject to a regulatory review period under Section 505(b)(1) of the FFDCA before its commercial marketing or use (see Exhibits B and H).

(6) First Marketing Approval [35 U.S.C. §156(a)(5)(A)]

The permission for commercial marketing of LETAIRIS™ tablets is the first permitted commercial marketing of ambrisentan.

(7) No Extension of Other Patent [35 U.S.C. §156(c)(4)]

No other patent has been extended for the same regulatory review period for the approved product, LETAIRIS™ tablets.

STATEMENT AS TO LENGTH OF EXTENSION CLAIMED

The extension period of U.S. '205, as calculated below, is **225 days** from the original patent term (7 October 2015) to **19 May 2016**.

Regulatory review period [§1.775(c)]

IND phase [§1.775(c)(1)]

The number of days in the period beginning on the date an exemption under FDCA §505(i) became effective for the approved product (4 July 2002) and ending on the date an NDA was initially submitted under FDCA §505 (18 December 2006)	1629 days
---	-----------

NDA phase [§ 1.775(c)(2)]

The number of days in the period beginning on the date the application was initially submitted for the approved product under FDCA §505 (18 December 2006) and ending on the date the NDA was approved (15 June 2007)	180 days
---	----------

Total regulatory review period

1809 days

Subtractions and limitations [§1.775(d)]

Reduction for regulatory review before patent grant [§1.775(d)(1)(i)]

The number of days in the periods of §1.775(c)(1) (IND phase) and (c)(2) (NDA phase) on or before the date the patent issued (19 September 2006)	1539 days
--	-----------

Reduction for lack of due diligence [§1.775(d)(1)(ii)]

The number of days in the periods of §1.775(c)(1) (IND phase) and (c)(2) (NDA phase) during which the applicant did not act with due diligence	0 days
--	--------

Net subtraction

One-half the number of days remaining in the period of §1.775 (c)(1) (IND phase) after the reductions above	45 days
---	---------

Net preliminary term extension [§1.775(d)(1)]

225 days

Fourteen Year Comparison [§1.775(d)(2)-(4)]

The new expiration date of U.S. '205 with the 225 day extension determined above is 19 May 2016 which is earlier than 15 June 2021, fourteen years from the approval date of NDA 22-081 (15 June 2007).

Five Year Comparison [§1.775(d)(5)]

The 225 day extension calculated above does not exceed five years.

Accordingly, it is respectfully requested that the term of U.S. '205 be extended 225 days from the original patent term (7 October 2015) to: 19 May 2016.

13. Duty of Disclosure [37 C.F.R. §1.740(a)(13)]

Applicant acknowledges a duty to disclose to the Commissioner of Patents and Trademarks and Secretary of Health and Human Services any information that is material to the determination of entitlement to the extension sought, particularly as that duty is defined in 37 C.F.R. §1.765.

Applicant advises that it is concurrently filing applications under 35 U.S.C. §156 and 37 C.F.R. §1.140, based on the Regulatory Review period for LETAIRIS product, to extend terms of following patents:

- U.S. Patent No. 5,703,017;
- U.S. Patent No. 5,840,722;
- U.S. Patent No. 5,932,730; and
- U.S. Patent No. 7,109,205.

Applicant will, during co-pendency of these four applications, elect one of the four applications to proceed to grant, and will withdraw the remaining three pending applications.

14. Fee Charge [37 C.F.R. §1.740(a)(14)]

The Commissioner of Patents and Trademarks is authorized to charge the prescribed \$1,120.00 fee set forth in 37 C.F.R. §1.20(j) for receiving and acting upon this application for extension of patent term, together with any additional fees that may be required during the entire pendency of this application for extension of patent term, to Deposit Account No. 01-0025. A Fee Transmittal (PTO/SB/17) expressly authorizing the charging of fees to Deposit Account No. 01-0025 in this matter is being submitted in duplicate with the pending application for extension of patent term.

15. Correspondence Address [37 C.F.R. §1.740(a)(15)]


Please direct all inquiries and correspondence relating to the application for patent term extension to:

Martin L. Katz
Registration No. 25,011
Wood, Phillips, Katz, Clark & Mortimer
Citigroup Center, Suite 3800
500 West Madison Street
Chicago, IL 60661-2511

Certification under 37 C.F.R. §1.740(b)

The present application of extension of patent term for U.S.'205 is being submitted as one original and two additional copies thereof.

Respectfully submitted,




John D. Conway
Registration No. 39,150
Attorney for Applicant
Abbott Bioresearch Center
100 Research Drive
Worcester, MA 01605
Tel.: 508-688-8046
Fax: 508-688-8110

Date: 7 August 2007

CERTIFICATE OF HAND DELIVERY

The undersigned certifies that one original and two duplicate copies of this APPLICATION FOR EXTENSION OF PATENT TERM UNDER 35 U.S.C. §156 (including all Exhibits and supporting papers) are being hand-delivered this 7th day of August 2007, to "Attention: Mary C. Till, Office of Patent Legal Administration, Room MDW 7D55, 600 Dulany Street (Madison Building), Alexandria, VA 22314", United States Patent and Trademark Office.

A handwritten signature in black ink, appearing to read "John D. Conway", is written over a horizontal line.

John D. Conway
Registration No. 39,150
Attorney for Applicant
Abbott Bioresearch Center
100 Research Drive
Worcester, MA 01605
Tel.: 508-688-8046
Fax: 508-688-8110

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: U.S. Patent No. 7,109,205
Title: CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION
AND USE
Issue Date: 19 September 2006
Inventors: Hartmut Riechers, Dagmar Klinge, Wilhem Amberg, Andreas
Kling, Stefan Müller, Ernst Baumann, Joachim Rheinheimer, Uwe
Josef Vogelbacher, Wolfgang Wernet, Liliane Unger, and Manfred
Raschack
Assignee and Owner: Abbott GmbH & Co. KG

APPLICATION FOR EXTENSION OF PATENT TERM UNDER 35 U.S.C. §156
EXHIBIT LIST

Exhibit A: Chain of Title/Ownership Recordation (Assignment)
Exhibit B: Copy of letter transmitting NDA 22-081 to the FDA
Exhibit C: FDA approval letter of NDA 22-081 to Gilead Sciences, Inc.
Exhibit D: Statement of Reliance
Exhibit E: Approved label for LETAIRIS™ tablets
Exhibit F: Copy of US Patent No. 7,109,205
Exhibit G: Post-Issuance Activity Documents
G-1: 24 August 2005 Terminal Disclaimer (U.S. Patent No. 5,932,730)
G-2: 24 August 2005 Terminal Disclaimer (U.S. Patent No. 6,197,958)
G-3: 24 August 2005 Terminal Disclaimer (U.S. Patent No. 6,600,043)
G-4: Copy of maintenance fee statement
Exhibit H: Copy of letter transmitting IND 64,915 to the FDA
Exhibit I: Copy of letter from the FDA acknowledging receipt of IND 64,915
Exhibit J: Copy of letter from the FDA acknowledging receipt of NDA 22-081

Exhibit K: Description of significant activities

K-1 IND 64,915 Chronology

K-2 NDA 22-081 Chronology

Exhibit L: Calculation of Length of Patent Term Extension for a Human Drug Product

EXHIBIT A

US Patent 7,109,205

HDP Reference 8493-500061

Chain of Title/Ownership Recordation

1. 014778/0028

8 Pages

Assignment

Inventors to Abbott GmbH & Co. KG



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)



Assignments on the Web > Patent Query

Patent Assignment Abstract of Title

**NOTE: Results display only for issued patents and published applications.
For pending or abandoned applications please consult USPTO staff.**

Total Assignments: 1

Patent #: 7109205

Issue Dt: 09/19/2006

Application #: 10602275

Filing Dt: 06/24/2003

Publication #: 20040092742

Pub Dt: 05/13/2004

Inventors: Hartmut Riechers, Dagmar Klinge, Wilhelm Amberg, Andreas Kling, Stefan Muller et al

Title: NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE

Assignment: 1

Reel/Frame: 014778/0028

Recorded: 12/11/2003

Pages: 8

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignors: RIECHERS, HARTMUT

Exec Dt: 06/24/2003

KLINGE, DAGMAR

Exec Dt: 06/24/2003

AMBERG, WILHELM

Exec Dt: 06/24/2003

KLING, ANDREAS

Exec Dt: 06/24/2003

MULLER, STEFAN

Exec Dt: 08/12/2003

BAUMANN, ERNST

Exec Dt: 08/27/2003

RHEINHEIMER, JOACHIM

Exec Dt: 09/02/2003

VOGELBACHER, UWE JOSEF

Exec Dt: 09/08/2003

WERNET, WOLFGANG

Exec Dt: 09/29/2003

UNGER, LILIANE

Exec Dt: 10/07/2003

RASCHACK, MANFRED

Exec Dt: 10/12/2003

Assignee: ABBOTT GMBH & CO. KG

MAX-PLANCK-RING 2

65205 WIESBADEN, GERMANY

Correspondent: WOOD, PHILLIPS, KATZ, CLARK & MORTIMER

MARTIN L. KATZ

500 W. MADISON STREET

CHICAGO, IL 60661

Search Results as of: 07/17/2007 05:48 PM

If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350. v.2.0.1
Web Interface last modified: April 20, 2007 v.2.0.1

| [HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)

12/11/03

12-15-2003

102622807

Form PTO-1595 (Rev. 10/02) REC

OMB No. 0651-0027 (exp. 6/30/2005)

Tab settings

U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

To the Honorable Commissioner of Patents. Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):
Hartmut Riechers
Dagmar Klinge
Wilhelm Amberg
Andreas Kling
Additional name(s) of conveying party(ies) attached? ☒ Yes ☐ No

2. Name and address of receiving party(ies)
Name: Abbott GmbH & Co. KG
Internal Address: _____
Street Address: Max-Planck-Ring 2
65205 Wiesbaden, Germany
City: _____ State: _____ Zip: _____
Additional name(s) & address(es) attached? ☐ Yes ☒ No

3. Nature of conveyance:
☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Other _____
Execution Date: 6/24/03

4. Application number(s) or patent number(s):
If this document is being filed together with a new application, the execution date of the application is: _____
A. Patent Application No.(s) 10/602,275
B. Patent No.(s) _____
Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:
Name: Martin L. Katz
Internal Address: Wood, Phillips, Katz, Clark & Mortimer
Street Address: 500 W. Madison Street
City: Chicago State: IL Zip: 60681

6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 3.41).....\$ 40.00
☐ Enclosed
☒ Authorized to be charged to deposit account

8. Deposit account number:
23-0785

DO NOT USE THIS SPACE

9. Signature.
Martin L. Katz
Name of Person Signing
Signature
December 8, 2003
Date

Total number of pages including cover sheet, attachments, and documents: 9

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231

12/15/2003 LKELLER 00000093 230785 10602275
01 FC:8031 40.00 BA

25.08.03 12:15

20:50:58

Assignment

Serial No.: 10/602,275Filed: June 24, 2003

In Consideration of One Dollar and other good and valuable considerations, the receipt of which is hereby acknowledged, the entire right, title and interest in the invention or improvements of the undersigned in Novel Carboxylic Acid Derivatives, Their Preparation and Use and in the application for Letters Patent of the United States therefor, executed by the undersigned concurrently herewith, and in any reissue or extension of any Letters Patent that may be granted upon said application are hereby assigned by the undersigned to Abbott GmbH & CO. KG a Germany corporation, having offices at Max-Planck-Ring 2, 65205 Wiesbaden, Germany and the heirs, successors, legal representatives and assigns of Abbott GmbH & CO. KG (hereinafter collectively called said Assignee), and the Commissioner of Patents and Trademarks is hereby authorized and requested by the undersigned to issue said Letters Patent to said Assignee.

For said considerations it is hereby agreed by the undersigned, upon the request of said Assignee, to execute any necessary and proper oaths or affidavits relating to said application or required for the filing or prosecution of any divisional or continuing application thereof or for the filing or prosecution of any application for the reissue or extension of any Letters Patent that may be granted on said invention or improvements that said Assignee may deem necessary or expedient, and for the said considerations it is further agreed by the undersigned, upon the request of said Assignee, in the event of said application or any division thereof, or Letters Patent issued thereon, or any reissue or application for the reissue thereof, becoming involved in Interference, to cooperate to the best of the ability of the undersigned with said Assignee in the matters of preparing and executing the preliminary statement and giving and producing evidence in support thereof, and further to perform, upon such request, any and all affirmative acts to obtain said Letters Patent and vest all rights therein hereby conveyed in the said Assignee as fully and entirely as the same would have been held and enjoyed by the undersigned if this assignment and sale had not been made. And for the said considerations the entire right, title and interest in said invention or improvements, including all priority rights, and the right to claim priority rights and the privileges and benefits thereof, including those under the International Convention, and all other Conventions, and the right to file applications for patent in said Assignee's own name for said invention or improvements in each and every country of the world are hereby assigned and granted by the undersigned to said Assignee. It is further agreed by the undersigned, upon the request of said Assignee, to execute any and all documents that shall be required of the undersigned to be executed in connection with any and all applications for foreign Letters Patent therefor, including the prosecution thereof, and to execute any and all documents necessary to invest title in said foreign applications and patents in said Assignee. The undersigned also further agrees, for the said considerations, upon the request of said Assignee, to promptly perform all lawful acts deemed by said Assignee to be necessary or advisable in connection with maintaining, enforcing, or transferring the resulting grants of said Letters Patent in the United States or foreign countries. It is agreed that such lawful acts include, but are not limited to, taking oaths, executing declarations, powers, assignments and other papers and giving testimony.

Serial No.: 10/602,275Filed: June 24, 2003

The attorneys of record in such application for patent are hereby authorized and requested by the undersigned to insert in this Assignment the date and serial number thereof in the places provided therefor.

Hartmut Riechers
Hartmut Riechers

Executed this 29th day of July, 2003.

State of _____

County of _____) ss.

On _____, 2003, Hartmut Riechers appeared before me, a Notary Public, in and for the State and County aforesaid, and acknowledged that he/she freely and voluntarily subscribed and executed the foregoing Assignment for the purposes and uses therein expressed.

(SEAL)

Notary Public

My Commission Expires: _____

Dagmar Klinge
Dagmar Klinge

Executed this 7th day of August, 2003.

State of _____

County of _____) ss.

On _____, 2003, Dagmar Klinge appeared before me, a Notary Public, in and for the State and County aforesaid, and acknowledged that he/she freely and voluntarily subscribed and executed the foregoing Assignment for the purposes and uses therein expressed.

(SEAL)

Notary Public

My Commission Expires: _____

Serial No.: 10/602,275Filed: June 24, 2003

Wilhelm AmbergExecuted this 15th day of September, 2003.

State of _____)

) ss.

County of _____)

On _____, 2003, Wilhelm Amberg appeared before me, a Notary Public, in and for the State and County aforesaid, and acknowledged that he/she freely and voluntarily subscribed and executed the foregoing Assignment for the purposes and uses therein expressed.

(SEAL)

Notary Public

My Commission Expires: _____



Andreas KlingExecuted this 12th day of September, 2003.

State of _____)

) ss.


County of _____)

On _____, 2003, Andreas Kling appeared before me, a Notary Public, in and for the State and County aforesaid, and acknowledged that he/she freely and voluntarily subscribed and executed the foregoing Assignment for the purposes and uses therein expressed.

(SEAL)

Notary Public

My Commission Expires: _____



Stefan MullerExecuted this 12th day of August, 2003.

Serial No.: 10/602,275Filed: June 24, 2003

State of _____)

County of _____) ss.

On _____, 2003, Stefan Muller appeared before me, a Notary Public, in and for the State and County aforesaid, and acknowledged that he/she freely and voluntarily subscribed and executed the foregoing Assignment for the purposes and uses therein expressed.

(SEAL)

Notary Public

My Commission Expires: _____

Ernst BaumannExecuted this 23rd day of August, 2003.

State of _____)

County of _____) ss.

On _____, 2003, Ernst Baumann appeared before me, a Notary Public, in and for the State and County aforesaid, and acknowledged that he/she freely and voluntarily subscribed and executed the foregoing Assignment for the purposes and uses therein expressed.

(SEAL)

Notary Public

My Commission Expires: _____

Joachim RheinheimerExecuted this 22nd day of September, 2003.

State of _____)

) ss.

Serial No.: 10/602,275Filed: June 24, 2003

County of _____)

On _____, 2003, Joachim Rheinheimer appeared before me, a Notary Public, in and for the State and County aforesaid, and acknowledged that he/she freely and voluntarily subscribed and executed the foregoing Assignment for the purposes and uses therein expressed.

(SEAL)

Notary Public

My Commission Expires: _____

Uwe Josef Vogelbacher

~~Uwe Josef Vogelbacher~~

Executed this 8th day of September, 2003.

State of _____)

County of _____) ss.

On _____, 2003, Uwe Josef Vogelbacher appeared before me, a Notary Public, in and for the State and County aforesaid, and acknowledged that he/she freely and voluntarily subscribed and executed the foregoing Assignment for the purposes and uses therein expressed.

(SEAL)

Notary Public

My Commission Expires: _____

Wolfgang Wernet

Wolfgang Wernet

Executed this 29th day of September, 2003.

State of _____)

County of _____) ss.

Serial No.: 10/602,275Filed: June 24, 2003

On _____, 2003, Wolfgang Wernert appeared before me, a Notary Public, in and for the State and County aforesaid, and acknowledged that he/she freely and voluntarily subscribed and executed the foregoing Assignment for the purposes and uses therein expressed.

(SEAL)

Notary Public

My Commission Expires: _____

Lilliane Unger

Lilliane UngerExecuted this 7 day of October, 2003.

State of _____)

County of _____) ss.

On _____, 2003, Lilliane Unger appeared before me, a Notary Public, in and for the State and County aforesaid, and acknowledged that he/she freely and voluntarily subscribed and executed the foregoing Assignment for the purposes and uses therein expressed.

(SEAL)

Notary Public

My Commission Expires: _____

Manfred Raschack

Manfred RaschackExecuted this 12 day of October, 2003.

State of _____)

County of _____) ss.

On _____, 2003, Manfred Raschack appeared before me, a Notary Public, in and for the State and County aforesaid, and acknowledged that he/she freely and voluntarily subscribed and executed the foregoing Assignment for the purposes and uses therein expressed.

FROM :

FAX NO. :

Jul. 18 2007 03:25PM P10

Serial No.: 10/602,275

Filed: June 24, 2003

(SEAL)

Notary Public

My Commission Expires: _____

EXHIBIT B



Linnea Tanner
Director, Regulatory Affairs

13 December 2006

Norman L. Stockbridge, M.D., Ph.D.
Director
Division of Cardiovascular and Renal Products
Food and Drug Administration
Center for Drug Evaluation & Research
Central Document Room
5901-B Ammendale Rd.
Beltsville, MD 20705-1266

Subject: **NDA 22-081 (022081-0000)**
LETAIRIS™ (ambrisentan) Tablets

NEW DRUG APPLICATION
Original Submission

Dear Dr. Stockbridge:

Pursuant to the Paragraph 505(b)(1) of the Federal Food, Drug and Cosmetic Act (the ACT) and 21 CFR 314.50, Gilead Sciences, Inc. (Gilead) hereby submits a New Drug Application (NDA) for LETAIRIS (ambrisentan) Tablets, 5 and 10 mg. Ambrisentan is a non-sulfonamide, propanoic acid-class, endothelin receptor antagonist (ERA) that is selective for the endothelin type A (ET_A) receptor. LETAIRIS is indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity, delay clinical worsening and improve symptoms.

Myogen, Inc. was acquired by Gilead Sciences, Inc. and became a wholly owned subsidiary known as Gilead Colorado, Inc., effective November 17, 2006. Thus, the NDA applicant is Gilead Sciences, Inc., which assumes all the responsibilities and obligations of the NDA. However, the name Myogen, Inc. is used throughout the NDA for historical reasons and because of the timing of acquisition.

Request for Priority Review

Ambrisentan was granted Fast Track designation for the treatment of pulmonary arterial hypertension (PAH) on February 15, 2006; therefore, we request that this application be given priority review. PAH is a rare, serious and life-threatening disease for which there is no cure. Although there are other therapies currently approved for this disease, there still is an unmet medical need for the treatment of PAH. LETAIRIS is an alternative, therapeutic option for these patients that has the potential to provide significant benefit over currently authorized therapies for the following reasons:

Confidentiality Statement

The confidential information contained in this document is the property of Gilead Sciences, Inc. Your acceptance of this document constitutes agreement that you will not disclose the information contained herein to others without written authorization from Gilead Sciences, Inc.

- Improved effects on exercise capacity, an efficacy measure that has been shown to correlate with and be prognostic of long-term survival
- Significant delay of the clinical worsening of PAH, an efficacy measure of disease progression in this ultimately fatal disease
- Improved effects on symptoms associated with PAH (WHO functional class, Borg dyspnea index, and SF-36[®] physical function scale)
- Low incidence of liver function test (LFT) abnormalities, a serious toxicity that can lead to discontinuation of treatment with other ERA therapies
- Potential to provide benefit to PAH patients who have previously discontinued ERA therapy due to LFT abnormalities
- No clinically significant cytochrome P450 (CYP) enzyme-related interactions with several drugs that are currently contraindicated, less effective, or associated with significant safety issues when co-administered with other PAH therapies

Orphan Drug Designation

Ambrisentan was granted orphan drug designation (Designation Request #04-1836) for the treatment of PAH and, therefore, qualifies for seven (7) years of exclusive marketing rights pursuant to Section 527 of the ACT (21 U.S.C. 360 cc). A letter dated December 07, 2006 was submitted to the Office of Orphan Drug Products Development to transfer the orphan designation from Myogen, Inc. to Gilead Sciences, Inc.

Application Fee

Under Section 736(a)(1)(E) of the ACT, this NDA is not subject to an application fee because LETAIRIS (ambrisentan) Tablets, 5 and 10 mg, is indicated for the treatment of a rare disease or condition designated under Section 526 of the ACT (orphan drug designation).

Pediatric Data

Since ambrisentan was granted orphan designation for PAH under Section 526 of the ACT (21 U.S.C. 360bb), no pediatric data is submitted in the original NDA 22-081. Pediatric data is not required for applications to market the product for the orphan-designated indications and a waiver is not needed [21 CFR 314.55(d) for NDAs and 601.27(d) for BLAs]. As agreed during the Pre-NDA meeting on May 19, 2006, Gilead will submit a pediatric study request and a proposal for a pediatric study following the NDA submission so that the Division can issue a written request to initiate pediatric studies that will be used to support pediatric exclusivity.

Proposed Proprietary Name

The proposed proprietary name of LETAIRIS was submitted for review on November 4, 2005 in Serial No. 094 of IND 64,915.

Application Format

The archive copy of NDA 22-081 (eCTD 022081-0000) is provided in its entirety as an electronic submission using the electronic Common Technical Document (eCTD) format in accordance with the guidance *M2: eCTD: Electronic Common Technical Document Specification* and as agreed in the Pre-NDA meeting on May 19, 2006. Gilead has notified the FDA Denver District office about the NDA submission in the eCTD format. A copy of the field copy certification is provided in Section m1.3.2.

Please refer to an attachment (Summary of FDA Interactions and Commitments for Ambrisentan Development Plan) to this cover letter for any other agreements of the format and content of the NDA, including the electronic datasets.

Required Regulatory Forms applicable to this submission have been included in the electronic submission and are signed electronically. Pursuant to 21 CFR 11.100, Gilead certifies that all electronic signatures executed by our employees, agents, or representatives, located anywhere in the world, are the legally binding equivalent of traditional handwritten signatures.

This submission is provided on a DVD-ROM and is approximately 4.2 GB. Gilead certifies that the submission is virus free as defined by the 11 December 2006 version of the McAfee® VirusScan® Enterprise-program, Version 8.0.0, Scan Engine 5100, with 4916 virus definitions.

Annotated ECG Waveform Data

In accordance with the instructions available on the CDER Electronic Regulatory Submissions and Review website, and confirmation with the Office of Business Process Support (OBPS), Gilead has submitted annotated ECG waveform data in XML format to the E-Scribe ECG Warehouse. These files are representative of data collected in a Phase 1 QTc study (AMB-104), and the two pivotal Phase 3 studies (AMB-320 and AMB-321). These data files are now available for your review through E-Scribe ECG Warehouse.

Contact Information

Regulatory Contact:

Linnea Tanner
Director, Regulatory Affairs
Gilead Colorado, Inc.
7575 West 103rd Ave., #102
Westminster, CO 80021-5426
Phone (direct): 303-410-3243
Facsimile: 303-410-3354
e-mail: linnea.tanner@gilead.com

Regulatory Contact - CMC:

Todd Marshall
Associate Director, CMC Regulatory
Gilead Colorado, Inc.
7575 West 103rd Ave., #102
Westminster, CO 80021-5426
Phone (direct): 303-464-3958
Facsimile: 303-410-3354
e-mail: todd.marshall@gilead.com

Technical Contact for the eCTD:

Liam Curran
Senior Manager, Regulatory Operations
Gilead Colorado, Inc.
7575 West 103rd Ave., #102
Westminster, CO 80021-5426
Phone (direct): 303-410-3206
Facsimile: 303-410-3354
e-mail: liam.curran@gilead.com

Please do not hesitate to contact me with any questions.

Sincerely,

{See appended electronic signature page}

Linnea Tanner
Director, Regulatory Affairs
Phone: 303-410-3243
Fax: 303-410-3354

Attachment: Summary of FDA Interactions and Commitments for Ambrisentan Development Plan



GILEAD

Document Approval Certificate

THE PRECEDING DOCUMENT HAS BEEN ELECTRONICALLY SIGNED BY:

UserName: ltanner

Title: Director, Regulatory Affairs

Date: Wednesday, 13 December 2006, 05:30 PM Mountain Daylight Time

Meaning: Document approved and signed

EXHIBIT C



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 22-081

Gilead Sciences, Inc.
Attention: Ms. Linnea Tanner
Director, Regulatory Affairs
Gilead Colorado
7575 West 103rd Ave., Suite #102
Westminster, CO 80021-5426

Dear Ms. Tanner:

Please refer to your new drug application (NDA) dated December 13, 2006 submitted under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act for Letairis (ambrisentan) 5 and 10 mg Tablets.

We acknowledge receipt of your submission(s) dated January 11 and 26, February 28, March 2, 13, 16, and 26, April 6, 17, and 24, May 1, 11, 14, 15, and 30, and June 1, 6, and 11, 2007.

This new drug application provides for the use of Letairis (ambrisentan) 5 and 10 mg Tablets for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening.

We have completed our review of this application. It is approved with restrictions to assure safe use under the provisions of the Subpart H regulations (21 CFR 314.520), effective on the date of this letter, for use as recommended in the enclosed labeling text, Medication Guide, RiskMAP, and carton and container labels. Marketing of this drug product and related activities must adhere to the substance and procedures of the referenced restricted distribution approval regulations.

Within 21 days of the date of this letter, submit content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/oc/datacouncil/spl.html>, that is identical in content to the enclosed labeling text. Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, Medication Guide, RiskMAP, immediate container and carton labels). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "FPL for approved NDA 22-081." Approval of this submission by FDA is not required before the labeling is used.

The Pediatric Research Equity Act is not applicable to drugs granted orphan drug designation.

The postmarketing study commitments that have been agreed upon based on your written correspondence dated 6/15/07 are listed below:

1. Gilead agrees to conduct a study examining the effects of LETAIRIS on 6-minute walk distance at peak and trough plasma concentrations, and further agrees to reach agreement on an appropriate study design with the Division.

Protocol Submission: by 10/1/2007
Study Start: by 06/2008
Final Report Submission: by 12/2009

2. Gilead agrees to submit the results of the Phase 1 ketoconazole drug interaction study that has already been completed.

Final Report Submission: by 10/2007

3. Gilead agrees to a post-approval commitment to explore the interaction potential of strong inhibitors of CYP2C19 (e.g. omeprazole) on ambrisentan pharmacokinetics in humans. Gilead further agrees to explore the interaction potential of cyclosporine A (strong inhibitor of OATP and P-gp) and rifampin (inhibitor of OATP and inducer of P-gp, CYPs 3A and 2C19) on ambrisentan pharmacokinetics in humans.

Protocol Submission: by 10/1/2007
Study Start: by 04/2008
Final Report Submission: by 12/2008

This commitment might also be addressed by analysis of existing data.

4. With regard to the RiskMAP, Gilead agrees to submit to the FDA by July 15, 2007, the following documents:

- i. The pregnancy exposure root cause analysis plan including the questionnaire that will be used in the analysis plan;
- ii. The patient and prescriber knowledge, attitude, and behavior survey tools for the RiskMAP evaluation plan;
- iii. The Pharmacy Standard Operating Procedures (SOPs); and
- iv. The Pharmacy Audit Plan.

Submit clinical protocols to your IND for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all study final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii), you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies, number of patients entered into each study. All submissions, including supplements, relating to these postmarketing study commitments must be prominently labeled "Postmarketing Study Commitment Protocol", "Postmarketing Study Commitment Final Report", or "Postmarketing Study Commitment Correspondence."

As required by 21 CFR 314.550, submit all promotional materials at least 30 days before the intended time of initial distribution of labeling or initial publication of the advertisement. Send two copies of all promotional materials directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

We have determined that Letairis poses a serious and significant public health concern relating to women of child-bearing potential and patients with liver impairment. This concern requires development and distribution of a Medication Guide under 21 CFR 208 in order to prevent serious adverse effects, inform patients of

information concerning risks that could affect their decision to use or continue to use the drug, and/or assure effective use of the drug.

Under 21 CFR 208, you are responsible for ensuring that the Medication Guide is available for every patient who is dispensed Letairis. Therefore, format the proposed Medication Guide in a manner that will assure its appropriate distribution to patients and include a plan to ensure distribution. In addition, submit proposed container and/or carton labels for Letairis that include a prominent and conspicuous instruction to provide the Medication Guide to each patient dispensed the drug. The labels must state how the Medication Guide is provided (e.g., affixed on the container, provided with the product, etc.).

We remind you that you must comply with the reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at www.fda.gov/medwatch/report/mmp.htm.

If you have any questions, please call Dan Brum, PharmD, MBA, Regulatory Project Manager, at (301)796-0578.

Sincerely,

{See appended electronic signature page}

Robert Temple, M.D.
Director
Office of Drug Evaluation I
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Robert Temple
6/15/2007 04:56:32 PM

EXHIBIT D



LETTER OF RELIANCE

Mail Stop **Hatch-Waxman PTE**
Office of Patent Legal Administration
Room MDW 7D55
600 Dulany Street (Madison Building)
Alexandria, VA 22314

Attn: Mary C. Till, Examiner
Office of Patent Legal Administration

Gilead Sciences, Inc., Licensee of the exclusive rights to U.S. Patent No. 7,109,205 ("U.S. '205"), authorizes **Abbott Laboratories**, Licensor and record-owner of U.S. '205, to rely on the activities of Gilead Sciences, Inc. supporting FDA approval of LETAIRIS™ (ambrisentan) product (5 and 10 mg tablets), for the purpose of obtaining extension of patent term of U.S. '205, as provided under 35 U.S.C. §156(d)(1), 37 C.F.R. §1.730 and MPEP 2752.

Date: 8/2/07

Authorized by Gilead Sciences, Inc.


By: 
Richard J. Gorczynski, PhD
SVP, Cardiovascular Therapeutics

EXHIBIT E

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use LETAIRIS™ tablets safely and effectively. See full prescribing information for LETAIRIS.

LETAIRIS (ambrisentan) tablets for oral use

Initial U.S. Approval: 2007

WARNING: POTENTIAL LIVER INJURY AND CONTRAINDICATION IN PREGNANCY

See full prescribing information for complete boxed warning.

- Elevations of liver aminotransferases (ALT, AST) have been reported with LETAIRIS and serious liver injury has been reported with related drugs.
- Monitor liver aminotransferases monthly and discontinue LETAIRIS if $>5 \times$ ULN or if elevations are accompanied by bilirubin $>2 \times$ ULN or by signs or symptoms of liver dysfunction.
- May cause fetal harm if taken during pregnancy (4.1)
- Must exclude pregnancy before the start of treatment (2.2)
- Prevent pregnancy thereafter by the use of two reliable methods of contraception (2.2)

INDICATIONS AND USAGE

LETAIRIS is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening (1).

DOSAGE AND ADMINISTRATION

- Initiate treatment at 5 mg once daily with or without food, and consider increasing the dose to 10 mg once daily if 5 mg is tolerated (2.1).
- Treat women of child-bearing potential only after a negative pregnancy test and treat only women who are using two reliable methods of contraception unless the patient has had a tubal sterilization or a Copper T 380A IUD or LNG 20 IUD inserted. Obtain monthly pregnancy tests (2.2).
- Not recommended in patients with moderate or severe hepatic impairment (2.3)

DOSAGE FORMS AND STRENGTHS

- 5 mg and 10mg film-coated, unscored tablets (3)

CONTRAINDICATIONS

- Do not administer LETAIRIS to a pregnant woman because it can cause fetal harm (4.1).

WARNINGS AND PRECAUTIONS

- Decreases in hemoglobin have been observed within the first few weeks; measure hemoglobin at initiation, at 1 month, and periodically thereafter (5.2).
- Mild to moderate peripheral edema (5.3)
- Use caution when LETAIRIS is co-administered with cyclosporine A (5.4 and 7).
- Use caution when LETAIRIS is co-administered with strong CYP3A and 2C19 inhibitors (5.5 and 7).

ADVERSE REACTIONS

Most common placebo-adjusted adverse reactions are peripheral edema, nasal congestion, sinusitis, flushing, palpitations, abdominal pain, and constipation (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Gilead Sciences, Inc. at (1-800-GILEAD5, Option 3) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

DRUG INTERACTIONS

- No significant interactions of LETAIRIS with warfarin or sildenafil have been observed (7).
- Other potential interactions are not well characterized, but, based on *in vitro* data, interactions with P-glycoprotein (P-gp), the Organic Anion Transport Protein (OATP), CYP3A4, and CYP2C19 inhibitors, and uridine 5'-diphosphate glucuronosyltransferases (UGTs) would be expected (7).

USE IN SPECIFIC POPULATIONS

- Pregnancy Category X: LETAIRIS is contraindicated in pregnant women (4.1 and 8.1).
- Nursing mothers: Breastfeeding while receiving LETAIRIS is not recommended (8.3).

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling (Medication Guide)

Revised: [06/2007]

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING – POTENTIAL LIVER INJURY; CONTRAINDICATED IN PREGNANCY

- 1 INDICATIONS AND USAGE
- 2 DOSAGE AND ADMINISTRATION
 - 2.1 Adult Dosage
 - 2.2 Women of Childbearing Potential
 - 2.3 Pre-existing Hepatic Impairment
- 3 DOSAGE FORMS AND STRENGTHS
- 4 CONTRAINDICATIONS
 - 4.1 Pregnancy Category X
- 5 WARNINGS AND PRECAUTIONS
 - 5.1 Potential Liver Injury
 - 5.2 Hematological Changes
 - 5.3 Peripheral Edema
 - 5.4 Co-administration of LETAIRIS and Cyclosporine A
 - 5.5 Co-administration of LETAIRIS with Strong CYP3A and 2C19 Inhibitors
 - 5.6 Prescribing and Distribution Program for LETAIRIS
- 6 ADVERSE REACTIONS
 - 6.1 Clinical Trials Experience
- 7 DRUG INTERACTIONS
 - 7.1 Cyclosporine A
 - 7.2 Strong CYP3A or 2C19 Inhibitors
 - 7.3 Inducers of P-gp, CYPs, and UGTs
 - 7.4 Warfarin
 - 7.5 Sildenafil
- 8 USE IN SPECIFIC POPULATIONS
 - 8.1 Pregnancy
 - 8.3 Nursing Mothers
 - 8.4 Pediatric Use
 - 8.5 Geriatric Use
 - 8.6 Renal Impairment
 - 8.7 Hepatic Impairment

- 10 OVERDOSAGE
- 11 DESCRIPTION
- 12 CLINICAL PHARMACOLOGY
 - 12.1 Mechanism of Action
 - 12.2 Pharmacodynamics
 - 12.3 Pharmacokinetics
- 13 NONCLINICAL TOXICOLOGY
 - 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 14 CLINICAL STUDIES
 - 14.1 Pulmonary Arterial Hypertension (PAH)
 - 14.2 Long-term Treatment of PAH
 - 14.3 Use in Patients with Prior Endothelin Receptor Antagonist Related Liver Function Abnormalities
- 16 HOW SUPPLIED/STORAGE AND HANDLING
- 17 PATIENT COUNSELING INFORMATION
 - 17.1 Importance of Preventing Pregnancy
 - 17.2 Adverse Liver Effects
 - 17.3 Hematological Change
 - 17.4 Administration
 - 17.5 FDA-Approved Medication Guide

*Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: POTENTIAL LIVER INJURY

LETAIRIS (ambrisentan) can cause elevation of liver aminotransferases (ALT and AST) to at least 3 times the upper limit of normal (ULN). LETAIRIS treatment was associated with aminotransferase elevations $>3 \times \text{ULN}$ in 0.8% of patients in 12-week trials and 2.8% of patients including long-term open-label trials out to one year. One case of aminotransferase elevations $>3 \times \text{ULN}$ has been accompanied by bilirubin elevations $>2 \times \text{ULN}$. Because these changes are a marker for potentially serious liver injury, serum aminotransferase levels (and bilirubin if aminotransferase levels are elevated) must be measured prior to initiation of treatment and then monthly.

In the post-marketing period with another endothelin receptor antagonist (ERA), bosentan, rare cases of unexplained hepatic cirrhosis were reported after prolonged (>12 months) therapy. In at least one case with bosentan, a late presentation (after >20 months of treatment) included pronounced elevations in aminotransferases and bilirubin levels accompanied by non-specific symptoms, all of which resolved slowly over time after discontinuation of the suspect drug. This case reinforces the importance of strict adherence to the monthly monitoring schedule for the duration of treatment.

Elevations in aminotransferases require close attention. LETAIRIS should generally be avoided in patients with elevated aminotransferases ($>3 \times \text{ULN}$) at baseline because monitoring liver injury may be more difficult. If liver aminotransferase elevations are accompanied by clinical symptoms of liver injury (such as nausea, vomiting, fever, abdominal pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin $>2 \times \text{ULN}$, treatment should be stopped. There is no experience with the re-introduction of LETAIRIS in these circumstances.

CONTRAINDICATION: PREGNANCY

LETAIRIS is very likely to produce serious birth defects if used by pregnant women, as this effect has been seen consistently when it is administered to animals [see *Contraindications (4.1)*]. Pregnancy must therefore be excluded before the initiation of treatment with LETAIRIS and prevented thereafter by the use of at least two reliable methods of contraception unless the patient has had a tubal sterilization or Copper T 380A IUD or LNG 20 IUD inserted, in which case no other contraception is needed. Obtain monthly pregnancy tests.

Because of the risks of liver injury and birth defects, LETAIRIS is available only through a special restricted distribution program called the LETAIRIS Education and Access Program (LEAP), by calling 1-866-664-LEAP (5327). Only prescribers and pharmacies registered with LEAP may prescribe and distribute LETAIRIS. In addition, LETAIRIS may be dispensed only to patients who are enrolled in and meet all conditions of LEAP [see *WARNINGS, Prescribing and Distribution Program for LETAIRIS*].

1 INDICATIONS AND USAGE

LETAIRIS is indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening.

2 DOSAGE AND ADMINISTRATION

2.1 Adult Dosage

Initiate treatment at 5 mg once daily with or without food, and consider increasing the dose to 10 mg once daily if 5 mg is tolerated.

Tablets may be administered with or without food. Tablets should not be split, crushed, or chewed. Doses higher than 10 mg once daily have not been studied in patients with pulmonary arterial hypertension (PAH). Liver function tests should be measured prior to initiation and during treatment with LETAIRIS [see *Warnings and Precautions* (5.1)].

2.2 Women of Childbearing Potential

Treat women of childbearing potential only after a negative pregnancy test and treat only women who are using two reliable methods of contraception unless the patient has had a tubal sterilization or a Copper T 380A IUD or LNG 20 IUD inserted. In those cases, no other contraception is needed. Pregnancy tests should be obtained monthly in women of childbearing potential taking LETAIRIS [see *Contraindications* (4.1)].

2.3 Pre-existing Hepatic Impairment

LETAIRIS is not recommended in patients with moderate or severe hepatic impairment [see *Special Populations* (8.7)]. Use caution in patients with mild hepatic impairment.

3 DOSAGE FORMS AND STRENGTHS

LETAIRIS is available as 5 mg and 10 mg film-coated, unscored tablets.

4 CONTRAINDICATIONS

4.1 Pregnancy Category X

LETAIRIS may cause fetal harm when administered to a pregnant woman. Ambrisentan was teratogenic at oral doses of ≥ 15 mg/kg/day in rats and ≥ 7 mg/kg/day in rabbits; it was not studied at lower doses. In both species, there were abnormalities of the lower jaw and hard and soft palate, malformation of the heart and great vessels, and failure of formation of the thymus and thyroid. Teratogenicity is a class effect of endothelin receptor antagonists. There are no data on the use of LETAIRIS in pregnant women.

LETAIRIS is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. Pregnancy must be excluded before the initiation of treatment with LETAIRIS and prevented thereafter by the use of two reliable methods of contraception [see *Dosage and Administration* (2.2)].

5 WARNINGS AND PRECAUTIONS

5.1 Potential Liver Injury (see BOXED WARNING)

Treatment with endothelin receptor antagonists has been associated with dose-dependent liver injury manifested primarily by elevation of serum aminotransferases (ALT or AST), but sometimes accompanied by abnormal liver function (elevated bilirubin). The combination of aminotransferases greater than 3-times the upper limit of normal ($>3 \times \text{ULN}$) and total bilirubin $>2 \times \text{ULN}$ is a marker for potentially serious hepatic injury.

Liver function tests were closely monitored in all clinical studies with LETAIRIS. For all LETAIRIS-treated patients (N=483), the 12-week incidence of aminotransferases $>3 \times \text{ULN}$ was 0.8% and $>8 \times \text{ULN}$ was 0.2%. For placebo-treated patients, the 12-week incidence of aminotransferases $>3 \times \text{ULN}$ was 2.3% and $>8 \times \text{ULN}$ was 0.0%. The 1-year rate of aminotransferase elevations $>3 \times \text{ULN}$ with LETAIRIS was 2.8% and $>8 \times \text{ULN}$ was 0.5%. One case of aminotransferase elevations $>3 \times \text{ULN}$ has been accompanied by bilirubin elevations $>2 \times \text{ULN}$.

Liver chemistries must be measured prior to initiation of LETAIRIS and at least every month thereafter. If there are aminotransferase elevations $>3 \times \text{ULN}$ and $\leq 5 \times \text{ULN}$, they should be re-measured. If the confirmed level is $>3 \times \text{ULN}$ and $\leq 5 \times \text{ULN}$, reduce the daily dose or interrupt treatment and continue to monitor every two weeks until the levels are $<3 \times \text{ULN}$. If there are aminotransferase elevations $>5 \times \text{ULN}$ and $\leq 8 \times \text{ULN}$, LETAIRIS should be discontinued and monitoring should continue until the levels are $<3 \times \text{ULN}$. LETAIRIS can then be re-initiated with more frequent measurement of aminotransferase levels. If there are aminotransferase elevations $>8 \times \text{ULN}$, treatment should be stopped and re-initiation should not be considered.

LETAIRIS is not recommended in patients with elevated aminotransferases ($>3 \times \text{ULN}$) at baseline because monitoring liver injury may be more difficult. If aminotransferase elevations are accompanied by clinical symptoms of liver injury (such as anorexia, nausea, vomiting, fever, malaise, fatigue, right upper quadrant abdominal discomfort, itching, or jaundice) or increases in bilirubin $>2 \times \text{ULN}$, LETAIRIS treatment should be stopped. There is no experience with the re-introduction of LETAIRIS in these circumstances.

5.2 Hematological Changes

Decreases in hemoglobin concentration and hematocrit have followed administration of other endothelin receptor antagonists and were observed in clinical studies with LETAIRIS. These decreases were observed within the first few weeks of treatment with LETAIRIS, and stabilized thereafter. The mean decrease in hemoglobin from baseline to end of treatment for those patients receiving LETAIRIS in the 12-week placebo-controlled studies was 0.8 g/dL.

Marked decreases in hemoglobin ($>15\%$ decrease from baseline resulting in a value below the lower limit of normal) were observed in 7% of all patients receiving LETAIRIS (and 10% of patients receiving 10 mg) compared to 4% of patients receiving placebo.

The cause of the decrease in hemoglobin is unknown, but it does not appear to result from hemorrhage or hemolysis.

Hemoglobin must be measured prior to initiation of LETAIRIS and should be measured at one month and periodically thereafter. If a clinically significant decrease in hemoglobin is observed and other causes have been excluded, discontinuation of treatment should be considered.

5.3 Peripheral Edema

Peripheral edema is a known class effect of endothelin receptor antagonists, and is also a clinical consequence of PAH and worsening PAH. In the placebo-controlled studies, there was an increased incidence of peripheral edema in patients treated with doses of 5 or 10 mg LETAIRIS compared to placebo [see *Adverse Reactions (6)*]. Most edema was mild to moderate in severity. If clinically significant peripheral edema develops, with or without associated weight gain, further evaluation should be undertaken to determine the cause, such as heart failure, and the possible need for specific treatment.

5.4 Co-administration of LETAIRIS and Cyclosporine A

Cyclosporine is a strong inhibitor of P-glycoprotein (P-gp), Organic Anion Transport Protein (OATP), and CYP3A4. *In vitro* data indicate ambrisentan is a substrate of P-gp, OATP and CYP3A4. Therefore, use caution when LETAIRIS is co-administered with cyclosporine A because cyclosporine A may cause increased exposure to LETAIRIS [see *Drug Interactions (7)*].

5.5 Co-administration of LETAIRIS and Strong CYP3A and 2C19 Inhibitors

Use caution when LETAIRIS is co-administered with strong CYP3A-inhibitors (e.g., ketoconazole) and CYP2C19-inhibitors (e.g., omeprazole) [see *Drug Interactions (7)*].

5.6 Prescribing and Distribution Program for LETAIRIS

Because of the risks of liver injury and birth defects, LETAIRIS is available only through a special restricted distribution program called the LETAIRIS Education and Access Program (LEAP). Only prescribers and pharmacies registered with LEAP may prescribe and distribute LETAIRIS. In addition, LETAIRIS may be dispensed only to patients who are enrolled in and meet all conditions of LEAP.

To enroll in LEAP, prescribers must complete the LEAP Prescriber Enrollment and Agreement Form indicating agreement to (see LEAP Prescriber Enrollment and Agreement Form for full prescribing physician agreement):

- Read the Prescribing Information (PI) and Medication Guide for LETAIRIS
- Enroll all patients in LEAP and re-enroll patients after the first 6 months of treatment and annually thereafter
- Review the LETAIRIS Medication Guide and patient education brochure(s) with every patient

- Educate patients on the risks of LETAIRIS, including the risks of hepatotoxicity and teratogenicity [see *Boxed Warning*]
- Educate and counsel women of childbearing potential to use two different forms of contraception including at least one primary form during LETAIRIS treatment and for one month following treatment discontinuation. If the patient has had a tubal sterilization or a Copper T 380A IUD or LNG 20 IUD inserted, no additional contraception is needed [see *Boxed Warning, Contraindication (4.1)*].

Primary forms of contraception include tubal sterilization, hormonal (combination oral contraceptives, transdermal patch, injectables, implantables, or vaginal ring), IUD, and a partner's vasectomy. A Copper T 380A IUD or LNG 20 IUD can be used alone, i.e. without a secondary form of contraception, as can tubal sterilization.

Secondary forms of contraception include barrier contraceptives such as latex condoms, diaphragms, and cervical caps.

- Order and review liver function tests (including aminotransferases and bilirubin) prior to initiation of LETAIRIS treatment and monthly during treatment
- For women of childbearing potential, order and review a pregnancy test prior to initiation of LETAIRIS treatment and monthly during treatment
- Counsel patients who fail to comply with the program requirements
- Notify LEAP of any adverse events, including liver injury, or if any patient becomes pregnant during LETAIRIS treatment

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Safety data for LETAIRIS were obtained from two 12-week, placebo-controlled studies in patients with PAH (ARIES-1 and ARIES-2) and four nonplacebo-controlled studies in 483 patients with PAH who were treated with doses of 1, 2.5, 5, or 10 mg once daily. The exposure to LETAIRIS in these studies ranged from 1 day to 4 years (N=418 for at least 6 months and N=343 for at least 1 year).

In ARIES-1 and ARIES-2, a total of 261 patients received LETAIRIS at doses of 2.5, 5, or 10 mg once daily and 132 patients received placebo. The adverse events that occurred in >3% of the patients receiving LETAIRIS and were more frequent on LETAIRIS than placebo are shown in Table 1.

Table 1 Adverse Events in >3% of PAH Patients Receiving LETAIRIS and More Frequent than Placebo

	Placebo (N=132)	LETAIRIS (N=261)	
Adverse event	n (%)	n (%)	Placebo-adjusted (%)
Peripheral edema	14 (11)	45 (17)	6
Nasal congestion	2 (2)	15 (6)	4
Sinusitis	0 (0)	8 (3)	3
Flushing	1 (1)	10 (4)	3
Palpitations	3 (2)	12 (5)	3
Nasopharyngitis	1 (1)	9 (3)	2
Abdominal pain	1 (1)	8 (3)	2
Constipation	2 (2)	10 (4)	2
Dyspnea	4 (3)	11 (4)	1
Headache	18 (14)	38 (15)	1

Note: This table includes all adverse events >3% incidence in the combined LETAIRIS treatment group and more frequent than in the placebo group, with a difference of ≥1% between the LETAIRIS and placebo groups.

Most adverse drug reactions were mild to moderate and only nasal congestion was dose-dependent. Fewer patients receiving LETAIRIS had adverse events related to liver function tests compared to placebo.

Few notable differences in the incidence of adverse drug reactions were observed for patients by age or sex. Peripheral edema was similar in younger patients (<65 years) receiving LETAIRIS (14%; 29/205) or placebo (13%; 13/104), and was greater in elderly patients (≥65 years) receiving LETAIRIS (29%; 16/56) compared to placebo (4%; 1/28). The results of such subgroup analyses must be interpreted cautiously.

The incidence of treatment discontinuations due to adverse events other than those related to pulmonary hypertension during the clinical trials in patients with pulmonary arterial hypertension was similar for LETAIRIS (2%; 5/261 patients) and placebo (2%; 3/132 patients). The incidence of patients with serious adverse events other than those related to pulmonary hypertension during the clinical trials in patients with pulmonary arterial hypertension was similar for placebo (7%; 9/132 patients) and for LETAIRIS (5%; 13/261 patients).

7 DRUG INTERACTIONS

Studies with human liver tissue indicate that ambrisentan is metabolized by CYP3A4, CYP2C19, and uridine 5'-diphosphate glucuronosyltransferases (UGTs) 1A9S, 2B7S, and 1A3S. *In vitro* studies suggest that ambrisentan is a substrate of Organic Anion Transport Protein (OATP). *In vitro* studies show ambrisentan is a substrate but not an inhibitor of P-gp.

The drug interaction potential of ambrisentan is not well characterized because *in vivo* drug interaction studies were not conducted with the following types of drugs: strong inhibitors of CYP3A4 (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin), and CYP2C19 (omeprazole), strong inducers of CYP3A and 2C19 (rifampin), strong inhibitors of the transporters P-gp (cyclosporine A) and OATP (cyclosporine A, rifampin); and inducers of CYPs, UGTs and P-gp (rifampin). The impact of co-administration of such drugs on ambrisentan exposure is therefore unknown.

7.1 Cyclosporine A

Use caution when LETAIRIS is co-administered with cyclosporine A (see Warnings and Precautions 5.4).

7.2 Strong CYP3A or 2C19 Inhibitors

Use caution when LETAIRIS is co-administered with strong CYP3A-inhibitors (e.g., ketoconazole) or CYP2C19-inhibitors (e.g., omeprazole) [see *Warnings and Precautions* (5.5)].

7.3 Inducers of P-gp, CYPs, and UGTs

Use caution when LETAIRIS is co-administered with inducers of P-gp, CYPs, and UGTs.

7.4 Warfarin

In healthy volunteers receiving warfarin, daily doses of LETAIRIS (10 mg once daily) did not have a clinically significant effect on prothrombin time (PT), International Normalized Ratio (INR), or the pharmacokinetics of S-warfarin (CYP2C9 substrate) or R-warfarin (CYP3A4 substrate).

In patients with PAH receiving warfarin-type anticoagulants, concomitant administration of LETAIRIS did not result in a clinically relevant change in PT, INR or anticoagulant dose. Therefore, no dose-adjustments for warfarin or LETAIRIS are required when co-administered.

7.5 Sildenafil

In healthy volunteers receiving a single dose of sildenafil (20 mg), daily doses of LETAIRIS (10 mg once daily) did not have a clinically relevant effect on the pharmacokinetics of sildenafil or the active metabolite, n-desmethyl sildenafil. Similarly, daily doses of sildenafil (20 mg tid) did not have a clinically relevant effect on the pharmacokinetics of a single dose of LETAIRIS (10 mg). Therefore, no dose-adjustments for sildenafil or LETAIRIS are required when co-administered.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category X [see *Contraindications* (4.1)].

8.3 Nursing Mothers

It is not known whether ambrisentan is excreted in human milk. Breastfeeding while receiving LETAIRIS is not recommended. A preclinical study in rats has shown decreased survival of newborn pups (mid and high doses) and effects on testicle size and fertility of pups (high dose) following maternal treatment with ambrisentan from late gestation through weaning. Doses tested were 17x, 51x, and 170x (low, mid, high dose, respectively) the maximum oral human dose of 10 mg on a mg/mm² basis.

8.4 Pediatric Use

Safety and effectiveness of LETAIRIS in pediatric patients have not been established.

8.5 Geriatric Use

In the two placebo-controlled clinical studies of LETAIRIS, 21% of patients were ≥65 years old and 5% were ≥75 years old. The elderly (age ≥65 years) showed less improvement in walk distances with LETAIRIS than younger patients did, but the results of such subgroup analyses must be interpreted cautiously. Peripheral edema was more common in the elderly than in younger patients.

8.6 Renal Impairment

The impact of renal impairment on the pharmacokinetics of ambrisentan has been examined using a population pharmacokinetic approach in PAH patients with creatinine clearances ranging between 20 and 150 mL/min. There was no significant impact of mild or moderate renal impairment on exposure to ambrisentan [see *Clinical Pharmacology* (12.3)]. Dose adjustment of LETAIRIS in patients with mild or moderate renal impairment is therefore not required. There is no information on the exposure to ambrisentan in patients with severe renal impairment.

The impact of hemodialysis on the disposition of ambrisentan has not been investigated.

8.7 Hepatic Impairment

The influence of pre-existing hepatic impairment on the pharmacokinetics of ambrisentan has not been evaluated. Because there is *in vitro* and *in vivo* evidence of significant metabolic and biliary contribution to the elimination of ambrisentan, hepatic impairment would be expected to have significant effects on the pharmacokinetics of ambrisentan [see *Clinical Pharmacology* (12.3)]. LETAIRIS is not recommended in patients with moderate or severe hepatic impairment. Use caution when administering LETAIRIS to patients with mild pre-existing impaired liver function who may require reduced doses of LETAIRIS [see *Dosage and Administration* (2.3)].


10 OVERDOSAGE

There is no experience with overdosage of LETAIRIS. The highest single dose of LETAIRIS administered to healthy volunteers was 100 mg and the highest daily dose administered to patients with PAH was 10 mg once daily. Massive overdosage could potentially result in hypotension that may require intervention.

11 DESCRIPTION

LETAIRIS is the brand name for ambrisentan, an endothelin receptor antagonist that is selective for the endothelin type-A (ET_A) receptor. The chemical name of ambrisentan is (+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid. It has a molecular formula of C₂₂H₂₂N₂O₄ and a molecular weight of 378.42. It contains a single chiral center determined to be the (S) configuration and has the following structural formula:

Figure 1 Ambrisentan Structural Formula



Ambrisentan is a white to off-white, crystalline solid. It is a carboxylic acid with a pKa of 4.0. Ambrisentan is practically insoluble in water and in aqueous solutions at low pH. Solubility increases in aqueous solutions at higher pH. In the solid state ambrisentan is very stable, is not hygroscopic, and is not light sensitive.

LETAIRIS is available as 5 mg and 10 mg film-coated tablets for once-daily oral administration. The tablets include the following inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate and microcrystalline cellulose. The tablets are film-coated with a coating material containing FD&C Red #40 aluminum lake, lecithin, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide. Each square, pale pink LETAIRIS tablet contains 5 mg of ambrisentan. Each oval, deep pink LETAIRIS tablet contains 10 mg of ambrisentan. LETAIRIS tablets are unscored.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Endothelin-1 (ET-1) is a potent autocrine and paracrine peptide. Two receptor subtypes, ET_A and ET_B, mediate the effects of ET-1 in the vascular smooth muscle and endothelium. The primary actions of ET_A are vasoconstriction and cell proliferation, while the predominant actions of ET_B are vasodilation, antiproliferation, and ET-1 clearance.

In patients with PAH, plasma ET-1 concentrations are increased as much as 10-fold and correlate with increased mean right atrial pressure and disease severity. ET-1 and ET-1 mRNA concentrations are increased as much as 9-fold in the lung tissue of patients with PAH, primarily in the endothelium of pulmonary arteries. These findings suggest that ET-1 may play a critical role in the pathogenesis and progression of PAH.

Ambrisentan is a high affinity ($K_i=0.011$ nM) ET_A receptor antagonist with a high selectivity for the ET_A versus ET_B receptor (>4000 -fold). The clinical impact of high selectivity for ET_A is not known.

12.2 Pharmacodynamics

Cardiac Electrophysiology

In a randomized, positive- and placebo-controlled, parallel-group study, healthy subjects received either LETAIRIS 10 mg daily followed by a single dose of 40 mg, placebo followed by a single dose of moxifloxacin 400 mg, or placebo alone. LETAIRIS 10 mg daily had no significant effect on the QTc interval. The 40 mg dose of LETAIRIS increased mean QTc at t_{max} by 5 ms with an upper 95% confidence limit of 9 ms. For patients receiving LETAIRIS 5-10 mg daily and not taking metabolic inhibitors, no significant QT prolongation is expected.

12.3 Pharmacokinetics

The absolute bioavailability of ambrisentan is not known. Ambrisentan is rapidly absorbed with peak concentrations occurring approximately 2 hours after oral administration in healthy subjects and PAH patients. Food does not affect its bioavailability. *In vitro* studies indicate that ambrisentan is a substrate of P-gp. Ambrisentan is highly bound to plasma proteins (99%). The elimination of ambrisentan is predominantly by non-renal pathways, but the relative contributions of metabolism and biliary elimination have not been well characterized. Based on *in vitro* data, interactions with strong inhibitors of P glycoprotein (P-gp), the Organic Anion Transport Protein (OATP), CYP3A4, CYP2C19, and uridine 5' diphosphate glucuronosyltransferases (UGTs) are possible [see *Drug Interactions* (7)]. The mean oral clearance of ambrisentan is 38 mL/min and 19 mL/min in healthy subjects and in PAH patients, respectively. Although ambrisentan has a 15-hour terminal half-life, the mean trough concentration of ambrisentan at steady-state is about 15% of the mean peak concentration and the accumulation factor is about 1.2 after long-term daily dosing, indicating that the effective half-life of ambrisentan is about 9 hours.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Oral carcinogenicity studies of up to two years duration were conducted at starting doses of 10, 30, and 60 mg/kg/day in rats (8 to 48 times the maximum recommended human dose [MRHD] on a mg/m^2 basis) and at 50, 150 and 250 mg/kg/day in mice (28 to 140 times the MRHD). In the rat study, the high and mid-dose male and female groups had their doses lowered to 40 and 20 mg/kg/day, respectively, in week 51 because of effects on survival. The high dose males and females were taken off drug completely in weeks 69 and 93, respectively. The only evidence of ambrisentan-related carcinogenicity was a positive trend in male rats, for the combined incidence of benign basal cell tumor and basal cell carcinoma of skin/subcutis in the mid-dose group (high-dose group excluded from analysis), and the occurrence of mammary fibroadenomas in males in the high-dose group. In the mouse study, high dose male and female groups had their doses lowered to 150 mg/kg/day in week 39 and were

taken off drug completely in week 96 (males) or week 76 (females). In mice, ambrisentan was not associated with excess tumors in any dosed group.

Positive findings of clastogenicity were detected, at drug concentrations producing moderate to high toxicity, in the chromosome aberration assay in cultured human lymphocytes. There was no evidence for genetic toxicity of ambrisentan when tested *in vitro* in bacteria (Ames test) or *in vivo* in rats (micronucleus assay, unscheduled DNA synthesis assay).

The development of testicular tubular atrophy and impaired fertility has been linked to the chronic administration of endothelin receptor antagonists in rodents. Testicular tubular degeneration was observed in rats treated with ambrisentan for two years at doses ≥ 10 mg/kg/day (8-fold MRHD). Increased incidences of testicular findings were also observed in mice treated for two years at doses ≥ 50 mg/kg/day (28-fold MRHD). Effects on sperm count, sperm morphology, mating performance and fertility were observed in fertility studies in which male rats were treated with ambrisentan at oral doses of 300 mg/kg/day (236-fold MRHD). At doses of ≥ 10 mg/kg/day, observations of testicular histopathology in the absence of fertility and sperm effects were also present. There are insufficient data on the effects of ambrisentan or other endothelin receptor antagonists on testicular function in man.

14 CLINICAL STUDIES

14.1 Pulmonary Arterial Hypertension (PAH)

Two 12-week, randomized, double-blind, placebo-controlled, multicenter studies were conducted in 393 patients with PAH (WHO Group 1). The two studies were identical in design except for the doses of LETAIRIS and the geographic region of the investigational sites. ARIES-1 compared once-daily doses of 5 mg and 10 mg LETAIRIS to placebo, while ARIES-2 compared once-daily doses of 2.5 mg and 5 mg LETAIRIS to placebo. In both studies, LETAIRIS or placebo was added to current therapy, which could have included a combination of anticoagulants, diuretics, calcium channel blockers, or digoxin, but not epoprostenol, treprostinil, iloprost, bosentan, or sildenafil. The primary study endpoint was 6-minute walk distance. In addition, clinical worsening, WHO functional class, dyspnea, and SF-36[®] Health Survey were assessed.

Patients had idiopathic PAH (64%) or PAH associated with connective tissue disease (32%), HIV infection (3%), or anorexigen use (1%). There were no patients with PAH associated with congenital heart disease.

Patients had WHO functional class I (2%), II (38%), III (55%), or IV (5%) symptoms at baseline. The mean age of patients was 50 years, 79% of patients were female, and 77% were Caucasian.

Submaximal Exercise Capacity

Results of the 6-minute walk distance at 12 weeks for the ARIES-1 and ARIES-2 studies are shown in Table 2 and Figure 2.


Table 2 Changes from Baseline in 6-Minute Walk Distance (meters)

	ARIES-1			ARIES-2		
	Placebo (N=67)	5 mg (N=67)	10 mg (N=67)	Placebo (N=65)	2.5 mg (N=64)	5 mg (N=63)
Baseline	342 ± 73	340 ± 77	342 ± 78	343 ± 86	347 ± 84	355 ± 84
Mean change from baseline	-8 ± 79	23 ± 83	44 ± 63	-10 ± 94	22 ± 83	49 ± 75
Placebo-adjusted mean change from baseline		31	51		32	59
Placebo-adjusted median change from baseline		27	39		30	45
p-value†		0.008	<0.001		0.022	<0.001

Mean ± standard deviation

† p-values are Wilcoxon rank sum test comparisons of LETAIRIS to placebo at Week 12 stratified by idiopathic PAH and non-idiopathic PAH patients

Figure 2 Mean Change in 6-minute Walk Distance



Mean change from baseline in 6-minute walk distance in the placebo and LETAIRIS groups. Values are expressed as mean \pm standard error of the mean.

In both studies, treatment with LETAIRIS resulted in a significant improvement in 6-minute walk distance for each dose of LETAIRIS and the improvements increased with dose. An increase in 6-minute walk distance was observed after 4 weeks of treatment with LETAIRIS, with a dose-response observed after 12 weeks of treatment. Improvements in walk distance with LETAIRIS were smaller for elderly patients (age ≥ 65) than younger patients and for patients with secondary PAH than for patients

with idiopathic PAH. The results of such subgroup analyses must be interpreted cautiously.

The effects of LETAIRIS on walk distances at trough drug levels are not known. Because only once daily dosing was studied in the clinical trials, the efficacy and safety of more frequent dosing regimens for LETAIRIS are not known. If exercise capacity is not sustained throughout the day in a patient, consider other PAH treatments that have been studied with more frequent dosing regimens.

Clinical Worsening

Time to clinical worsening of PAH was defined as the first occurrence of death, lung transplantation, hospitalization for PAH, atrial septostomy, study withdrawal due to the addition of other PAH therapeutic agents or study withdrawal due to early escape. Early escape was defined as meeting two or more of the following criteria: a 20% decrease in the 6-minute walk distance; an increase in WHO functional class; worsening right ventricular failure; rapidly progressing cardiogenic, hepatic, or renal failure; or refractory systolic hypotension. The clinical worsening events during the 12-week treatment period of the LETAIRIS clinical trials are shown in Table 3 and Figure 3.

Table 3 Time to Clinical Worsening

	ARIES-1		ARIES-2	
	Placebo (N=67)	LETAIRIS (N=134)	Placebo (N=65)	LETAIRIS (N=127)
Clinical worsening, no. (%)	7 (10%)	4 (3%)	13 (22%)	8 (6%)
Hazard ratio		0.28		0.30
p-value, Fisher exact test		0.044		0.006
p-value, Log-rank test		0.030		0.005


Intention-to-treat population

Note: Patients may have had more than one reason for clinical worsening.

Nominal p-values

There was a significant delay in the time to clinical worsening for patients receiving LETAIRIS compared to placebo. Results in subgroups such as the elderly were also favorable.

Figure 3 Time to Clinical Worsening



Time from randomization to clinical worsening with Kaplan-Meier estimates of the proportions of failures in ARIES-1 and ARIES-2.

p-values shown are the log-rank comparisons of LETAIRIS to placebo stratified by idiopathic PAH and non-idiopathic PAH patients

14.2 Long-term Treatment of PAH

The long-term follow-up of the patients who were treated with LETAIRIS in the two pivotal studies and their open-label extension (N=383) shows that 95% were still alive at one year and 94% were still receiving LETAIRIS monotherapy. These uncontrolled observations do not allow comparison with a group not given LETAIRIS and cannot be used to determine the long-term effect of LETAIRIS.

14.3 Use in Patients with Prior Endothelin Receptor Antagonist (ERA) Related Liver Function Abnormalities

In an uncontrolled, open-label study, 36 patients who had previously discontinued endothelin receptor antagonists (ERAs: bosentan, an investigational drug, or both) due to aminotransferase elevations $>3 \times$ upper limit of normal (ULN) were treated with LETAIRIS. Prior elevations were predominantly moderate, with 64% of the ALT elevations $<5 \times$ ULN, but 9 patients had elevations $>8 \times$ ULN. Eight patients had been re-challenged with bosentan and/or the investigational ERA and all eight had a recurrence of aminotransferase abnormalities that required discontinuation of ERA therapy. All patients had to have normal aminotransferase levels on entry to this study. Twenty-five of the 36 patients were also receiving prostanoid and/or phosphodiesterase type 5 (PDE5) inhibitor therapy. Two patients discontinued early (including one of the patients with a prior $8 \times$ ULN elevation). Of the remaining 34 patients, one patient experienced a mild aminotransferase elevation at 12 weeks on LETAIRIS 5 mg that resolved with decreasing the dosage to 2.5 mg, and that did not recur with later escalations to 10 mg. With a median follow-up of 13 months and with 50% of patients increasing the dose of LETAIRIS to 10 mg, no patients were discontinued for aminotransferase elevations. While the uncontrolled study design does not provide information about what would have occurred with re-administration of previously used ERAs or show that LETAIRIS led to fewer aminotransferase elevations than would have been seen with those drugs, the study indicates that LETAIRIS may be tried in patients who have experienced asymptomatic aminotransferase elevations on other ERAs after aminotransferase levels have returned to normal.

16 HOW SUPPLIED/STORAGE AND HANDLING

Because of the risk of liver injury and birth defects, LETAIRIS may be prescribed only through the LETAIRIS Education and Access Program (LEAP) by calling 1-866-664-LEAP (5327) or by logging on to www.letairis.com. Adverse events can also be reported directly via this number.

LETAIRIS film-coated, unscored tablets are supplied as follows:

Package Configuration	Tablet Strength	NDC No.	Description of Tablet; Debossed on Tablet; Size
30 count blister	5 mg	61958-0801-2	Square convex, pale pink; "5" on side 1 and "GSI" on side 2; 6.6 mm Square
30 count blister	10 mg	61958-0802-2	Oval convex; deep pink; "10" on side 1 and "GSI" on side 2; 9.8 mm x 4.9 mm Oval

Rx only

Store at 25 °C (77 °F); excursions permitted to 15-30 °C (59-86 °F) [see USP controlled room temperature]. Store LETAIRIS in its original packaging.

17 PATIENT COUNSELING INFORMATION

As a part of patient counseling, doctors must review the LETAIRIS Medication Guide with every patient [see FDA-Approved Medication Guide (17.5)].

17.1 Importance of Preventing Pregnancy

Patients should be advised that LETAIRIS may cause fetal harm. LETAIRIS treatment should only be initiated in women of childbearing potential following a negative pregnancy test. Women of childbearing potential should be informed of the importance of monthly pregnancy tests and the need to use two different forms of contraception including at least one primary form simultaneously during LETAIRIS treatment and for one month following treatment discontinuation. Primary forms of contraception other than tubal sterilization include hormonal (combination oral contraceptives, transdermal patch, injectables, implantables, or vaginal ring), IUD, and a partner's vasectomy. A Copper T 380A IUD or LNG 20 IUD can be used alone, i.e. without a secondary form of contraception, as can tubal sterilization. Patients should be instructed to immediately contact their physician if they suspect they may be pregnant [see Prescribing and Distribution Program for LETAIRIS (5.5)].

17.2 Adverse Liver Effects

Patients should be advised of the importance of monthly liver function testing and instructed to immediately report any symptoms of potential liver injury (such as anorexia, nausea, vomiting, fever, malaise, fatigue, right upper quadrant abdominal discomfort, jaundice, dark urine or itching) to their physician.

17.3 Hematological Change

Patients should be advised of the importance of hemoglobin testing.

17.4 Administration

Patients should be advised not to split, crush, or chew tablets.

17.5 FDA-Approved Medication Guide

*Sections or subsections omitted from the full prescribing information are not listed.

Gilead Sciences, Inc., Foster City, CA 94404

June 2007

LETAIRIS and the Gilead logo are trademarks of Gilead Sciences, Inc. Other brands noted herein are the property of their respective owners.

©2007 Gilead Sciences, Inc.

GS22-081-000

Medication Guide
LETAIRIS™ (le-TAIR-is)
Tablets
(ambrisentan)

Read this Medication Guide before you start taking LETAIRIS and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment.

What is the most important information I should know about LETAIRIS?

- **Possible liver injury.**

LETAIRIS can cause liver injury. You must have a blood test to check your liver function before you start LETAIRIS and each month after that. Your doctor will order these blood tests. (See "What are the possible side effects of LETAIRIS?" for information about the signs of liver problems.) **Tell your doctor if you have had moderate or severe liver problems, including liver problems while taking other medicines.**

- **Serious birth defects.**

LETAIRIS can cause serious birth defects if taken during pregnancy. Women must not be pregnant when they start taking LETAIRIS or become pregnant during treatment. Women who are able to get pregnant must have a negative pregnancy test before beginning treatment with LETAIRIS and each month during treatment. Your doctor will decide when to do the test, depending on your menstrual cycle.

Women who are able to get pregnant must use two different reliable forms of birth control at the same time, during LETAIRIS treatment and for one month after stopping LETAIRIS. Talk with your doctor or gynecologist (a doctor who specializes in female reproduction) to find out about how to prevent pregnancy. **Do not have unprotected sex. Tell your doctor right away if you miss a menstrual period or think you may be pregnant.**

LETAIRIS is available only through a restricted program called the LETAIRIS Education and Access Program (LEAP). To receive LETAIRIS, you must talk to your doctor, understand the benefits and risks of LETAIRIS, and agree to all of the instructions in the LEAP program.

What is LETAIRIS?

LETAIRIS is a prescription medicine to treat pulmonary arterial hypertension (PAH), which is high blood pressure in the arteries of your lungs.

LETAIRIS can improve your ability to exercise and it can help slow down the worsening of your physical condition and symptoms.

Who should not take LETAIRIS?

Do not take LETAIRIS if:

- **you are pregnant, plan to become pregnant, or become pregnant during treatment with LETAIRIS. LETAIRIS can cause serious birth defects.** (See "What is the most important information I should know about LETAIRIS?") Serious birth defects from LETAIRIS happen early in pregnancy.
- **your blood tests show possible liver injury.**

Tell your doctor about all your medical conditions and all the medicines you take including prescription and nonprescription medicines. LETAIRIS and other medicines may affect each other causing side effects. Do not start any new medicines until you check with your doctor.

LETAIRIS has not been studied in children.

How should I take LETAIRIS?

LETAIRIS will be mailed to you by a specialty pharmacy. Your doctor will give you complete details.

- Take LETAIRIS exactly as your doctor tells you. Do not stop taking LETAIRIS unless your doctor tells you.
- You can take LETAIRIS with or without food.
- Do not split, crush or chew LETAIRIS tablets.
- It will be easier to remember to take LETAIRIS if you take it at the same time each day.
- If you take more than your regular dose of LETAIRIS, call your doctor right away.
- If you miss a dose, take it as soon as you remember that day. Take your next dose at the regular time. Do not take two doses at the same time to make up for a missed dose.
- During treatment your doctor will test your blood for signs of side effects to your liver and red blood cells.

What should I avoid while taking LETAIRIS?

- **Do not get pregnant** while taking LETAIRIS. (See the serious birth defects section of “What is the most important information I should know about LETAIRIS?”) If you miss a menstrual period, or think you might be pregnant, call your doctor right away.
- **Breastfeeding is not recommended** while taking LETAIRIS. It is not known if LETAIRIS can pass through your milk and harm your baby.

What are the possible side effects of LETAIRIS?

Serious side effects of LETAIRIS include:

- **Possible liver injury.** (See “What is the most important information I should know about LETAIRIS?”) Call your doctor right away if you have any of these symptoms of liver problems: loss of appetite, nausea, vomiting, fever, unusual tiredness, right upper stomach pain, yellowing of the skin or the whites of your eyes (jaundice), dark urine, or itching.
- **Serious birth defects.** (See “What is the most important information I should know about LETAIRIS?”)
- **Low sperm count.** LETAIRIS can lower sperm count in animals. If this happens in men, they may lose the ability to father children. Talk with your doctor if you have any questions or concerns.

The most common side effects of LETAIRIS are:

- Lowering of red blood cell count
- Swelling of legs and ankles (edema)
- Stuffy nose (nasal congestion)
- Inflamed nasal passages (sinusitis)
- Hot flashes or getting red in the face (flushing)
- Feeling your heart beat (palpitations)
- Red and sore throat and nose
- Stomach pain
- Constipation
- Shortness of breath
- Headache

How should I store LETAIRIS?

Store LETAIRIS at less than 86 °F (30 °C), in the package it comes in.

General information about LETAIRIS

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. If you have any concerns or questions about LETAIRIS, ask your doctor or other healthcare provider. This Medication Guide is only a summary of some important information about LETAIRIS. Your doctor can give you information about LETAIRIS that was written for healthcare professionals. Do not use LETAIRIS

for any condition other than that for which it was prescribed. Do not share LETAIRIS with other people. It may harm them.

Call 1-866-664-LEAP (5327) or visit www.letairis.com or www.gilead.com for more information.

What are the ingredients in LETAIRIS?

Active ingredient: ambrisentan

Inactive Ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate and microcrystalline cellulose. The tablets are film-coated with a coating material containing FD&C Red #40 aluminum lake, lecithin, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.

This medication guide has been approved by the U.S. Food and Drug Administration.

Gilead Sciences, Inc., Foster City, CA 94404

June 2007

LETAIRIS and the Gilead logo are trademarks of Gilead Sciences, Inc. Other brands noted herein are the property of their respective owners.

©2007 Gilead Sciences, Inc.

GS22-081-000

EXHIBIT F



US007109205B2

(12) **United States Patent**
Riechers et al.(10) **Patent No.:** **US 7,109,205 B2**
(45) **Date of Patent:** **Sep. 19, 2006**(54) **CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE**(75) **Inventors:** Hartmut Riechers, Neustadt (DE); Dagmar Klinge, Heidelberg (DE); Wilhelm Amberg, Friedrichsdorf (DE); Andreas Kling, Mannheim (DE); Stefan Müller, Speyer (DE); Ernst Baumann, Dudenhofen (DE); Joachim Rheimelmer, Ludwigshafen (DE); Uwe Josef Vogelbacher, Ludwigshafen (DE); Wolfgang Wernet, Hassloch (DE); Lillane Unger, Ludwigshafen (DE); Manfred Raschack, Weisenheim (DE)(73) **Assignee:** Abbott GmbH & Co. KG, Wiesbaden (DE)(*) **Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 261 days.(21) **Appl. No.:** 10/602,275(22) **Filed:** Jun. 24, 2003(65) **Prior Publication Data**

US 2004/0092742 A1 May 13, 2004

Related U.S. Application Data

(60) Continuation of application No. 09/748,184, filed on Dec. 27, 2000, now Pat. No. 6,600,043, which is a division of application No. 09/309,770, filed on May 11, 1999, now Pat. No. 6,197,958, which is a division of application No. 09/184,152, filed on Nov. 2, 1998, now Pat. No. 5,969,134, which is a division of application No. 08/809,699, filed as application No. PCT/EP95/03903 on Oct. 7, 1995, now Pat. No. 5,932,730.

(30) **Foreign Application Priority Data**Oct. 14, 1994 (DE) 44 36 851
Sep. 7, 1995 (DE) 195 33 023(51) **Int. Cl.**

C07D 239/02 (2006.01)

A61K 31/505 (2006.01)

(52) **U.S. Cl.** 514/274; 544/302; 544/315; 544/318(58) **Field of Classification Search** 544/302, 544/315, 318; 514/274
See application file for complete search history.(56) **References Cited****U.S. PATENT DOCUMENTS**5,178,663 A 1/1993 Harada et al.
5,270,289 A 12/1993 Harde et al.
5,318,945 A 6/1994 Baumann et al.
5,376,620 A 12/1994 Abe et al.
5,387,575 A 2/1995 Harada et al.
5,389,601 A 2/1995 Abe et al.5,541,148 A 7/1996 Glock et al.
5,661,106 A 8/1997 Baumann et al.
5,703,017 A 12/1997 Baumann et al.
5,840,722 A 11/1998 Baumann et al.
5,932,730 A 8/1999 Riechers et al.
5,969,134 A 10/1999 Riechers et al.
6,197,780 B1 3/2001 Munter et al.

(Continued)

FOREIGN PATENT DOCUMENTSDE 403578 A1 11/1990
DE 4123469 A1 7/1991
DE 4201875 A1 1/1992
DE 4313412 A1 4/1993
DE 4313413 A1 4/1993
DE 4411225 A1 3/1994
DE 4335950 A 10/1994
EP 347811 A1 6/1989
EP 347811 A 12/1989
EP 00409368 A2 7/1990
EP 00481512 A1 10/1991
EP 481512 A 4/1992
EP 00517215 A1 6/1992
EP 517215 A 12/1992
EP 0567014 A1 4/1993
EP 0581184 A1 7/1993
EP 695295 4/1994
EP 695296 4/1994
JP 1991031266 A 2/1991
JP 1991240777 A 10/1991

(Continued)

OTHER PUBLICATIONS

Raschack et al., Journal of Cardiovascular Pharmacology (1995), 26(Suppl. 3), S397-S399.*


(Continued)

Primary Examiner—Bruck Kifle(74) *Attorney, Agent, or Firm*—Wood, Phillips, Katz, Clark & Mortimer

(57)

ABSTRACT

Carboxylic acid derivatives

where R-R⁶, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.**18 Claims, No Drawings**

U.S. PATENT DOCUMENTS

6,197,958	B1	3/2001	Riechers et al.
6,329,384	B1	12/2001	Munter et al.
6,352,992	B1	3/2002	Kirchengast et al.
6,559,338	B1	5/2003	Bernard et al.
6,600,043	B1	7/2003	Riechers et al.
6,677,465	B1	1/2004	Jansen

FOREIGN PATENT DOCUMENTS

WO	WO 09400987	A2	1/1994
----	-------------	----	--------

WO	WO 09400987	A3	1/1994
WO	WO 09600219	A1	6/1995
WO	WO 95/26716		10/1995

OTHER PUBLICATIONS

Riechers et al., Journal of Medicinal Chemistry (1996), 39(11), 2123-8.*
 Ciba-Geigy AG "Neue selektiv-herbizide Mittel" Research Disclosure Journal.

* cited by examiner

CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 09/748,184, filed Dec. 27, 2000, now U.S. Pat. No. 6,600,043, which is a division of application Ser. No. 09/309,770, filed May 11, 1999, now U.S. Pat. No. 6,197,958; which is a division of application Ser. No. 09/184,152, filed Nov. 2, 1998, now U.S. Pat. No. 5,969,134; which is a division of application Ser. No. 08/809,699, filed Mar. 27, 1997, now U.S. Pat. No. 5,932,730; which is a Section 371 Application of PCT/EP95/03903, filed Oct. 7, 1995, which claims the priority of German Application Numbers 19533023.4, filed Sep. 7, 1995 and P 44 36 851.8, filed Oct. 14, 1994.

The present invention relates to novel carboxylic acid derivatives, their preparation and use.


Endothelin is a peptide which is composed of 21 amino acids and is synthesized and released by the vascular endothelium. Endothelin exists in three isoforms, ET-1, ET-2 and ET-3. In the following text, "endothelin" or "ET" signifies one or all isoforms of endothelin. Endothelin is a potent vasoconstrictor and has a potent effect on vessel tone. It is known that this vasoconstriction is caused by binding of endothelin to its receptor (Nature, 332, (1988) 411-415; FEBS Letters, 231, (1988) 440-444 and Biochem. Biophys. Res. Commun., 154, (1988) 868-875).

Increased or abnormal release of endothelin causes persistent vasoconstriction in the peripheral, renal and cerebral blood vessels, which may lead to illnesses. It has been reported in the literature that elevated plasma levels of endothelin were found in patients with hypertension, acute myocardial infarct, pulmonary hypertension, Raynaud's syndrome, atherosclerosis and in the airways of asthmatics (Japan J. Hypertension, 12, (1989) 79, J. Vascular Med. Biology 2, (1990) 207, J. Am. Med. Association 264, (1990) 2868).

Accordingly, substances which specifically inhibit the binding of endothelin to the receptor ought also to antagonize the various abovementioned physiological effects of endothelin and therefore be valuable drugs.

We have found that certain carboxylic acid derivatives are good inhibitors of endothelin receptors.

The invention relates to carboxylic acid derivatives of the formula I



where R is formyl, tetrazole [sic], nitrile [sic], a COOH group or a radical which can be hydrolyzed to COOH, and the other substituents have the following meanings:

R² hydrogen, hydroxyl, NH₂, NH(C₁-C₄-alkyl), N(C₁-C₄-alkyl)₂, halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy or C₁-C₄-alkylthio;

X nitrogen or CR¹⁴ where R¹⁴ is hydrogen or C₁₋₅-alkyl, or CR¹⁴ forms together with CR³ a 5- or 6-membered alkyl-

lene or alkenylene ring which can be substituted by one or two C₁₋₄-alkyl groups and in which in each case a methylene group can be replaced by oxygen, sulfur, —NH or —NC₁₋₄-alkyl;

R³ hydrogen, hydroxyl, NH₂, NH(C₁-C₄-Alkyl), N(C₁-C₄-alkyl)₂, halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, —NH—O—C₁₋₄-alkyl, C₁-C₄-alkylthio or CR³ is linked to CR¹⁴ as indicated above to give a 5- or 6-membered ring;

R⁴ and R⁵ (which can be identical or different):

phenyl or naphthyl, which can be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxyl, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, phenoxy, C₁-C₄-alkylthio, amino, C₁-C₄-alkylamino or C₁-C₄-dialkylamino; or phenyl or naphthyl, which are connected together in the ortho positions via a direct linkage, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an SO₂—, NH— or N-alkyl group, or C₃-C₇-cycloalkyl;

R⁶ hydrogen, C₁-C₈-alkyl, C₃-C₆-alkenyl, C₃-C₆-alkynyl or C₃-C₈-cycloalkyl, where each of these radicals can be substituted one or more times by: halogen, nitro, cyano, C₁-C₄-alkoxy, C₃-C₆-alkenyloxy, C₃-C₆-alkynyloxy, C₁-C₄-alkylthio, C₁-C₄-haloalkoxy, C₁-C₄-alkylcarbonyl, C₁-C₄-alkoxycarbonyl, C₃₋₈-alkylcarbonylalkyl, C₁-C₄-alkylamino, di-C₁-C₄-alkylamino, phenyl or phenyl or phenoxy which is substituted one or more times, eg. one to three times, by halogen, nitro, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy or C₁-C₄-alkylthio;

phenyl or naphthyl, each of which can be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxyl, amino, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, phenoxy, C₁-C₄-alkylthio, C₁-C₄-alkylamino, C₁-C₄-dialkylamino, dioxomethylene [sic] or dioxoethylene [sic];

a five- or six-membered heteroaromatic moiety containing one to three nitrogen atoms and/or one sulfur or oxygen atom, which can carry one to four halogen atoms and/or one or two of the following radicals: C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, phenyl, phenoxy or phenylcarbonyl, it being possible for the phenyl radicals in turn to carry one to five halogen atoms and/or one to three of the following radicals: C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy and/or C₁-C₄-alkylthio;

with the proviso that R⁶ can be hydrogen only when Z is not a single bond;

Y sulfur or oxygen or a single bond;

Z sulfur or oxygen or a single bond.


The compounds, and the intermediates for preparing them, such as IV and VI, may have one or more asymmetrical substituted carbon atoms. Such compounds may be in the form of the pure enantiomers or pure diastereomers or a mixture thereof. The use of an enantiomerically pure compound as active substance is preferred.

The invention furthermore relates to the use of the abovementioned carboxylic acid derivatives for producing drugs, in particular for producing endothelin receptor inhibitors.


The invention furthermore relates to the preparation of the compounds of the formula IV in enantiomerically pure form. Enantio-selective epoxidation of an olefin with two phenyl substituents is known (J. Org. Chem. 59, 1994, 4378-4380). We have now found, surprisingly, that even ester groups in these systems permit epoxidation in high optical purity.

3

The preparation of the compounds according to the invention where Z is sulfur or oxygen starts from the epoxides IV, which are obtained in a conventional manner, eg. as described in J. March, *Advanced Organic Chemistry*, 2nd ed., 1983, page 862 and page 750, from the ketones II or the olefins III:



Carboxylic acid derivatives of the general formula VI can be prepared by reacting the epoxides of the general formula IV (eg. with $R=ROOR^{10}$ [sic]) with alcohols or thiols of the general formula V where R^6 and Z have the meanings stated in claim 1.



To do this, compounds of the general formula IV are heated with compounds of the formula V, in the molar ratio of about 1:1 to 1:7, preferably 1 to 3 mole equivalents, to 50–200 ° C., preferably 80–150° C.

The reaction can also take place in the presence of a diluent. All solvents which are inert toward the reagents used can be used for this purpose.

Examples of such solvents or diluents are water, aliphatic, alicyclic and aromatic hydrocarbons, which may in each case be chlorinated, such as hexane, cyclohexane, petroleum ether, naphtha, benzene, toluene, xylene, methylene chloride, chloroform, carbon tetrachloride, ethyl chloride and trichloroethylene, ethers such as diisopropyl ether, dibutyl ether, methyl tert-butyl ether, propylene oxide, dioxane and tetrahydrofuran, ketones such as acetone, methyl ethyl ketone, methyl isopropyl ketone and methyl isobutyl ketone, nitriles such as acetonitrile and propionitrile, alcohols, such as methanol, ethanol, isopropanol, butanol and ethylene glycol, esters such as ethyl acetate and amyl acetate, amides such as dimethylformamide, dimethylacetamide and N-methylpyrrolidone, sulfoxides and sulfones, such as dimethyl sulfoxide and sulfolane, bases such as pyridine, cyclic ureas such as 1,3-dimethylimidazolidin-2-one and 1,3-dimethyl-3,4,5,6-tetra-hydro-2(1H)-pyrimidinone.

The reaction is preferably carried out at a temperature in the range from 0° C. to the boiling point of the solvent or mixture of solvents.

The presence of a catalyst may be advantageous. Suitable catalysts are strong organic and inorganic acids, and Lewis acids. Examples thereof are, inter alia, sulfuric acid, hydro-

4


chloric acid, trifluoroacetic acid, p-toluenesulfonic acid, boron trifluoride etherate and titanium(IV) alcoholates.

Compounds of the formula VI where R^4 and R^5 are cycloalkyl can also be prepared by subjecting compounds of the formula VI where R^4 and R^5 are phenyl, naphthyl, or phenyl or naphthyl substituted as described above, to a nuclear hydrogenation.

Compounds of the formula VI can be obtained in enantiomerically pure form by starting from enantiomerically pure compounds of the formula IV and reacting them in the manner described with compounds of the formula V.

It is furthermore possible to obtain enantiomerically pure compounds of the formula VI by carrying out a classical racemate resolution on racemic or diastereomeric compounds of the formula VI using suitable enantiomerically pure bases such as brucine, strychnine, quinine, quinidine, chinchonidine [sic], chinchonine [sic], yohimbine, morphine, dehydroabietylamine, ephedrine (-), (+), deoxyephedrine (+), (-) threo-2-amino-1-(p-nitrophenyl)-1,3-propanediol (+), (-) threo-2-(N,N-dimethylamino)-1-(p-nitrophenyl)-1,3-propanediol (+), (-) threo-2-amino-1-phenyl-1,3-propanediol (+), (-), α -methylbenzylamine (+), (-), α -(1-naphthyl)ethylamine (+), (-), α -(2-naphthyl)ethylamine (+), (-), aminomethylpinane, N,N-dimethyl-1-phenylethylamine, N-methyl-1-phenylethylamine, 4-nitrophenylethylamine, pseudoephedrine, norephedrine, norpseudoephedrine, amino acid derivatives, peptide derivatives.

The compounds according to the invention where Y is oxygen, and the remaining substituents have the meanings stated under the general formula I, can be prepared, for example, by reacting the carboxylic acid derivatives of the general formula VI where the substituents have the stated meanings with compounds of the general formula VII



where R^{15} is halogen or $R^{16}-SO_2-$, where R^{16} can be C_1-C_4 -alkyl, C_1-C_4 -haloalkyl or phenyl. The reaction preferably takes place in one of the abovementioned inert diluents with the addition of a suitable base, ie. of a base which deprotonates the intermediate VI, in a temperature range from room temperature to the boiling point of the solvent.


Compounds of the formula VII are known, some of them can be bought, or they can be prepared in a generally known manner.

It is possible to use as base an alkali metal or alkaline earth metal hydride such as sodium hydride, potassium hydride or calcium hydride, a carbonate such as an alkali metal carbonate, eg. sodium or potassium carbonate, an alkali metal or alkaline earth metal hydroxide such as sodium or potassium hydroxide, an organometallic compound such as butyllithium, or an alkali metal amide such as lithium diisopropylamide.

The compounds according to the invention where Y is sulfur, and the remaining substituents have the meanings stated under the general formula I, can be prepared, for

5


example, by reacting carboxylic acid derivatives of the general formula VIII, which can be obtained in a known manner from compounds of the general formula VI and in which the substituents have the abovementioned meanings, with compounds of the general formula IX, where R², R³ and X have the meanings stated under general formula I.



The reaction preferably takes place in one of the abovementioned inert diluents with the addition of a suitable base, ie. a base which deprotonates the intermediate IX, in a temperature range from room temperature to the boiling point of the solvent.

It is possible to use as base, besides those mentioned above, organic bases such as triethylamine, pyridine, imidazole or diazabicycloundecane [sic].

Carboxylic acid derivatives of the formula VIa (Z in formula VI=direct linkage) can be prepared by reacting epoxides of the formula IV with cuprates of the formula XI:



The cuprates can be prepared as described in Tetrahedron Letters 23, (1982) 3755.

Compounds of the formula I can also be prepared by starting from the corresponding carboxylic acids, ie. compounds of the formula I where R is COOH, and initially converting these in a conventional manner into an activated form, such as a halide, an anhydride or imidazolidine, and then reacting the latter with an appropriate hydroxy compound HOR¹⁰. This reaction can be carried out in the usual solvents and often requires addition of a base, in which case those mentioned above are suitable. These two steps can also be simplified, for example, by allowing the carboxylic acid to act on the hydroxy compound in the presence of a dehydrating agent such as a carbodiimide.

In addition, it is also possible for compounds of the formula I to be prepared by starting from the salts of the corresponding carboxylic acids, ie. from compounds of the formula I where R is COR¹ and R¹ is OM, where M can be an alkali metal cation or the equivalent of an alkaline earth metal cation. These salts can be reacted with many compounds of the formula R¹-A where A is a conventional nucleofugic leaving group, for example halogen such as chlorine, bromine, iodine or aryl- or alkylsulfonyl which is unsubstituted or substituted by halogen, alkyl or haloalkyl, such as toluenesulfonyl and methylsulfonyl, or another equivalent leaving group. Compounds of the formula R¹-A with a reactive substituent A are known or can be easily obtained with general expert knowledge. This reaction can be carried out in conventional solvents and advantageously

6


takes place with the addition of a base, in which case those mentioned above are suitable.

The radical R in formula I may vary widely. For example, R is a group



where R¹ has the following meanings:

- a) hydrogen;
- b) succinylimidoxy [sic];
- c) a five-membered heteroaromatic moiety linked by a nitrogen atom, such as pyrrolyl, pyrazolyl, imidazolyl and triazolyl, which may carry one or two halogen atoms, in particular fluorine and chlorine and/or one or two of the following radicals:
 - C₁-C₄-alkyl such as methyl, ethyl, 1-propyl, 2-propyl, 2-methyl-2-propyl, 2-methyl-1-propyl, 1-butyl, 2-butyl;
 - C₁-C₄-haloalkyl, in particular C₁-C₂-haloalkyl such as fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, trichloromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl and pentafluoroethyl;
 - C₁-C₄-haloalkoxy, in particular C₁-C₂-haloalkoxy such as difluoromethoxy, trifluoromethoxy, chlorodifluoromethoxy, 1-fluoroethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 1,1,2,2-tetrafluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-1,1,2-trifluoroethoxy and pentafluoroethoxy, in particular trifluoromethoxy;
 - C₁-C₄-alkoxy such as methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, 1,1-dimethylethoxy, in particular methoxy, ethoxy, 1-methylethoxy;
 - C₁-C₄-alkylthio such as methylthio, ethylthio, propylthio, 1-methylethylthio, butylthio, 1-methylpropylthio, 2-methylpropylthio, 1,1-dimethylethylthio, in particular methylthio and ethylthio;
- d) R¹ furthermore a radical



where m is 0 or 1 and R⁷ and R⁸, which can be identical or different, have the following meanings:

- hydrogen
- C₁-C₈-alkyl, in particular C₁-C₄-alkyl as mentioned above;
- C₃-C₆-alkenyl such as 2-propenyl, 2-butenyl, 3-butenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1,1-dimethyl-2-propenyl, 1,2-dimethyl-2-propenyl, 1-ethyl-2-propenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-methyl-4-pentenyl,

7

2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, 1,1-dimethyl-2-butenyl, 1,1-dimethyl-3-butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl-2-butenyl, 1,3-dimethyl-3-butenyl, 2,2-dimethyl-3-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1,1,2-trimethyl-2-propenyl, 1-ethyl-1-methyl-2-propenyl and 1-ethyl-2-methyl-2-propenyl, in particular 2-propenyl, 2-butenyl, 3-methyl-2-butenyl and 3-methyl-2-pentenyl;

C₃-C₆-alkynyl such as 2-propynyl, 2-butylnyl, 3-butylnyl, 1-methyl-2-propynyl, 2-pentylnyl, 3-pentylnyl, 4-pentylnyl, 1-methyl-3-butylnyl, 2-methyl-3-butylnyl, 1-methyl-2-butylnyl, 1,1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentylnyl, 1-methyl-2-pentylnyl, 1-methyl-3-pentylnyl, 1-methyl-4-pentylnyl, 2-methyl-3-pentylnyl, 2-methyl-4-pentylnyl, 3-methyl-4-pentylnyl, 4-methyl-2-pentylnyl, 1,1-dimethyl-2-butylnyl, 1,1-dimethyl-3-butylnyl, 1,2-dimethyl-3-butylnyl, 2,2-dimethyl-3-butylnyl, 1-ethyl-2-butylnyl, 1-ethyl-3-butylnyl, 2-ethyl-3-butylnyl and 1-ethyl-1-methyl-2-propynyl, preferably 2-propynyl, 2-butylnyl, 1-methyl-2-propynyl and 1-methyl-2-butylnyl, in particular 2-propynyl

C₃-C₈-cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, cyclooctyl, where these alkyl, cycloalkyl, alkenyl and alkynyl groups can each carry one to five halogen atoms, in particular fluorine or chlorine and/or one or two of the following groups:

C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-alkylthio, C₁-C₄-haloalkoxy as mentioned above, C₃-C₆-alkenyl, C₃-C₆-alkynylthio, C₃-C₆-alkynylthio, C₃-C₆-alkynylthio, C₃-C₆-alkynylthio, where the alkenyl and alkynyl constituents present in these radicals preferably have the abovementioned meanings;

C₁-C₄-alkylcarbonyl such as, in particular, methylcarbonyl, ethylcarbonyl, propylcarbonyl, 1-methylethylcarbonyl, butylcarbonyl, 1-methylpropylcarbonyl, 2-methylpropylcarbonyl, 1,1-dimethylethylcarbonyl;

C₁-C₄-alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, propyloxycarbonyl, 1-methylethoxycarbonyl, butyloxycarbonyl, 1-methylpropyloxycarbonyl, 2-methylpropyloxycarbonyl, 1,1-dimethylethoxycarbonyl;

C₃-C₆-alkenylcarbonyl, C₃-C₆-alkynylcarbonyl, C₃-C₆-alkenylloxycarbonyl and C₃-C₆-alkynylloxycarbonyl, where the alkenyl and alkynyl radicals are preferably defined as detailed above;

phenyl, unsubstituted or substituted one or more times, eg. one to three times, by halogen, nitro, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy or C₁-C₄-alkylthio, such as 2-fluorophenyl, 3-chlorophenyl, 4-bromophenyl, 2-methylphenyl, 3-nitrophenyl, 4-cyanophenyl, 2-trifluoromethylphenyl, 3-methoxyphenyl, 4-trifluoroethoxyphenyl, 2-methylthiophenyl, 2,4-dichlorophenyl, 2-methoxy-3-methylphenyl, 2,4-dimethoxyphenyl, 2-nitro-5-cyanophenyl, 2,6-difluorophenyl;

di-C₁-C₄-alkylamino such as, in particular, dimethylamino, dipropylamino, N-propyl-N-methylamino, N-propyl-N-ethylamino, diisopropylamino, N-isopropyl-N-methylamino, N-isopropyl-N-ethylamino, N-isopropyl-N-propylamino;


R⁷ and R⁸ furthermore phenyl which can be substituted by one or more, eg. one to three, of the following radicals:

8

halogen, nitro, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy or C₁-C₄-alkylthio, as mentioned above in particular;

or R⁷ and R⁸ together form a C₄-C₇-alkylene chain which is closed to form a ring, is unsubstituted or substituted, eg. substituted by C₁-C₄-alkyl, and may contain a heteroatom selected from the group consisting of oxygen, sulfur or nitrogen, such as $-(CH_2)_4-$, $-(CH_2)_5-$, $-(CH_2)_6-$, $-(CH_2)_7-$, $-(CH_2)_2-O-(CH_2)_2-$, $-(CH_2)_2-S-(CH_2)_3-$, $-(CH_2)_2-O-(CH_2)_3-$, $-(CH_2)_2-NH-(CH_2)_3-$, $-(CH_2)_2-NH-(CH_2)_2-$, $-(CH_2)_2-CH=CH-$, $-(CH_2)_3-$;

e) R¹ furthermore a group



where k is 0, 1 and 2, p is 1, 2, 3 and 4 and R⁹ is

C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₃-C₆-alkenyl, C₃-C₆-alkynyl or unsubstituted or substituted phenyl, as mentioned above in particular.

f) R¹ furthermore a radical OR¹⁰, where R¹⁰ is:

hydrogen, the cation of an alkali metal such as lithium, sodium, potassium or the cation of an alkaline earth metal such as calcium, magnesium and barium or an environmentally compatible organic ammonium ion such as tertiary C₁-C₄-alkylammonium or the ammonium ion;

C₃-C₈-cycloalkyl as mentioned above, which may carry one to three C₁-C₄-alkyl groups;

C₁-C₈-alkyl such as, in particular, methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,2-dimethylpropyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-methylpentyl,

2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethylbutyl, 2-ethylbutyl, 1-ethyl-2-methylpropyl, which can carry one to five halogen atoms, in particular fluorine and chlorine and/or one of the following radicals:

C₁-C₄-alkoxy, C₁-C₄-alkylthio, cyano, C₁-C₄-alkylcarbonyl, C₃-C₈-cycloalkyl, C₁-C₄-alkoxycarbonyl, phenyl, phenoxy or phenylcarbonyl, where the aromatic radicals in turn can carry in each case one to five halogen atoms and/or one to three of the following radicals: nitro, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy and/or C₁-C₄-alkylthio, as mentioned above in particular;

a) C₁-C₈-alkyl as mentioned above, which can carry one to five halogen atoms, in particular fluorine and/or chlorine, and carries one of the following radicals: a 5-membered heteroaromatic moiety containing one to three nitrogen atoms, or a 5-membered heteroaromatic moiety containing a nitrogen atom and an oxygen or sulfur atom, which can carry one to four halogen atoms and/or one or two of the following radicals:

nitro, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, phenyl, C₁-C₄-haloalkoxy and/or C₁-C₄-alkylthio. Particular mention may be made of: 1-pyrazolyl,

3-methyl-1-pyrazolyl, 4-methyl-1-pyrazolyl, 3,5-dimethyl-1-pyrazolyl, 3-phenyl-1-pyrazolyl, 4-phenyl-1-pyrazolyl, 4-chloro-1-pyrazolyl, 4-bromo-1-pyrazolyl, 1-imidazolyl, 1-benzimidazolyl, 1,2,4-triazol-1-yl, 3-methyl-1,2,4-triazol-1-yl, 5-methyl-1,2,4-triazol-1-yl, 1-benzotriazolyl, 3-isopropyl-5-isoxazolyl, 3-methyl-5-isoxazolyl, 2-oxazolyl, 2-thiazolyl, 2-imidazolyl, 3-ethyl-5-isoxazolyl, 3-phenyl-5-isoxazolyl, 3-tert-butyl-5-isoxazolyl;

a C₂-C₆-alkyl group which carries one of the following radicals in position 2: C₁-C₄-alkoxyimino, C₃-C₆-alkynyloxyimino, C₃-C₆-haloalkenyloxyimino or benzyloxyimino;


a C₃-C₆-alkenyl or C₃-C₆-alkynyl group, it being possible for these groups in turn to carry one to five halogen atoms;

R¹⁰ furthermore a phenyl radical which can carry one to five halogen atoms and/or one to three of the following radicals: nitro, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy,

C₁-C₄-haloalkoxy and/or C₁-C₄-alkylthio, as mentioned above in particular;

a 5-membered heteroaromatic moiety which is linked via a nitrogen atom, contains one to three nitrogen atoms and can carry one or two halogen atoms and/or one or two of the following radicals: C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, phenyl, C₁-C₄-haloalkoxy and/or C₁-C₄-alkylthio. Particular mention may be made of: 1-pyrazolyl, 3-methyl-1-pyrazolyl, 4-methyl-1-pyrazolyl, 3,5-dimethyl-1-pyrazolyl, 3-phenyl-1-pyrazolyl, 4-phenyl-1-pyrazolyl, 4-chloro-1-pyrazolyl, 4-bromo-1-pyrazolyl, 1-imidazolyl, 1-benzimidazolyl, 1,2,4-triazol-1-yl, 3-methyl-1,2,4-triazol-1-yl, 5-methyl-1,2,4-triazol-1-yl, 1-benzotriazolyl, 3,4-dichloro-1-imidazolyl;

R¹⁰ furthermore a group




where R¹¹ and R¹², which can be identical or different, are:

C₁-C₈-alkyl, C₃-C₆-alkenyl, C₃-C₆-alkynyl, C₃-C₈-cycloalkyl, it being possible for these radicals to carry a C₁-C₄-alkoxy, C₁-C₄-alkylthio and/or an unsubstituted or substituted phenyl radical, as mentioned above in particular;

phenyl which can be substituted by one or more, eg. one to three, of the following radicals: halogen, nitro, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy or C₁-C₄-alkylthio, where these radicals are, in particular, those mentioned above;

or R¹¹ and R¹² together form a C₃-C₁₂-alkylene chain which can carry one to three C₁-C₄-alkyl groups and contain a heteroatom from the group consisting of oxygen, sulfur and nitrogen, as mentioned in particular for R⁷ and R⁸.

g) R¹ furthermore a radical




10 where R¹³ is:

C₁-C₄-alkyl, C₃-C₆-alkenyl, C₃-C₆-alkynyl, C₃-C₈-cycloalkyl as mentioned above in particular, it being possible for these radicals to carry a C₁-C₄-alkoxy, C₁-C₄-alkylthio and/or a phenyl radical as mentioned above;

phenyl, unsubstituted or substituted, in particular as mentioned above.

h) R¹ a radical



where R¹³ has the abovementioned meaning.

R can furthermore be:

tetrazole [sic] or nitrile [sic].

In respect of the biological effect, preferred carboxylic acid derivatives of the general formula I, both as pure enantiomers and pure diastereomers or as mixture thereof, are those where the substituents have the following meanings:

R² hydrogen, hydroxyl, N(C₁-C₄-alkyl)₂, the C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio groups and halogen atoms mentioned in detail for R¹, especially chlorine, methyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy;

X nitrogen or CR¹⁴ where

R¹⁴ is hydrogen or alkyl, or CR¹⁴ forms together with CR³ a 4- to 5-membered alkylene or alkenylene ring in which, in each case, a methylene group can be replaced by oxygen or sulfur, such as $\text{---CH}_2\text{---CH}_2\text{---O---}$, ---CH=CH---O--- , $\text{---CH}_2\text{---CH}_2\text{---S---}$, ---CH=CH---S--- , $\text{---CH}_2\text{---CH}_2\text{---O---}$, $\text{---CH(CH}_3\text{)---CH(CH}_3\text{)---O---}$, $\text{---C(CH}_3\text{)=C(CH}_3\text{)---O---}$, $\text{---CH=C(CH}_3\text{)---O---}$ or $\text{---C(CH}_3\text{)=C(CH}_3\text{)---S---}$;

R³ the hydrogen, hydroxyl, N(C₁-C₄-alkyl)₂, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio groups and halogen atoms mentioned for R¹, especially chlorine, methyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy or is linked to R¹⁴ as mentioned above to give a 5- or 6-membered ring;

R⁴ and R⁵ phenyl or naphthyl, which can be substituted by one or more, eg. one to three, of the following radicals: halogen, nitro, cyano, hydroxyl, mercapto, amino, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-alkylamino, di-C₁-C₄-alkylamino, C₁-C₄-alkylcarbonyl, C₁-C₄-alkoxycarbonyl; phenyl or naphthyl, which are connected together in the ortho positions by a direct linkage, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an SO₂, NH or N-alkyl group, or C₃-C₇-cycloalkyl;

11

R⁶ C₁-C₈-alkyl, C₃-C₆-alkenyl, C₃-C₆-alkynyl or C₃-C₈-cycloalkyl as mentioned above in particular, it being possible for these radicals in each case to be substituted one or more times by: halogen, hydroxyl, nitro, cyano, C₁-C₄-alkoxy, C₃-C₆-alkenyloxy, C₃-C₆-alkynyloxy, C₁-C₄-alkylthio, C₁-C₄-haloalkoxy, C₁-C₄-alkylcarbonyl, hydroxycarbonyl, C₁-C₄-alkoxycarbonyl, C₁-C₄-alkylamino, di-C₁-C₄-alkylamino or unsubstituted or substituted phenyl or phenoxy, as mentioned above in particular;

phenyl or naphthyl, which can be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxyl, amino, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, phenoxy, C₁-C₄-alkylthio, C₁-C₄-alkylamino [sic] or C₁-C₄-dialkylamino, as mentioned in particular for R⁷ and R⁴;

a five- or six-membered heteroaromatic moiety which contains one to three nitrogen atoms and/or one sulfur or oxygen atom and which can carry one to four halogen atoms and/or one or two of the following radicals: C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, phenyl, phenoxy or phenylcarbonyl, it being possible for the phenyl radicals in turn to carry one to five halogen atoms and/or one to three of the following radicals: C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy and/or C₁-C₄-alkylthio, as mentioned for R⁴ in particular;

Y sulfur, oxygen or a single bond;

Z sulfur, oxygen, —SO—, —SO₂— or a single bond.

Particularly preferred compounds of the formula I, both as pure enantiomers and pure diastereomers or as mixture thereof, are those in which the substituents have the following meanings:

R² C₁-C₄-alkyl, C₁-C₄-alkoxy

X nitrogen or CR¹⁴, where

R¹⁴ is hydrogen or alkyl, or CR¹⁴ forms together with CR³ a 4- or 5-membered alkylene or alkenylene ring such as —CH₂—CH₂—CH₂—, —CH=CH—CH₂—, in which in each case a methylene group can be replaced by oxygen or sulfur, such as —CH₂—CH₂—O—, —CH=CH—O—, —CH₂—CH₂—CH₂—H—, —CH=CH—CH₂—O—, in particular hydrogen, —CH₂—CH₂—O—, —CH(CH₃)—CH(CH₃)—O—, —C(CH₃)=C(CH₃)—O—, —CH=C(CH₃)—O— or —C(CH₃)=C(CH₃)—S—;

R³ the C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-alkylthio groups mentioned for R¹, or is linked to R¹⁴ as mentioned above to give a 5- or 6-membered ring;

R⁴ and R⁵ phenyl (identical or different) which can be substituted by one or more, eg. one to three, of the following radicals: halogen, nitro, hydroxyl, C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-alkylthio or

R⁴ and R⁵ are phenyl groups which are connected together in the ortho positions by a direct linkage, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an SO₂, NH or N-alkyl group; or

R⁴ and R⁵ are C₃-C₇-cycloalkyl;

R⁶ C₁-C₈-alkyl, C₃-C₆-alkenyl or C₃-C₈-cycloalkyl, it being possible for these radicals in each case to be substituted one or more times by: halogen, hydroxyl, nitro, cyano, C₁-C₄-alkoxy, C₃-C₆-alkenyloxy, C₁-C₄-alkylthio;

phenyl or naphthyl, which can be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxyl, amino, C₁-C₄-alkyl, C₁-C₄-haloalkyl,

12

C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, phenoxy, C₁-C₄-alkylthio, C₁-C₄-alkylamino [sic] or C₁-C₄-dialkylamino;

a five- or six-membered heteroaromatic moiety which contains a nitrogen atom and/or a sulfur or oxygen atom and which can carry one to four halogen atoms and/or one or two of the following radicals: C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-alkylthio, phenyl, phenoxy or phenylcarbonyl, it being possible for the phenyl radicals in turn to carry one to five halogen atoms and/or one to three of the following radicals: C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and/or C₁-C₄-alkylthio;

Y sulfur, oxygen or a single bond;

Z sulfur, oxygen, —SO—, —SO₂— or a single bond.

The compounds of the present invention provide a novel therapeutic potential for the treatment of hypertension, pulmonary hypertension, myocardial infarct, angina pectoris, acute kidney failure, renal insufficiency, cerebral vasospasms, cerebral ischemia, subarachnoid hemorrhages, migraine, asthma, atherosclerosis, endotoxic shock, endotoxin-induced organ failure, intravascular coagulation, restenosis after angioplasty, benign prostate hyperplasia, or hypertension or kidney failure caused by ischemia or intoxication.

The good effect of the compounds can be shown in the following tests:

30 Receptor Binding Studies

Cloned human ET_A receptor-expressing CHO cells and guinea pig cerebellar membranes with >60% ET_B compared with ET_A receptors were used for binding studies.

The ET_A receptor-expressing CHO cells were grown in F₁₂ medium containing 10% fetal calf serum, 1% glutamine, 100 U/ml penicillin and 0.2% streptomycin (Gibco BRL, Gaithersburg, Md., U.S.A.). After 48 h, the cells were washed with PBS and incubated with 0.05% trypsin-containing PBS for 5 min. Neutralization was then carried out with F₁₂ medium, and the cells were collected by centrifugation at 300 xg. To lyse the cells, the pellet was briefly washed with lysis buffer (5 mM Tris-HCl, pH 7.4 with 10% glycerol) and then incubated at a concentration of 10⁷ cells/ml of lysis buffer at 4° C. for 30 min. The membranes were centrifuged at 20,000xg for 10 min, and the pellet was stored in liquid nitrogen.

Guinea pig cerebella were homogenized in a Potter-Elvehjem homogenizer and [lacuna] obtained by differential centrifugation at 1000xg for 10 min and repeated centrifugation of the supernatant at 20,000xg for 10 min.

Binding Assays

For the ET_A and ET_B receptor binding assay, the membranes were suspended in incubation buffer (50 mM TrisHCl, pH 7.4 with 5 mM MnCl₂, 40 µg/ml bacitracin and 0.2% BSA) at a concentration of 50 µg of protein per assay mixture and incubated with 25 pM [125I]-ET₁ (ET_A receptor assay) or 25 pM [125I]-RZ₃ (ET_B receptor assay) in the presence and absence of test substance at 25° C. The nonspecific binding was determined using 10⁻⁷ M ET₁. After 30 min, the free and bound radioligand were separated by filtration through GF/B glass fiber filters (Whatman, England) on a Skatron cell collector (Skatron, Lie, Norway) and the filters were washed with ice-cold Tris-HCl buffer, pH 7.4 with 0.2% BSA. The radioactivity collected on the filters was quantified using a Packard 2200 CA liquid scintillation counter.

13

Functional in Vitro Assay System to Look for Endothelin Receptor (Subtype A) Antagonists

This assay system is a functional, cell-based assay for endothelin receptors. When certain cells are stimulated with endothelin 1 (ET1) they show an increase in the intracellular calcium concentration. This increase can be measured in intact cells loaded with calcium-sensitive dyes.

1-Fibroblasts which had been isolated from rats and in which an endogenous endothelin receptor of the A subtype had been detected were loaded with the fluorescent dye Fura 2-am as follows: after trypsinization, the cells were resuspended in buffer A (120 mM NaCl, 5 mM KCl, 1.5 mM MgCl₂, 1 mM CaCl₂, 25 mM HEPES, 10 mM glucose, pH 7.4) to a density of 2×10⁶/ml and incubated with Fura 2-am (2 μM), Pluronic F-127 (0.04%) und DMSO (0.2%) at 37° C. in the dark for 30 min. The cells were then washed twice with buffer A and resuspended at 2×10⁶/ml.

The fluorescence signal from 2×10⁵ cells per ml with Ex/Em 380/510 was recorded continuously at 30° C. The test substances and, after an incubation time of 3 min, ET1 [lacuna] to the cells, the maximum change in the fluorescence was determined. The response of the cells to ET1 without previous addition of a test substance was used as control and was set equal to 100%.

Testing of ET Antagonists in Vivo

Male SD rats weighting 250–300 g were anesthetized with amobarbital, artificially ventilated, vagotomized and pithed. The carotid artery and jugular vein were cathetized [sic].

In control animals, intravenous administration of 1 μg/kg ET1 led to a distinct rise in blood pressure which persisted for a lengthy period.

The test animals received an i.v. injection of the test compounds (1 ml/kg) 5 min before the administration of ET1. To determine the ET-antagonistic properties, the rise in blood pressure in the test animals was compared with that in the control animals.

Endothelin-1-Induced Sudden Death in Mice

The principle of the test is the inhibition of the sudden heart death caused in mice by endothelin, which is probably induced by constriction of the coronary vessels, by pretreatment with endothelin receptor antagonists. Intravenous injection of 10 nmol/kg endothelin in a volume of 5 ml/kg of body weight results in death of the animals within a few minutes.

The lethal endothelin-1 dose is checked in each case on a small group of animals. If the test substance is administered intravenously, the endothelin-1 injection which was lethal in the reference group usually takes place 5 min thereafter. With other modes of administration, the times before administration are extended, where appropriate up to several hours.

The survival rate is recorded, and effective doses which protect 50% of the animals (ED 50) from endothelin-induced heart death for 24 h or longer are determined.

Functional Test on Vessels for Endothelin Receptor Antagonists

Segments of rabbit aorta are, after an initial tension of 2 g and a relaxation time of 1 h in Krebs-Henseleit solution at 37° C. and pH 7.3–7.4, first induced to contract with K⁺. After washing out, an endothelin dose-effect plot up to the maximum is constructed.

Potential endothelin antagonists are administered to other preparations of the same vessel 15 min before starting the endothelin dose-effect plot. The effects of the endothelin are

14

calibrated as a % of the K⁺-induced contraction. Effective endothelin antagonists result in a shift to the right in the endothelin dose-effect plot.

The compounds according to the invention can be administered orally or parenterally (subcutaneously, intravenously, intramuscularly, intraperitoneally) in a conventional way. Administration can also take place with vapors or sprays through the nasopharyngeal space.

The dosage depends on the age, condition and weight of the patient and on the mode of administration. The daily dose of active substance is, as a rule, about 0.5–50 mg/kg of body weight on oral administration and about 0.1–10 mg/kg of body weight on parenteral administration.

The novel compounds can be used in conventional solid or liquid pharmaceutical forms, eg. as uncoated or (film-) coated tablets, capsules, powders, granules, suppositories, solutions, ointments, creams or sprays. These are produced in a conventional way. The active substances can for this purpose be processed with conventional pharmaceutical aids such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers wetting agents, dispersants, emulsifiers, solvents, release-slowing agents, antioxidants and/or propellant gases (cf. H. Sucker et al.: Pharmazeutische Technologie, Thieme-Verlag, Stuttgart, 1991). The administration forms obtained in this way normally contain from 0.1 to 90% by weight of the active substance.

SYNTHESIS EXAMPLES

Example 1

Methyl

2-hydroxy-3-methoxy-3,3-diphenylpropionate

5 g (19.6 mmol) of methyl 3,3-diphenyl-2,3-epoxypropionate were dissolved in 50 ml of absolute methanol and, at 0° C., 0.1 ml of boron trifluoride etherate was added. The mixture was stirred at 0° C. for 2 h and at room temperature for a further 12 h. The solution vent was distilled out, the residue was taken up in ethyl acetate, washed with sodium bicarbonate solution and water and dried over magnesium sulfate. After removal of the solvent by distillation there remained 5.5 g (88%) of a pale yellow oil.

Example 2

Methyl

2-hydroxy-3-phenoxy-3,3-diphenylpropionate

5 g (19.6 mmol) of methyl 3,3-diphenyl-2,3-epoxypropionate and 5.6 g (60 mmol) of phenol were heated together at 100° C. for 6 h. Removal of the excess phenol by distillation under high vacuum and purification of the residue by chromatography on silica gel with hexane/ethyl acetate mixtures resulted in 4.9 g (77%) of a pale yellow oil.

Example 3

Methyl 2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionate

2.86 g (10 mmol) of methyl 2-hydroxy-3-methoxy-3,3-diphenylpropionate were dissolved in 40 ml of dimethylformamide, and 0.3 g (12 mmol) of sodium hydride was added. The mixture was stirred for 1 h and then 2.2 g (10 mmol) of 4,6-dimethoxy-2-methylsulfonylpyrimidine were added.

15

After stirring at room temperature for 24 h, cautious hydrolysis was carried out with 10 ml of water, the pH was adjusted to 5 with acetic acid, and the solvent was removed by distillation under high vacuum. The residue was taken up in 100 ml of ethyl acetate, washed with water and dried over magnesium sulfate, and the solvent was distilled out. The residue was mixed with 10 ml of ether, and the resulting precipitate was filtered off with suction. After drying, 3.48 g (82%) of a white powder remained.

Melting point 81° C.

Example 4

2-(4,6-Dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionic acid

2.12 g (5 mmol) of methyl 2-(4,6-dimethoxy-pyrimidin-2-yl-oxy)-3-methoxy-3,3-diphenylpropionate were dissolved in 50 ml of dioxane, 10 ml of 1 N KOH solution were added, and the mixture was stirred at 100° C. for 3 h. The solution was diluted with 300 ml of water and extracted with ethyl acetate to remove unreacted ester. The aqueous phase was then adjusted to pH 1-2 with dilute hydrochloric acid and extracted with ethyl acetate. After drying over magnesium sulfate and removal of the solvent by distillation, the residue was mixed with an ether/hexane mixture, and the precipitate which formed was filtered off with suction. After drying, 1.85 g (90%) of a white powder remained.

Melting point 167° C.

Example 5

2-(4,6-Dimethoxy-2-pyrimidin-yloxy)-3-methoxy-3,3-diphenyl Sodium [sic] Propionate

1.68 g (4 mmol) of 2-(4,6-dimethoxy-2-pyrimidin-yloxy)-3-methoxy-3,3-diphenylpropionic acid are dissolved in 4 ml of 1N NaOH+100 ml of water. The solution is freeze-dried, and the sodium salt of the carboxylic acid used is obtained quantitatively.

10 g (34.9 mmol) of methyl 2-hydroxy-3-methoxy-3,3-diphenylpropionate were dissolved in 50 ml each of methanol and glacial acetic acid, 1 ml of RuO(OH)₂ in dioxane was added, and hydrogenation was carried out with H₂ in an autoclave at 100° C. under 100 bar for 30 h. The catalyst was filtered off, the mixture was concentrated, mixed with ether and washed with NaCl solution, and the organic phase was dried and concentrated. 10, 1 g of methyl 3,3-dicyclohexyl-2-hydroxy-3-methoxypropionate were obtained as an oil.

Example 7

Methyl 2-[(4,6-dimethoxy-pyrimidin-2-yl)thio]-3-methoxy-3,3-diphenylpropionate [sic]

7.16 g (25 mmol) of methyl 2-hydroxy-3-methoxy-3,3-diphenylpropionate were dissolved in 50 ml of dichloromethane, 3 g (30 mmol) of triethylamine were added, and 3.2 g (28 mmol) of methanesulfonyl chloride were added dropwise while stirring. The mixture was stirred at room temperature for 2 h, washed with water, dried over magnesium sulfate and concentrated under reduced pressure. The residue was taken up in DMF and added dropwise at 0° C. to a suspension of 12.9 g (75 mmol) of 4,6-dimethoxypyrimidine-2-thiol and 8.4 g (100 mmol) of sodium bicarbonate in 100 ml of DMF. After stirring at room temperature for 2 h and at 60° C. for a further 2 h, the mixture was poured

16

into 1 liter of ice-water, and the resulting precipitate was filtered off with suction. After drying, 3.19 g (29%) of a white powder remained.

Example 8

Methyl 2-hydroxy-3,3-diphenylbutyrate

1.5 g (5.9 mmol) of methyl 3,3-diphenyl-2,3-epoxypropionate dissolved in 10 ml of absolute ether were added dropwise to a cuprate solution which had been prepared from 635 mg (7 mmol) of copper(I) cyanide dissolved in 10 ml of absolute ether and 8.14 ml (13 mmol) of a 1.6 normal methyl lithium solution and had been cooled to -78° C. The solution was stirred at -78° C. for 1 h and then allowed to warm to room temperature. It was subsequently diluted with 100 ml of ether and 100 ml of water, and the ether phase was washed with dilute citric acid and with sodium bicarbonate solution and dried over magnesium sulfate. The crude product was purified by chromatography on silica gel with cyclohexane/ethyl acetate mixtures to result in 250 mg (16%) of a pale yellow oil.

Example 9

2-Hydroxy-3-methoxy-3,3-diphenylpropionic Acid

91.11 g (0.5 mol) of benzophenone and 45.92 g (0.85 mol) of sodium methoxide were suspended in 150 ml of methyl tert-butyl ether (MTB) at room temperature. After cooling to -10° C., 92.24 g (0.85 mol) of methyl chloroacetate were added in such a way that the internal temperature rose to 40° C. while continuing to cool in a bath at -10° C. The mixture was then stirred without cooling at the autogenous temperature for one hour. After addition of 250 ml of water and brief stirring, the aqueous phase was separated off. The MTB phase was washed with 250 ml of dilute sodium chloride solution. After the solvent had been changed to methanol (250 ml), a solution of 1 g of p-toluenesulfonic acid in 10 ml of methanol was added at room temperature. The mixture was stirred at autogenous temperature for one hour and then heated to reflux. While distilling out the methanol, 400 g of a 10% strength sodium hydroxide solution was added dropwise, and finally 60 ml of water were added. The methanol was distilled out until the bottom temperature reached 97° C. After cooling to 55° C., 190 ml of MTB were added and the mixture was acidified to pH 2 with about 77 ml of concentrated HCl. After cooling to room temperature, the aqueous phase was separated off and the organic phase was concentrated by distilling out 60 ml of MtB [sic]. The product was crystallized by adding 500 ml of heptane and slowly cooling to room temperature. The coarsely crystalline solid was filtered off with suction, washed with heptane and dried to constant weight in a vacuum oven at 40° C.

Yield: 108.9 g (80%), HPLC>99.5% area.

Example 10

S-2-Hydroxy-3-methoxy-3,3-diphenylpropionic Acid (Racemate Resolution with L-proline Methyl Ester)

148.8 g of a 30% strength methanolic sodium methanolate solution (0.826 mol) were added dropwise to 240 g of a 57%

17

strength methanolic L-proline methyl ester hydrochloride solution (0.826 mol) at room temperature, and 2.4 l of MTB and 225 g (0.826 mol) of 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid were added. After 2680 ml of MTB/methanol mixture had been distilled out with simultaneous dropwise addition of 2.4 l of MTB, the mixture was slowly cooled to room temperature, the crystals (R-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid×L-proline methyl ester) were filtered off with suction, and the solid was washed with 150 ml of MTB. The filtrate was concentrated by distilling out 1.5 l of MTB, and 1.0 l of water was added. The pH was adjusted to 1.2 with concentrated hydrochloric acid at room temperature and, after stirring and phase separation, the aqueous phase was separated off and extracted with 0.4 l of MTB. The combined organic phases were extracted with 0.4 l of water. The residue after the MTB had been stripped off was dissolved in 650 ml of toluene under reflux, and the product was crystallized by seeding and slow cooling. Filtration with suction, washing with toluene and drying in a vacuum oven resulted in 78.7 g of S-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid (yield 35% based on the racemate).

Chiral HPLC: 100% pure HPLC: 99.8%

Example 11

S-2-Hydroxy-3-methoxy-3,3-diphenylpropionic Acid (Racemate Resolution with (S)-1-(4-nitrophenyl)ethylamine)

30.5 g (0.184 mol) of (S)-1-(4-nitrophenyl)ethylamine were added to 100 g (0.368 mol) of 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid in 750 ml of acetone and 750 ml of MTB under reflux, the mixture was seeded, boiled under reflux for one hour and slowly cooled to room temperature for crystallization. The crystals (S-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid x (S)-1-(4-nitrophenyl)ethylamine) were filtered off with suction and washed with MTB. The residue was suspended in 500 ml of water and 350 ml of MTB and then the pH was adjusted to 1.2 with concentrated hydrochloric acid at room temperature, and, after stirring and phase separation, the aqueous phase was separated off and extracted with 150 ml of MTB. The combined organic phases were extracted with 100 ml of water. 370 ml of MTB were distilled out and then 390 ml of n-heptane were added under reflux, and the mixture was slowly cooled to room temperature while the product crystallized. Filtration with suction, washing with n-heptane and drying in a vacuum oven resulted in 35.0 g of S-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid (yield 35% based on the racemate).

Chiral HPLC: 100% pure HPLC: 99.8%

Example 12

Benzyl 3-methoxy-2-(4-methoxy-6,7-dihydro-5H-cyclopentapyrimidin-2-yloxy)-3,3-diphenylpropionate

24.48 g (90 mmol) of 3-methoxy-3,3-diphenyl-2-hydroxypropionic acid were dissolved in 150 ml of DMF, and 13.7 g (99 mmol) of potassium carbonate were added. The suspension was stirred at room temperature for 30 min. Then 10.7 ml (90 mmol) of benzyl bromide were added dropwise over the course of 5 min, and the mixture was stirred for 1 h, during which the temperature rose to 32° C.

18

To this mixture were successively added 24.84 g (180 mmol) of K₂CO₃ and 20.52 g (90 mmol) of 2-methanesulfonyl-4-methoxy-6,7-dihydro-5H-cyclopentapyridine [sic], and the mixture was stirred at 80° C. for 3 h.

For workup, the contents of the flask were diluted with about 600 ml of H₂O and cautiously acidified with concentrated HCl, and 250 ml of ethyl acetate were added. 31.4 g of pure product precipitated and were filtered off.

The ethyl acetate phase was separated from the mother liquor, the aqueous phase was extracted again with ethyl acetate, and the combined organic phases were concentrated. The oily residue (19 g) was purified by chromatography (cyclohexane/ethyl acetate=9/1) to result in a further 10.5 g of pure product.

Total yield: 41.9 g (82.2 mmol)=91% Melting point 143–147° C. MS: MH⁺=511

Example 13

3-Methoxy-2-(4-methoxy-(6,7-dihydro-5H-cyclopentapyrimidin-2-yloxy)-3,3-diphenylpropionic [sic] Acid

40 g (78.4 mmol) of benzyl 3-methoxy-2-(4-methoxy-6,7-dihydro-5H-cyclopentapyrimidin-2-yloxy)-3,3-diphenylpropionate were dissolved in 400 ml of ethyl acetate/methanol (4:1), about 500 mg of palladium on active carbon (10%) were added, and the mixture was exposed to a hydrogen atmosphere until no further gas was taken up. The catalyst was filtered off, the solution was evaporated, and the residue was crystallized from ether.

Example 14

Ethyl 2S-3,3-diphenyloxirane-2-carboxylate

2.57 g (10.2 mmol) of ethyl 3,3-diphenylacrylate and 464 mg of 4-phenylpyridine N-oxide were dissolved in 24 ml of methylene chloride, and 432 mg (6.5 mol %) of (5,5-(+)-N,N'-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediaminomanganese(III) chloride were added. While cooling in ice, 6.4 ml of a 12% strength sodium hypochlorite [sic] solution were added, and the mixture was stirred while cooling in ice for 30 min and at room temperature overnight. The solution was diluted to 200 ml with water, extracted with ether, dried and evaporated. 2.85 g of a colorless oil were obtained. Purification by NPLC [sic] (cyclohexane: ethyl acetate=9:1) resulted in 1.12 g of oil with an enantiomer ratio of about 8:1 in favor of the S configuration.

¹H-NMR [CDCl₃], δ=1.0 (t, 3H); 3.9 (m, 3H); 7.3 (m, 10H)

Example 15

2-Methylsulfonyl-6,7-dihydro-5H-cyclopentapyrimidin-4-ol [sic]

46.9 g (330 mmol) of methyl cyclopentanone-2-carboxylate and 53.5 g (192 mmol) of 5-methylisothiurea [sic] sulfate were successively added to 29.6 g (528 mmol) of KOH in 396 ml of methanol, and the mixture was stirred at room temperature overnight, acidified with 1N hydrochloric acid and diluted with water. The crystals which separated out were filtered off with suction and dried. 20 g of crystals were obtained.

19

Example 16

Sulfanyl 4-Chloro-2-methyl-6,7-dihydro-5H-cyclopentapyrimidine [sic]

255 ml of phosphorus oxychloride were added to 20 g (110 mmol) [lacuna], and the mixture was stirred at 80° C. for 3 hours. Phosphorus oxychloride was evaporated off, ice was added to the residue, and the crystals which separated out were filtered off with suction. 18.5 g of a brownish solid were obtained.

Example 17

4-Methoxy-2-methylsulfonyl-6,7-dihydro-5H-cyclopentapyrimidine [sic]

18.05 g (90 mmol) of 4-chloro-2-methylsulfonyl-6,7-dihydro-5H-cyclopentapyrimidine [sic] were dissolved in 200 ml of methanol. At 45° C., 16.7 g of sodium methoxide (as 30% strength solutions [sic] in methanol) were added dropwise, and the mixture was stirred for 2 hours. The solution was evaporated, taken up in ethyl acetate and acidified with dilute hydrochloric acid, and the ethyl acetate extract was evaporated. 15.5 g of an oil remained.

¹H-NMR [DMSO], δ=2.1 (quintet, 2H); 2.5 (s, 3H); 2.8 (dt, 4H); 3.9 (s, 3H) ppm

Example 18

2-Methylsulfonyl-4-methoxy-6,7-dihydro-5H-cyclopentapyrimidine [sic]

15 g (76.2 mmol) of 4-methoxy-2-methylsulfonyl-6,7-dihydro-5H-cyclopentapyrimidine [sic] were dissolved in 160 ml of glacial acetic acid/methylene chloride (1:1), and 1.3 g of sodium tungstate were added. At 35° C., 17.5 ml (170 ml [sic]) of a 30% strength H₂O₂ solution were added dropwise. The mixture was then diluted with 500 ml of water and 100 ml of methylene chloride, and the organic phase was separated off, dried and evaporated. 14 g of oil remained and were crystallized from ether.

¹H-NMR [CDCl₃], δ=2.2 (quintet, 2H); 3.0 (dt., 4H); 3.3 (s, 3H); 4.1 (s, 3H) ppm

Example 19

1-Benzenesulfonyl-3-(4,6-dimethoxy-2-pyrimidinyl-4-methoxy-4,4-diphenyl-2-butanone

0.37 g (2.4 mmol) of phenyl methane [sic] sulfone were dissolved in 10 ml of dry THF and then, at -70° C., 2 eq. of butyllithium (2.94 ml; 1.6 molar solution in hexane) were added dropwise. After 1 h at -70° C., 1 g (2.4 mmol) of methyl 2-(4,6-dimethoxy-2-pyrimidinyl-3-methoxy-3,3-diphenylpropynoate [sic] dissolved in 5 ml of THF was added dropwise. The reaction mixture was then stirred at -70° C. for 1 h and at -10° C. for 1 h and then warmed to room temperature.

For workup, about 10 ml of saturated NH₄Cl solution were added dropwise, thorough extraction with ethyl acetate was carried out, and the combined organic phases [lacuna] with-saturated N-Cl [sic] solution and dried over Na₂SO₄. The residue obtained after drying and concentration was purified by chromatography on silica gel (n-heptane/ethyl acetate 15%→30%) and subsequently MPLC on RP silica

20

gel (acetonitrile/H₂O+TFA); 0.3 g of a white amorphous powder was obtained as product.

Example 20

3,3-Diphenyloxiram-2-carbonitrile [sic]

3.1 g (54.9 mmol) of sodium methoxide were suspended in 20 ml of dry THF and then, at -10° C., a mixture of 5 g (27.4 mmol) of benzophenone and 4.2 g (54.9 mmol) of chloroacetonitrile was added dropwise.

The reaction mixture was stirred at -10° C. for about 2 h, then poured into water and extracted several times with ethyl acetate. The combined organic phases were dried over Na₂SO₄ and concentrated, and the residue was purified by chromatography on silica gel (n-heptane/ethyl acetate).

Yield: 1.2 g (20%) ¹H-NMR [CDCl₃], δ=3.9 (s, 1H); 7.4-7.5 (m, 10 H) ppm

Example 21

2-Hydroxy-3-methoxy-3,3-diphenylpropionitrile

6.5 [lacuna] (29.4 mmol) of 3,3-diphenyloxirane-2-carbonitrile were dissolved in 60 ml of methanol and, at 0° C., about 2 ml of boron trifluoride etherate solution were added. The mixture was stirred further at 0° C. for 1 h and then at room temperature overnight. For workup it was diluted with diethyl ether and washed with saturated NaCl solution, and the organic phase was dried over Na₂SO₄ and concentrated. The residue comprised 7.3 g of a white amorphous powder which was used directly in the subsequent reactions.

¹H-NMR [CDCl₃], δ=2.95 (broad s, OH), 3.15 (s, 3H), 5.3 (s, 1H), 7.3-7.5 (m, 10) ppm

Example 22

2-(4,6-Dimethoxy-2-pyrimidinyl-3-methoxy-3,3-diphenylpropionitrile

7.3 g (28.8 mmol) of 2-hydroxy-3-methoxy-3,3-diphenylpropionitrile were dissolved in 90 ml of DMF, and 4 g (28.8 mmol) of K₂CO₃ and 6.3 g (28 mmol) of 2-methanesulfonyl-4,6-dimethoxypyrimidine were added. The mixture was stirred at room temperature for about 12 h, then poured into water and extracted with ethyl acetate. The combined organic phases were washed again with H₂O, dried and concentrated. The residue obtained in this way was then purified by chromatography on silica gel (n-heptane/ethyl acetate).

Yield: 6.9 g of white amorphous powder FAB-MS: 392 (M+H⁺) ¹H-NMR [CDCl₃], δ=3.3 (s, 3H); 4.95 (s, 6H), 5.85 (s, 1H); 6.3 (s, 1H); 7.3-7.5 (m, 10H) ppm

Example 23

5-[2-(4,6-Dimethoxy-2-pyrimidinyl-3-methoxy-3,3-diphenyl)propyl]-1H-tetrazole [sic]

0.5 g (1.3 mmol) of nitrile was dissolved in 10 ml of toluene, and 85 mg (1.3 mmol) of NaN₃ and 460 mg (1.4 mmol) of Bu₃SnCl were successively added, and then the mixture was refluxed for about 40 h. Cooling was followed by dilution with ethyl acetate and washing with 10% aqueous KF solution and with NaCl solution. After drying over

21

MgSO₄ and concentration there remained 1.0 g of a yellow oil, which was purified by chromatography on silica gel (n-heptane/ethyl acetate).

Concentration of the fractions resulted in 60 mg of the 1H-tetra-zole and 110 mg of the 1-methyltetrazole, each as amorphous white solids.

5-[2-(4,6-Dimethoxy-2-pyrimidinylloxy)-3-methoxy-3,3-diphenylpropyl]-1H-tetrazole [sic]

Electrospray-MS: 435 (M+H⁺) ¹H-NMR (CDCl₃): δ (ppm) 3.28 (s, 3H), 3.85 (s, 6H), 5.75 (s, 1H), 7.25–7.40 (m, 10H), 7.50 (s, 1H).

5-[2-(4,6-Dimethoxy-2-pyrimidinylloxy)-3-methoxy-3,3-diphenylpropyl]-1-methyltetrazole [sic]

Electrospray-MS; 471 (M+H⁺) ¹H-NMR (CDCl₃): δ (ppm) 3.0 (s, 3H), 3.35 (s, 3H) [sic], 3.80 (s, 6H), 5.75 (s, 1H), 7.30–7.40 (m, 11H).

Example 24

2-(4,6-Dimethoxy-2-pyrimidinylloxy)-3-methylsulfonyl-3,3-diphenylpropionic Acid

1.2 g (2.9 mmol) of 2-(4,6-dimethoxy-2-pyrimidinylloxy)-3-methylsulfonyl-3,3-diphenylpropionic [sic] acid were

22

introduced into 15 ml of glacial acetic acid at 0° C. and 294 μl of 30% strength H₂O₂ were added dropwise. The mixture was stirred at room temperature overnight, poured into water, extracted with CH₂Cl₂ and washed with sodium thiosulfate solution and brine. After drying, 1 g of substance was isolated as a white foam.

Example 25

2-(4,6-Dimethoxy-2-pyrimidinylloxy)-3-methylsulfonyl-3,3-diphenylpropionic Acid


0.6 g (1.45 mmol) of 2-(4,6-dimethoxy-2-pyrimidinylloxy)-3-methylsulfonyl-3,3-diphenylpropionic [sic] acid was introduced into 15 ml of glacial acetic acid at room temperature, and 294 μl of 30% strength H₂O₂ were added dropwise. The mixture was stirred at room temperature overnight, heated at 50° C. for a further 3 h, poured into water and washed with sodium thiosulfate solution and brine. After drying, 400 mg were isolated as a white solid.

The compounds listed in Table 1 [sic] can be prepared in a similar way.

TABLE I


No.	R ¹	R ⁴ , R ⁵	R ⁶	R ²	R ³	X	Y	Z	m. p. [° C.]
I-195	OMe	Phenyl	Methyl	OMe	OMe	CH	O	O	81
I-196	OH	Phenyl	Methyl	OMe	OMe	CH	O	O	167
I-197	OH	Phenyl	CH ₂ —CH ₂ —S—CH ₃	OMe	OMe	CH	O	O	
I-198	OH	Phenyl	Ethyl	OMe	OMe	CH	O	O	81 (decomp.)
I-199	OH	Phenyl	iso-Propyl	OMe	OMe	CH	O	O	182
I-200	OH	Phenyl	Methyl	OMe	OMe	CH	O	S	168
I-201	OH	Phenyl	CH ₂ —CH ₂ —SO ₂ — CH(CH ₃) ₂	OMe	OMe	CH	O	O	
I-202	OH	Phenyl	CH ₂ —CH ₂ —SO ₂ — CH(CH ₃) ₂	OMe	OMe	CH	S	O	
I-203	OH	Phenyl	CH ₂ —CH ₂ —SO ₂ — CH(CH ₃) ₂	OMe	OMe	C—CH(CH ₃) ₂	O	O	
I-204	OH	Phenyl	CH ₂ —CH ₂ —SO ₂ — CH(CH ₃) ₂	OMe	OMe	C—CH(CH ₃) ₃	O	O	
I-205	OH	Phenyl	CH ₂ —CH ₂ —SO ₂ — CH(CH ₃) ₂	OMe	NH-OCH ₃	CH	O	O	
I-206	OH	Phenyl	n-Propyl	OMe	OMe	CH	O	O	174
I-207	OMe	Phenyl	n-Propyl	OMe	OMe	CH	O	O	
I-208	OH	Phenyl	n-Prmpyl	OMe	OMe	CH	O	O	
I-209	OH	Phenyl	n-Butyl	OMe	OMe	CH	O	O	
I-210	OH	Phenyl	iso-Butyl	OMe	OMe	CH	O	O	
I-211	OH	Phenyl	iso-Butyl	OMe	OMe	O—CH ₂ —CH ₂ —C	O	O	
I-212	OH	Phenyl	tert.-Butyl	OMe	OMe	CH	O	O	
I-213	OH	Phenyl	Cyclopropyl	OMe	OMe	CH	O	O	
I-214	OH	Phenyl	Cyclopentyl	OMe	OMe	CH	O	O	
I-215	OH	Phenyl	Cyclohexyl	OMe	OMe	CH	O	O	
I-216	OH	Phenyl	(CH ₃) ₃ C—CH ₂ —CH ₂	OMe	OMe	CH	O	O	
I-217	OH	Phenyl	(CH ₃) ₂ CH—CH ₂ —CH ₂ — CH ₂	OMe	OMe	CH	O	O	173
I-218	OH	Phenyl	HO—CH ₂ —CH ₂	OMe	OMe	CH	O	O	
I-219	OH	Phenyl	HO ₂ C—(CH ₂) ₂ —	OMe	OMe	CH	O	O	
I-220	OH	Phenyl	Cyclopropylmethylene [sic]	OMe	OMe	CH	O	O	115
I-221	OH	Phenyl	H	OMe	OMe	CH	O	O	

TABLE I-continued




No.	R ¹	R ⁴ , R ⁵	R ⁶	R ²	R ³	X	Y	Z	m. p. [° C.]
I-222	OH	Phenyl	Methyl	OMe	OMe	CH	O	—	136
I-223	OH	Phenyl	Phenyl	OMe	OMe	CH	O	O	
I-224	OH	Phenyl	Phenyl	OMe	OMe	O—CH(CH ₃)—CH ₂ —C	O	O	
I-225	OMe	Phenyl	Phenyl	OMe	OMe	CH	O	O	
I-226	OH	Phenyl	4-Isopropyl-Phenyl	OMe	OMe	CH	O	O	
I-227	OH	Phenyl	4-Me-S-Phenyl	OMe	OMe	CH	O	O	
I-228	OH	Phenyl	4-Me-O-Phenyl	OMe	OMe	CH	O	O	
I-229	OH	Phenyl	3-Et-Phenyl	OMe	OMe	CH	O	O	
I-230	OH	Phenyl	2-Me-Phenyl	OMe	OMe	CH	O	O	
I-231	OH	Phenyl	2-Cl-Phenyl	OMe	OMe	CH	O	O	
I-232	OH	Phenyl	3-Br-Phenyl	OMe	OMe	CH	O	O	
I-233	OH	Phenyl	4-F-Phenyl	OMe	OMe	CH	O	O	
I-234	OH	Phenyl	4-F-Phenyl	OMe	OMe	CH	S	O	
I-235	OH	Phenyl	4-CH ₃ -Phenyl	OMe	OMe	CH	O	O	
I-236	OH	Phenyl	3-NO ₂ -Phenyl	OMe	OMe	CH	O	O	
I-237	OH	Phenyl	2-HO-Phenyl	OMe	OMe	CH	O	O	
I-238	OH	Phenyl	3,4-Dimethoxyphenyl	OMe	OMe	CH	O	O	
I-239	OH	Phenyl	3,4-Dioxomethylenephenyl [sic]	OMe	OMe	CH	O	O	
I-240	OH	Phenyl	3,4,5-Trimethoxyphenyl	OMe	OMe	CH	O	O	163–165 (decomp.)
I-241	OH	Phenyl	Benzyl	OMe	OMe	CH	O	O	
I-242	OH	Phenyl	2-Cl-Benzyl	OMe	OMe	CH	O	O	
I-243	OH	Phenyl	3-Br-Benzyl	OMe	OMe	CH	O	O	
I-244	OH	Phenyl	4-F-Benzyl	OMe	OMe	CH	O	O	
I-245	OH	Phenyl	2-Me-Benzyl	OMe	OMe	CH	O	O	
I-246	OH	Phenyl	2-Me-Benzyl	OMe	OMe	O—CH=CH—C	O	O	
I-247	OH	Phenyl	3-Et-Benzyl	OMe	OMe	CH	O	O	
I-248	OH	Phenyl	4-iso-Propyl-Benzyl	OMe	OMe	CH	O	O	
I-249	OH	Phenyl	4-NO ₂ -Propyl-Benzyl	OMe	OMe	CH	O	O	
I-250	OH	Phenyl	2-Me-5-Propyl-Benzyl	OMe	OMe	CH	O	O	
I-251	OH	Phenyl	2-Me-5-Propyl-Benzyl	OEt	OEt	CH	O	O	
I-252	OH	Phenyl	4-Me-2-Propyl-Benzyl	OMe	OMe	CH	O	O	
I-253	OH	Phenyl	3,4-Dioxomethylenebenzyl [sic]	OMe	OMe	CH	O	O	
I-254	OH	4-F-Phenyl	Methyl	OMe	OMe	CH	O	O	
I-255	OMe	4-F-Phenyl	Methyl	OEt	OEt	CH	O	O	193–194 (decomp.)
I-256	OH	4-Cl-Phenyl	Methyl	OMe	OMe	CH	O	O	
I-257	OH	4-Me-O-Phenyl	Methyl	OMe	OMe	CH	O	O	
I-258	OH	4-Me-O-Phenyl	Ethyl	OMe	OMe	CH	O	O	
I-259	OH	4-Me-Phenyl	Methyl	OMe	OMe	CH	O	O	
I-260	OH	4-Me-Phenyl	Methyl	OMe	OMe	O—CH ₂ —CH ₂ —C	O	O	
I-261	OH	3-CF ₃ -Phenyl	n-Propyl	OMe	OMe	CH	O	O	
I-262	OH	3-CF ₃ -Phenyl	n-Propyl	OMe	OMe	O—CH(CH ₃)—CH ₂ —C	O	O	
I-263	OH	4-NO ₂ -Phenyl	Methyl	OMe	OMe	CH	O	O	
I-264	OH	4-NO ₂ -Phenyl	Methyl	OMe	OMe	O—CH=CH—C	O	O	
I-265	OH	3-Cl-Phenyl	Ethyl	OMe	OMe	CH	O	O	
I-266	OH	2-F-Phenyl	Methyl	OMe	OMe	CH	O	O	
I-267	OH	2-F-Phenyl	Methyl	OMe	OMe	CH	O	O	
I-268	OH	2-Me-O-Phenyl	Methyl	OMe	OMe	CH	O	O	
I-269	OH	2-Me-O-Phenyl	Methyl	OMe	OMe	CH	O	O	
I-270	OH	3,4-Dimethoxyphenyl	Methyl	OMe	OMe	CH	O	O	
I-271	OH	3,4-Dioxomethylenephenyl [sic]	Methyl	OMe	OMe	CH	O	O	
I-272	OH	p-CF ₃ -Phenyl	Methyl	OMe	OMe	CH	O	O	
I-273	OH	Phenyl	Methyl	OMe	OEt	CH	O	O	
I-274	OMe	Phenyl	Methyl	OMe	OEt	CH	S	O	
I-275	OH	Phenyl	Ethyl	OMe	NH-OMe	CH	O	O	
I-276	OH	p-Me-O-Phenyl	n-Propyl	OMe	OCF ₃	CH	O	O	
I-277	OH	Phenyl	Methyl	OMe	CF ₃	CH	O	O	
I-278	OH	Phenyl	Methyl	OMe	CF ₃	N	O	O	
I-279	OH	3,4-Dimethoxyphenyl	Benzyl	Me	Me		O	O	

TABLE I-continued




No.	R ¹	R ⁴ , R ⁵	R ⁶	R ²	R ³	X	Y	Z	m. p. [° C.]
I-280	OH	3,4-Dimethoxyphenyl	Methyl	OMe		O—CH ₂ —CH ₂ —C	O	O	
I-281	OH	Phenyl	Methyl	OMe		O—CH ₂ —CH ₂ —C	O	O	126 (decomp.)
I-282	OH	Phenyl	Methyl	OMe		O—CH(CH ₃)—CH ₂ —C	O	O	
I-283	OH	Phenyl	Methyl	OMe		N(CH ₃)—CH=CH—C	O	O	118
I-284	OH	Phenyl	Methyl	OMe		S—C(CH ₃)=C(CH ₃)—C	O	O	
I-285	OH	Phenyl	Methyl	OMe		O—C(CH ₃)=CH—C	O	O	
I-286	OH	Phenyl	Methyl	Me		O—C(CH ₃)=CH—C	O	O	
I-287	OH	Phenyl	Methyl	Me		O—CH=CH—C	O	O	
I-288	OH	4-F-phenyl	Methyl	Me		S—CH=CH—C	O	O	
I-289	OH	4-F-phenyl	H	OMe	OMe	CH	O	O	
I-290	OH	Phenyl	Methyl	OMe		CH ₂ —CH ₂ —CH ₂ —C	O	O	149–151 (decomp.)
I-291	OH	Phenyl	Methyl	Methyl		CH ₂ —CH ₂ —CH ₂ —C	O	O	157 (decomp.)
I-292	OH	Phenyl	Methyl	Ethyl		CH ₂ —CH ₂ —CH ₂ —C	O	O	
I-293	OH	Phenyl	Methyl	OMe		CH ₂ —CH ₂ —CH ₂ —C	O	O	
I-294	OH	Phenyl	Methyl	Me	Me	CH	O	O	
I-295	OH	Phenyl	Methyl	Et	Et	CH	O	O	
I-296	OH	Phenyl	Methyl	Me	Me	C—CH ₃	O	O	
I-297	OH	Phenyl	Methyl	OMe	Me	CH	O	O	
I-298	OH	Cyclohexyl	Methyl	OMe	OMe	CH	O	O	
I-299	OH	Cyclohexyl	Methyl	OMe		CH ₂ —CH ₂ —CH ₂ —C	O	O	
I-300	OH	Phenyl	Methyl	OCH ₃	OCH ₃	CH	S	S	
I-301	OH	Phenyl	Methyl	OCH ₃	OCH ₃	CH	O	S	134
I-302	OCH ₃	Phenyl	Methyl	OCH ₃	OCH ₃	CH	S	S	
I-303	OH	Phenyl	Methyl	OCH ₃	OCH ₃	CH	O	O	
I-304	OCH ₃	2-Fluorophenyl	Methyl	OCH ₃	OCH ₃	CH	O	O	
I-305	OC ₂ H ₅	3-Chlorophenyl	Methyl	OCH ₃	OCH ₃	N	O	O	
I-306	ON(CH ₃) ₂	4-Bromophenyl	Methyl	CF ₃	CF ₃	CH	S	O	
I-307	O—CH ₂ —C=CH	Phenyl	Ethyl	OCH ₃	CF ₃	CH	O	O	
I-308	OH	Phenyl	Propyl	OCH ₃	OCF ₃	CH	O	S	
I-309	OCH ₃	Phenyl	i-Propyl	OCH ₃	CH ₃	CH	O	O	
I-310	OC ₂ H ₅	Phenyl	s-Butyl	OCH ₃	Cl	CH	S	O	
I-311	ON(CH ₃) ₂	2-Methylphenyl	Methyl	OCH ₃	OCH ₃	CH	O	O	
I-312	ON(CH ₃) ₂	3-Methoxyphenyl	Methyl	OCH ₃	OCH ₃	CH	O	O	
I-313	ON=C(CH ₃) ₂	4-Nitrophenyl	Methyl	OCH ₃	OCH ₃	CH	O	O	
I-314	ON(CH ₃) ₂	Phenyl	1-Phenylpropyn-3-yl	OCH ₃	OCF ₃	N	O	S	
I-315	ON=C(CH ₃) ₂	2-Hydroxyphenyl	Methyl	OCH ₃	CH ₃	N	O	O	
I-316	ONSO ₂ C ₆ H ₅	3-Trifluoromethylphenyl	Methyl	OCH ₃	Cl	N	O	O	
I-317	NHPhenyl	4-Dimethylaminophenyl	Methyl	OCH ₃	OCH ₃	CH	S	O	
I-318	OC ₂ H ₅	Phenyl	Trifluoroethyl	CH ₃	CH ₃	CH	O	O	
I-319	ON(CH ₃) ₂	Phenyl	Benzyl	Cl	Cl	CH	O	O	
I-320	ON(CH ₃) ₂	Phenyl	2-Methoxyethyl	OCH ₃		—O—CH ₂ —CH ₂ —	S	O	
I-321	OH	Phenyl	Phenyl	OCH ₃	OCH ₃	CH	O	O	
I-322	OH	Phenyl	Phenyl	OCH ₃		—O—CH ₂ —CH ₂ —	O	O	
I-323	OH	Phenyl	Phenyl	OCH ₃	OCH ₃	N	O	O	
I-324	OH	Phenyl	Phenyl	OCH ₃	OCH ₃	CH	S	O	
I-325	OH	Phenyl	Phenyl	OCH ₃	OCH ₃	CH	S	S	
I-326	OH	Phenyl	Phenyl	OCH ₃	OCH ₃	CH	O	O	
I-327	OH	Phenyl	Phenyl	OCH ₃	OCH ₃	CH	O	O	
I-328	OH	Phenyl	Phenyl	OCH ₃	OCH ₃	CH	O	O	
I-329	OH	—(CH ₂) ₅ —	Phenyl	Phenyl	OCH ₃	CH	O	O	
I-330	OH	Phenyl	2-Thiazolyl	OCH ₃	OCH ₃	CH	O	O	
I-331	OCH ₃	2-Fluorophenyl	Phenyl	OCH ₃	OCH ₃	CH	O	O	
I-332	OC ₂ H ₅	3-Chlorophenyl	Phenyl	OCH ₃	OCH ₃	N	O	O	
I-333	ON(CH ₃) ₂	4-Bromophenyl	Phenyl	CF ₃	CF ₃	CH	O	O	
I-334	O—CH ₂ ≡CH	Phenyl	2-Fluorophenyl	OCH ₃	CF ₃	CH	O	O	
I-335	OH	Phenyl	3-Chlorophenyl	OCH ₃	OCF ₃	CH	O	S	
I-336	OCH ₃	Phenyl	4-Bromophenyl	OCH ₃	CH ₃	CH	O	O	
I-337	OC ₂ H ₅	Phenyl	4-Thiazolyl	OCH ₃	Cl	CH	S	O	
I-338	ON(CH ₃) ₂	2-Methylphenyl	Phenyl	OCH ₃	OCH ₃	CH	O	O	
I-339	ON=C(CH ₃) ₂	3-Methoxyphenyl	Phenyl	OCH ₃	OCH ₃	CH	O	O	

TABLE I-continued



No.	R ¹	R ⁴ , R ⁵	R ⁶	R ²	R ³	X	Y	Z	m. p. [° C.]
I-340	OH	Phenyl	Methyl	OCH ₃		—CH ₂ —CH ₂ —CH ₂ —C	O	O	168 (decomp.)
I-341	OH	4-Fluorophenyl	Methyl	OCH ₃	OCH ₃	CH	O	O	
I-342	OH	4-Fluorophenyl	Methyl	OCH ₃		—CH ₂ —CH ₂ —CH ₂ —C	O	O	
I-343	NH—SO—C ₆ H ₅	4-Nitrophenyl	Phenyl	OCH ₃	OCH ₃	CH	O	O	168 (decomp.)
I-344	OCH ₃	Phenyl	3-Imidazolyl	OCH ₃		—O—CH ₂ —CH ₂ —	O	O	
I-345	OC ₂ H ₅	Phenyl	4-Imidazolyl	OCH ₃	CF ₃	N	S	O	
I-346	ON(CH ₃) ₂	Phenyl	2-Pyrazolyl	OCH ₃	OCF ₃	N	O	S	168 (decomp.)
I-347	ON=C(CH ₃) ₂	2-Hydroxyphenyl	Phenyl	OCH ₃	N	O	O	O	
I-348	NH—SO ₂ —C ₆ H ₅	3-Trifluoromethylphenyl	Phenyl	OCH ₃	Cl	N	O	O	
I-349	NHPhenyl	4-Dimethylaminophenyl	Phenyl	OCH ₃	OCH ₃	CH	S	O	168 (decomp.)
I-350	ONa	Phenyl	Phenyl	OCH ₃	OCH ₃	CH	S	S	
I-351	O—CH ₂ —C≡C	Phenyl	Phenyl	OCH ₃	OCH ₃	N	S	S	
I-352	OH	Phenyl	Phenyl	CF ₃	CF ₃	CH	O	S	168 (decomp.)
I-353	OCH ₃	Phenyl	Phenyl	OCF ₃	OCF ₃	CH	O	O	
I-354	OC ₂ H ₅	Phenyl	2-Dimethylaminophenyl	CH ₃	CH ₃	CH	O	O	
I-355	ON(CH ₃) ₂	Phenyl	3-Hydroxyphenyl	Cl	Cl	CH	O	O	168 (decomp.)
I-356	ON=C(CH ₃) ₂	Phenyl	4-Trifluoromethylphenyl	OCH ₃		—O—CH ₂ —CH ₂ —	S	O	
I-357	NH—SO ₂ —C ₆ H ₅	Phenyl	2-Oxazolyl	OCH ₃	CF ₃	N	S	S	
I-358	OH	Phenyl	Methyl	CH ₃	CH ₃	CH	O	O	168 (decomp.)
I-359	OH	Cyclohexyl	Methyl	OCH ₃	OCH ₃	CH	O	O	
I-360	OH	Cyclohexyl	Methyl	OCH ₃		CH ₂ —CH ₂ —CH—C	O	O	
I-361	OH	Phenyl	Methyl	N(CH ₃) ₂	N(CH ₃) ₂	CH	O	O	168 (decomp.)
I-362	OH	Phenyl	Methyl	OCH ₃	OCH ₃	CH	O	SO ₂	
I-363	OH	Phenyl	Methyl	OCH ₃	OCH ₃	CH	O	SO ₂	
I-364	OH	3-F-Phenyl	Me	OMe	OMe	CH	O	O	168 (decomp.)
I-365	OH	3-F-Phenyl	Me	OMe		CH ₂ —CH ₂ —CH ₂ —C	O	O	
I-366	OH	4-F-Phenyl	Me	OMe		CH ₂ —CH ₂ —CH ₂ —C	O	O	
I-367	OH	3-MeO-Phenyl	Me	OMe		CH ₂ —CH ₂ —CH ₂ —C	O	O	142–143 191° C. 158–161 (decomp.)
I-368	OH	3-MeO-Phenyl	Me	OMe	OMe	CH	O	O	168 (decomp.)
I-369	OH	3-MeO-Phenyl	Et	OMe		CH ₂ —CH ₂ —CH ₂ —C	O	O	
I-370	OH	Phenyl	HO—CH ₂ —CH ₂	OMe		CH ₂ —CH ₂ —CH ₂ —C	O	O	
I-371	OH	Phenyl	Me	NMe ₂	NMe ₂	N	O	O	181
I-372	OH	Phenyl	Me	OMe	OMe	N	O	O	
I-373	OH								
I-374	NH—SO ₂ -Phenyl	Phenyl	Me	OMe	OMe	CH	O	O	167
I-375	NH—SO ₂ -Me	Phenyl	Me	OMe	OMe	CH	O	O	
I-376	CH ₂ —SO ₂ -Phenyl	Phenyl	Me	OMe	OMe	CH	O	O	
I-377	CH ₂ —SO ₂ -Me	Phenyl	Me	OMe	OMe	CH	O	O	167
I-378	—CN	Phenyl	Me	OMe	OMe	CH	O	O	
I-379	Tetrazole [sic]	Phenyl	Me	OMe	OMe	CH	O	O	
I-380	NH—SO ₂ -Phenyl	Phenyl	Me	OMe	OMe	CH	O	O	167
I-381	N-Methyltetrazole [sic]	Phenyl	Me	OMe	Me	CH	O	O	
I-382	ONa	Phenyl	Me	OMe		—O—CH ₂ —CH ₂ —C—	O	O	
I-383	OH	o-F-Phenyl	Me	OMe		—O—CH ₂ —CH ₂ —C—	O	O	122–139 (zers.) 140–144 (decomp.)
I-384	OH	m-Me-Phenyl	Me	OMe	OMe	CH	O	O	169–177 119–135 (decomp.)
I-385	OH	m-Me-Phenyl	Me	OMe		—O—CH ₂ —CH ₂ —C—	O	O	
I-386	OH	p-F-Phenyl	Me	OMe	Me	CH	O	O	
I-387	OH	m-F-Phenyl	Me	Me		—O—CH ₂ —CH ₂ —C—	O	O	137–140 (decomp.)
I-388	OH	p-F-Phenyl	Me	Me		—O—CH ₂ —CH ₂ —C—	O	O	150–152 169–170

TABLE II



No.	R ¹	A	R ⁶	R ²	R ³	X	Y	Z	m. p. [° C.]
II-1	OH	Bond	Methyl	OMe	OMe	CH	O	O	96-98
II-2	OH	CH ₂	Methyl	OMe	OMe	CH	O	O	
II-3	OH	CH ₂ -CH ₂	Methyl	OMe	OMe	CH	O	O	
II-4	OH	CH=CH	Methyl	OMe	OMe	CH	O	O	
II-5	OH	O	Methyl	OMe	OMe	CH	O	O	
II-6	OH	S	Methyl	OMe	OMe	CH	O	O	
II-7	OH	NH(CH ₃)	Methyl	OMe	OMe	CH	O	O	
II-8	OH	Bond	Isopropyl	OMe	OMe	CH	O	O	137-139
II-9	OH	Bond	p-Isopropylphenyl	OMe	OMe	CH	O	O	
II-10	OH	Bond	Benzyl	OMe	OMe	CH	O	O	
II-11	OH	CH=CH	Ethyl	OMe	OMe	CH	O	O	
II-12	OH	CH=CH	(CH ₃) ₂ -CH ₂ -CH ₂	OMe	OMe	CH	O	O	
II-13	OH	CH=CH	Cyclopropylmethylene [sic]	OMe	OMe	CH	O	O	
II-14	OH	CH=CH	Methyl	OMe	O-CH ₂ -CH ₂ -C	O	O	O	
II-15	OH	CH ₂ -CH ₂	Ethyl	OMe	O-CH=CH-C	O	O	O	
II-16	OH	CH ₂ =CH ₂	Methyl	OMe	CH ₂ -CH ₂ -CH ₂ -C	O	O	O	
II-17	OH	Bond	Methyl	OMe	CH ₂ -CH ₂ -CH ₂ -C	O	O	O	147

Example 35

Receptor binding data were measured by the binding assay described above for the compounds listed below.

The results are shown in Table 2 [sic].


TABLE 2[sic]

Receptor binding data (K _i values)		
Compound	ET _A [nM]	ET _B [nM]
I-2	6	34
I-29	86	180
I-5	12	160
I-4	7	2500
I-87	1	57
I-89	86	9300
I-103	0.4	29
I-107	3	485
I-12	19	1700
I-26	23	2000
I-23	209	1100
I-47	150	1500
I-60	33	970
I-96	0.6	56
II-3	107	7300
II-1	28	2300

30

We claim:

1. A compound having the formula:



40

wherein:

X is CH;

Y is oxygen;

Z is oxygen;

R is CO₂H;

R² is methyl;

50 R³ is methyl;

R⁴ is phenyl;

R⁵ is phenyl; and

R⁶ is methyl,

or a pharmaceutically acceptable salt thereof.

55 2. The compound of claim 1, wherein said compound is an optically active enantiomer.

3. The compound of claim 2, wherein the enantiomer is the S enantiomer.


60 4. The compound of claim 3, wherein the enantiomer is the pure form of the S enantiomer.

5. The compound of claim 2, wherein the enantiomer is the R enantiomer.

65 6. The compound of claim 5, wherein the enantiomer is the pure form of the R enantiomer.

7. A pharmaceutical composition comprising a compound having the formula:

31



wherein:

X is CH;
Y is oxygen;
Z is oxygen;
R is CO₂H;
R² is methyl;
R³ is methyl;
R⁴ is phenyl;
R⁵ is phenyl;
R⁶ is methyl; or a

pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

8. The composition of claim 7, wherein said composition is suitable for oral, parenteral, or nasopharyngeal delivery.

9. The composition of claim 7, wherein the composition is in a solid form.

10. The composition of claim 7, wherein the composition is in a liquid form.

11. The composition of claim 7, wherein the composition is in the form of a tablet, capsule, powder, granule, suppository, solution, colloid, ointment, cream, vapor or spray.

32

12. The composition of claim 7, wherein the carrier comprises a tablet binder, filler, preservative, tablet disintegrant, flow regulator, plasticizer, wetting agent, dispersant, emulsifier, solvent, release-slowing agent, antioxidant, or propellant gas.

13. The composition of claim 7, wherein the compound is an optically active enantiomer.


14. The composition of claim 13, wherein the enantiomer is the S enantiomer.

15. The composition of claim 14, wherein the enantiomer is the pure form of the S enantiomer.

16. The composition of claim 13, wherein the enantiomer is the R enantiomer.

17. The composition of claim 16, wherein the enantiomer is the pure form of the R enantiomer.

18. The compound



* * * * *

EXHIBIT G



**TERMINAL DISCLAIMER TO OBTAIN A DOUBLE PATENTING
REJECTION OVER A "PRIOR" PATENT**

Docket No.:
ABB10010P0114US

Applicant(s): Relchiers et al.

Confirmation No.:

Serial No.: 10/602,275

Filing Date: June 24, 2003

Group Art Unit: 1624

Examiner: Bruck Kifle

Invention: Novel Carboxylic Acid Derivatives, Their Preparation And Use

The owner, Abbott GmbH & Co. KG, of 100% (one hundred percent) interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term prior patent No. 5,932,730 as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later:

- expires for failure to pay a maintenance fee;
- is held unenforceable;
- is found invalid by a court of competent jurisdiction;
- is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;
- has all claims canceled by a reexamination certificate;
- is reissued; or
- is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2, if appropriate.

1. ☐ For submission on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney of record.*

☒ Terminal Disclaimer fee under 37 CFR 1.20(d) is enclosed in the amount of: ☒ \$130.00 (large entity)
☐ \$ 65.00 (small entity)

☐ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account Number 23-0785. A duplicate copy of this sheet is enclosed.

8/24/05

Date

Martin L. Katz, Reg. No. 25,011

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER
Citigroup Center, Suite 3800
500 West Madison Street
Chicago, Illinois 60661-2511
312/876-1800

* Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP §324.

08/26/2005 CHGUYH2 00000016 10602275

03 FC:1814

130.00 0P

U.S.S.N. 10/602,275

Page 1 of 2

AUG 24 2005

TERMINAL DISCLAIMER TO OBTAIN A DOUBLE PATENTING
REJECTION OVER A "PRIOR" PATENTDocket No.:
ABB10010P0114US

Applicant(s): Reichers et al.

Confirmation No.:

Serial No.: 10/602,275

Filing Date: June 24, 2003

Group Art Unit: 1624

Examiner: Bruck Kifle

Invention: Novel Carboxylic Acid Derivatives, Their Preparation And Use

The owner*, Abbott GmbH & Co. KG, of 100% (one hundred percent) interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term prior patent No. 6,197,958 as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later:

- expires for failure to pay a maintenance fee;
- is held unenforceable;
- is found invalid by a court of competent jurisdiction;
- is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;
- has all claims canceled by a reexamination certificate;
- is reissued; or
- is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2, if appropriate.

1. ☐ For submission on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney of record.*

☒ Terminal Disclaimer fee under 37 CFR 1.20(d) is enclosed in the amount of: ☒ \$130.00 (large entity)
☐ \$ 65.00 (small entity)

☐ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account Number 23-0785. A duplicate copy of this sheet is enclosed.

8/24/05

Date

Martin L. Katz, Reg. No. 25,011

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER
Citigroup Center, Suite 3800
500 West Madison Street
Chicago, Illinois 60661-2511
312/876-1800

* Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP §324.

08/26/2005 LRGUYER2 00000016 10602275

04 FC:1814

130.00 DP

U.S.S.N. 10/602,275

Page 1 of 2

AUG 24 2005

PATENT & TRADEMARK OFFICE
**TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING
REJECTION OVER A "PRIOR" PATENT**Docket No.:
ABB10010P0114US

Applicant(s): Reichers et al.

Confirmation No.:

Serial No.: 10/602,275

Filing Date: June 24, 2003

Group Art Unit: 1624

Examiner: Bruck Kifle

Invention: Novel Carboxylic Acid Derivatives, Their Preparation And Use

The owner, Abbott GmbH & Co. KG, of 100% (one hundred percent) interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term prior patent No. 6,600,043 as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later:

expires for failure to pay a maintenance fee;

is held unenforceable;

is found invalid by a court of competent jurisdiction;

is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;

has all claims canceled by a reexamination certificate;

is reissued; or

is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2, if appropriate.

1. ☐ For submission on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney of record.*

☒ Terminal Disclaimer fee under 37 CFR 1.20(d) is enclosed in the amount of: ☒ \$130.00 (large entity)☐ \$ 65.00 (small entity)☐ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account Number 23-0785. A duplicate copy of this sheet is enclosed.

8/24/05

Date


Martin L. Katz, Reg. No. 25,019

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER
Citigroup Center, Suite 3800
500 West Madison Street
Chicago, Illinois 60661-2511
312/878-1800

* Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner) Form PTO/SB/96 may be used for making this certification. See MPEP §324.

08/26/2005 CNGUYEN2 00000016 10602275

05 FC:1814

130.00 OP

U.S.S.N. 10/602,275

Page 1 of 2

[Return To:](#)[USPTO
Home
Page](#)[Finance
Online
Shopping
Page](#)

**United States
Patent and
Trademark Office**

Maintenance Fees Window Dates**07/30/2007 10:42 AM EDT****Patent Number: 7109205****Application Number: 10602275**

	4th Year	8th Year	12th Year
Open Date	09/21/2009	09/19/2013	09/19/2017
Surcharge Date	03/22/2010	03/20/2014	03/20/2018
Close Date	09/20/2010	09/19/2014	09/19/2018

[Need Help?](#) | [USPTO Home Page](#) | [Finance Online Shopping Page](#)

Return To:**USPTO
Home
Page**
**United States
Patent and
Trademark Office**
**Finance
Online
Shopping
Page**

Patent Maintenance Fees		07/30/2007 10:43 AM EDT	
Patent Number:	7109205	Application Number:	10602275
Issue Date:	09/19/2006	Filing Date:	06/24/2003
Window Opens:	09/21/2009	Surcharge Date:	03/22/2010
Window Closes:	09/20/2010	Payment Year:	
Entity Status:	LARGE		
Customer Number:	000000		
Street Address:	WOOD, PHILLIPS, KATZ, CLARK & MORTIMER		
City:	CHICAGO		
State:	IL		
Zip Code:	60661		
Phone Number:	(312) 876-1800		
Currently there are no fees due.			

[Need Help?](#) | [USPTO Home Page](#) | [Finance Online Shopping Page](#)

EXHIBIT H

 QUINTILES

Quintiles, Inc.
Post Office Box 9708
Kansas City, MO 64134-0708
(816) 767-6000

June 3, 2002

Central Document Room
Center for Drug Evaluation and Research
Food and Drug Administration
12229 Wilkins Avenue
Rockville, MD 20852

Subject: **Investigational New Drug Application** **Serial No. 000**
 BSF 208075 for Pulmonary Arterial Hypertension **(Initial Submission)**

Dear Sir or Madam:

On behalf of Myogen, Inc., Quintiles, Inc. is submitting with this correspondence an initial Investigational New Drug Application (IND) for a new chemical entity, BSF 208075, an ETA selective endothelin receptor antagonist, being investigated in patients with pulmonary arterial hypertension. In accordance with 21 CFR Part 312 this thirty volume IND is submitted in triplicate.


To aid in the evaluation of the application, Section 10 of this IND contains additional information regarding communication with the Division of Cardio-Renal Drug Products that took place previously under IND 63,412. This includes a summary of the actions taken by Myogen in response to the Division's recommendations and copies of correspondence and meeting minutes that discussed the investigation of BSF 208075 for the indication of pulmonary arterial hypertension. In addition, Section 11 of this IND contains a copy of the informed consent form for protocol AMB-220, which is submitted in Section 6.

Also, please find enclosed for submission a letter from Myogen, Inc. transferring the responsibility as US Agent and Authorized Representative to Quintiles, Inc.; a letter from Quintiles accepting the transfer of responsibility; and an official Transfer of US Regulatory Obligations form delineating the duties being transferred.


Any questions concerning this Investigational New Drug Application should be directed to:

Marguerite Enlow, Pharm.D., RAC
Associate Regulatory Director,
Regulatory and Technical Services
Quintiles, Inc.
P.O. Box 9708
Kansas City, MO 64134-0708
Telephone: (816) 767-6408
Fax: (816) 767-7373

Sincerely,


Cynthia Kirk, Ph.D., RAC
Executive Director
Regulatory and Technical Services
Quintiles, Inc. Kansas City

June 3, 2002



Douglas Throckmorton, M.D.
Director, Division of Cardio-Renal Drug Products
Center for Drug Evaluation and Research (HFD-110)
Food and Drug Administration

**Subject: BSF 208075
Selective Endothelin Receptor Antagonist
For Pulmonary Arterial Hypertension**

**General Correspondence:
Transfer of responsibility as
US Agent and Authorized
Representative**

Dear Dr. Throckmorton:

Effective June 3, 2002, Myogen, Inc. is authorizing Quintiles, Inc., Kansas City, MO to act as its U.S. Agent and Authorized Representative for BSF 208075, an ETA Selective Endothelin Receptor Antagonist, being investigated in patients with pulmonary arterial hypertension. The duties to be performed by Quintiles, Inc. are:

- Submission of the IND
- Verbal and written interaction with the FDA
- Conduct of meetings with the FDA
- Submission of the IND annual reports
- Submission of IND amendments
- General IND maintenance

The contact person at Quintiles, Inc., is:

Marguerite Enlow, Pharm.D., RAC
Associate Regulatory Director,
Regulatory and Technical Services
Quintiles, Inc.
P.O. Box 9708
Kansas City, MO 64134-0708
Telephone: (816) 767-6408
Fax: (816) 767-7373

If you have any questions regarding the above information, please do not hesitate to contact me at Myogen, Inc., 7577 West 103rd Ave. #212, Westminster, CO 80021-5426, telephone (303) 464-5221.

Sincerely,

A handwritten signature in dark ink, appearing to read "J. William Freytag".

J. William Freytag
President, CEO and Chairman
Myogen, Inc.



Quintiles, Inc.
Post Office Box 9708
Kansas City, MO 64134-0708
(816) 767-6000

June 3, 2002

Douglas Throckmorton, M.D.
Director, Division of Cardio-Renal Drug Products
Center for Drug Evaluation and Research (HFD-110)
Food and Drug Administration

**Subject: BSF 208075
Selective Endothelin Receptor Antagonist
For Pulmonary Arterial Hypertension**

**General Correspondence:
Acceptance of responsibility
as US Agent and Authorized
Representative**

Dear Dr. Throckmorton:

Effective June 3, 2002, Quintiles, Inc., Kansas City, MO assumes the responsibility from Myogen, Inc. as the U.S. Agent and Authorized Representative for BSF 208075, an ET_A Selective Endothelin-Receptor Antagonist, being investigated in patients with pulmonary arterial hypertension. The duties to be performed by Quintiles, Inc. are:

- Submission of the IND
- Verbal and written interaction with the FDA
- Conduct of meetings with the FDA
- Submission of the IND annual reports
- Submission of IND amendments
- General IND maintenance

The contact person at Quintiles, Inc., is:

Marguerite Enlow, Pharm.D., RAC
Associate Regulatory Director,
Regulatory and Technical Services
Quintiles, Inc.
P.O. Box 9708
Kansas City, MO 64134-0708
Telephone: (816) 767-6408
Fax: (816) 767-7373

If you have any questions regarding the above information, please do not hesitate to contact me at Quintiles, Inc., P.O. Box 9708, Kansas City, Missouri 64134-0708, telephone (816) 767-6493.

Sincerely,

Cynthia Kirk, Ph.D., RAC
Executive Director
Regulatory and Technical Services
Quintiles, Inc. Kansas City

TRANSFER OF US FDA REGULATORY OBLIGATIONS FOR INVESTIGATIONAL
PHARMACEUTICAL AND BIOLOGIC PRODUCTS UNDER AN INVESTIGATIONAL NEW DRUG (IND)
APPLICATION (21 CFR 312.52)

Form No: CRO.FM.AMR.RA002.V02

Page 1 of 3

Sponsor:	Myogen	Project Code/ Work Order Number:	Not Assigned
Product Name:	BSF 208075	IND Number:	Not Available
Indication:	Pulmonary Arterial Hypertension	Protocol Number:	All protocols

Responsibility	21 CFR Reference	Obligation Assigned to:	
		Sponsor	Quintiles
A. 1. Preparation of all or part of an IND application	312.23	X	X
2. Submission of IND application to FDA		<input type="checkbox"/>	X
B. Maintain an IND with the following amendments, as necessary:			
1. Preparation of Protocol amendments (includes new protocols, changes in protocols, adding new investigators)	312.30	X	<input type="checkbox"/>
2. Preparation of Chemistry, Manufacturing, and Control amendments	312.31	X	<input type="checkbox"/>
3. Preparation of Pharmacology and Toxicology amendments	312.31	X	<input type="checkbox"/>
4. Preparation of Clinical amendments	312.31	X	<input type="checkbox"/>
5. Safety Reports	312.32		
(a) Preparation of initial report		X	<input type="checkbox"/>
(b) Preparation of follow-up reports		X	<input type="checkbox"/>
(c) Notifications to FDA (phone/fax or written)		<input type="checkbox"/>	X
(d) Notifications to investigators		X	<input type="checkbox"/>
6. Preparation of Annual Reports	312.33	X	X
7. Preparation of response to request for information or clinical hold	312.41, 42	X	X
8. Preparation of letter to withdraw an IND	312.38	X	X
9. Act as IND agent; submit all amendments to FDA	312.23 -42	<input type="checkbox"/>	X
C. Selecting investigators and monitors	312.53		
1. Select qualified investigators ¹	312.53 (a)	X	<input type="checkbox"/>
2. Control of drug ¹			
(a) Approve drug shipment after review of required information from investigator (including signed Form FDA 1572, CV)	312.53 (c)	X	<input type="checkbox"/>
(b) Ship drug to approved investigators	312.53 (b)	<input type="checkbox"/>	X
3. Provide qualified monitors ¹	312.53 (d)	X	<input type="checkbox"/>

TRANSFER OF US FDA REGULATORY OBLIGATIONS FOR INVESTIGATIONAL
PHARMACEUTICAL AND BIOLOGIC PRODUCTS UNDER AN INVESTIGATIONAL NEW DRUG (IND)
APPLICATION (21 CFR 312.52)

Form No: CRO.FM.AMR.RA002.V02

Page 2 of 3

4. Informing investigators ¹			
(a) Review with investigators their regulatory responsibilities	312.60 -.69	X	<input type="checkbox"/>
(b) Supply investigator's brochure	312.55 (a)	X	<input type="checkbox"/>
(c) Inform investigators of new safety information about the study drug	312.55 (b)	X	<input type="checkbox"/>
D. Review of ongoing investigations	312.56		
1. Monitoring the investigation (includes ensuring that investigator is complying with all commitments in Section 9 of the signed Form FDA-1572) ¹	312.56(a)	X	<input type="checkbox"/>
2. Discontinue investigator participation if not compliant ¹ Note: If the sponsor does not discontinue an investigator who Quintiles believes to be significantly non-compliant, Quintiles will request a complete transfer of regulatory obligation for that site back to the sponsor.	312.56(b)	X	<input type="checkbox"/>
3. Initial evaluation of all adverse events ¹	312.56 (c)	X	<input type="checkbox"/>
4. Upon discontinuation of a study ¹ :	312.56 (d)		
(a) Notify FDA		<input type="checkbox"/>	X
(b) Notify IRBs and investigators		X	<input type="checkbox"/>
(b) Assure disposition of drug from sites to sponsor		X	<input type="checkbox"/>
E. Recordkeeping and record retention	312.57		
1. Maintain sponsor records and reports for 2 years after study end or marketing application approved, for	312.57(a)(b)		
(a) Records of drug shipment and disposition		X	<input type="checkbox"/>
(b) All correspondence with sponsor, FDA, IRB, investigators		X	<input type="checkbox"/>
(c) Records concerning adverse effects		X	<input type="checkbox"/>
(d) Other records required by FDA		X	<input type="checkbox"/>
2. Retain reserve samples of test articles and reference standards used in bioequivalence or bioavailability studies	312.57 (c)	X	<input type="checkbox"/>
F. Disposition of unused supply of investigational drug	312.59		
1. Assure return of drug from site to sponsor ¹		X	<input type="checkbox"/>
2. Conduct final disposition or destruction of drug ¹		X	<input type="checkbox"/>
G. If requested by FDA, submission of sponsor's records and reports to FDA for inspection	312.58 (a)	X	X
H. Apply for FDA approval to export investigational drug if:	312.110	<input type="checkbox"/>	<input type="checkbox"/>
(a) Drug is not approved for marketing in any country, AND			
(b) Drug is not under an active IND, AND			
(c) Drug is not being exported to one of listed countries ²			
X Not applicable			
I. Represent sponsor in resolution of disputes with FDA	312.48	X	X
J. Obtain investigator financial disclosure information	[FR 2/2/98]	X	<input type="checkbox"/>

Sponsor's name
Project code

TRANSFER OF US FDA REGULATORY OBLIGATIONS FOR INVESTIGATIONAL
PHARMACEUTICAL AND BIOLOGIC PRODUCTS UNDER AN INVESTIGATIONAL NEW DRUG (IND)
APPLICATION (21 CFR 312.52)

Form No.: CRO.FM.AMR.RA002.V02

Page 3 of 3

¹ If responsibility for an item is shared between the sponsor and Quintiles, both boxes will be checked. Quintiles' responsibility for the item is limited to the list of sites attached to this document. This must be confirmed in the contract.

² Listed countries: Australia, Canada, Israel, Japan, New Zealand, Switzerland, South Africa, and current member nations of the European Union and European Economic Area.

According to 21 CFR 312.52(b), "A contract research organization that assumes any obligation of a sponsor shall comply with the specific regulations in this chapter applicable to this obligation and shall be subject to the same regulatory action as a sponsor for failure to comply with any obligation assumed under these regulations." The assignment of responsibility does not preclude either the sponsor or the CRO from participating in the requirements of the CFR.

The sponsor hereby transfers to Quintiles, Inc. the responsibilities indicated above under the column titled "Obligation Assigned to QUINTILES," effective Jan 18 2002 (date).

Sponsor: MYOGEN

J. William Freytag
Signature

J. William Freytag
Printed Name

President, CEO and Chairman
Title

1-18-02
Date

QUINTILES

Marguerite Enlow
Regulatory & Technical Services Signature

Marguerite Enlow
Printed Name

Associate Director
Title

1/18/02
Date

EXHIBIT I



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

IND 64,915

Myogen, Inc.
Attention: Mr. J. William Freytag
7575 West 103rd Avenue, Suite #102
Westminster, CO 80021

Dear Mr. Freytag:

We acknowledge receipt of your Investigational New Drug Application (IND) submitted under section 505(i) of the Federal Food, Drug, and Cosmetic Act. Please note the following identifying data:

IND Number Assigned: 64,915

Sponsor: Myogen, Inc.

Name of Drug: BSF 208075

Date of Submission: June 3, 2002

Date of Receipt: June 4, 2002

Studies in humans may not be initiated until 30 days after the date of receipt shown above. If, on or before July 3, 2002, we identify deficiencies in the IND that require correction before human studies begin or that require restriction of human studies, we will notify you immediately that (1) clinical studies may not be initiated under this IND ("clinical hold") or that (2) certain restrictions apply to clinical studies under this IND ("partial clinical hold"). In the event of such notification, you must not initiate or you must restrict such studies until you have submitted information to correct the deficiencies, and we have notified you that the information you submitted is satisfactory.

It has not been our policy to object to a sponsor, upon receipt of this acknowledgement letter, either obtaining supplies of the investigational drug or shipping it to investigators listed in the IND. However, if the drug is shipped to investigators, they should be reminded that studies may not begin under the IND until 30 days after the IND receipt date or later if the IND is placed on clinical hold.

As sponsor of this IND, you are responsible for compliance with the Federal Food, Drug, and Cosmetic Act and the implementing regulations (Title 21 of the Code of Federal Regulations). Those responsibilities include (1) reporting any unexpected fatal or life-threatening adverse experience associated with use of the drug by telephone or fax no later than 7 calendar days after initial receipt of the information [21 CFR 312.32(c)(2)]; (2) reporting any adverse experience associated with use of the drug that is both serious and unexpected in writing no later than 15 calendar days after initial receipt of the information [21 CFR 312.32(c)(1)]; and (3) submitting annual progress reports [21 CFR 312.33].

Please forward all future communications concerning this IND in triplicate, identified by the above IND number, to either of the following addresses:

U.S. Postal Service:

Center for Drug Evaluation and Research
Division of Cardio-Renal Drug Products, HFD-110
Attention: Division Document Room
5600 Fishers Lane
Rockville, Maryland 20857

Courier/Overnight Mail:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Cardio-Renal Drug Products, HFD-110
Attention: Division Document Room
1451 Rockville Pike
Rockville, Maryland 20852

If you have any questions, please call me at (301) 594-5333.

Sincerely yours,

Zelda McDonald
Regulatory Project Manager
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

cc:

Quintiles, Inc.
Cynthia Kirk, Ph.D., RAC
P.O. Box 9708 (Dock 6, F3-M3026)
Kansas City, MO 64134-0708

This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.

/s/

Zelda McDonald
6/10/02 02:21:20 PM

EXHIBIT J



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
Food and Drug Administration
Rockville, MD 20857

NDA 22-081

Gilead Colorado, Inc.
Attention: Ms. Linnea Tanner
Director, Regulatory Affairs
7575 West 103rd Ave., #102
Westminster, CO 80021-5426

Dear Ms. Tanner:

We have received your new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Letairis (ambrisentan) 5 and 10 mg Tablets

Date of Application: December 13, 2006

Date of Receipt: December 18, 2006

Our Reference Number: NDA 22-081

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, we will file the application on February 16, 2007 in accordance with 21 CFR 314.101(a).

Please cite the NDA number listed above at the top of the first page of all submissions to this application. Send all submissions, electronic or paper, including those sent by overnight mail or courier, to the following address:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Cardiovascular and Renal Products
5901-B Ammendale Road
Beltsville, MD 20705-1266

RECEIVED

JAN 17 2007

Per LOT

If you have any questions, please contact:

Ms. Melissa Robb
Regulatory Health Project Manager
(301) 796-1138

Sincerely,

{See appended electronic signature page}

Edward Fromm
Chief, Project Management Staff
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Edward Fromm

1/10/2007 02:31:37 PM

EXHIBIT K

REGULATORY REVIEW PERIOD ACTIVITIES

The table below summarizes representative formal submissions and contacts between the drug sponsor and FDA throughout the regulatory review period. The table is not comprehensive as to every event corresponding to a given type of submission, nor does it reflect regular email and telephone contacts throughout the regulatory review period to discuss upcoming submissions and provide preliminary information. Following the table below is a more comprehensive list of regulatory review activities.

2002-06-03	Initial submission date of IND No. 64,915
2002-06-04	Receipt date of IND No. 64,915
2002-06-28	Revised informed consent form
2002-07-17	Updated information for drug substance and drug product
2002-08-30	Clinical protocol amendment
2002-10-29	Response to request for information – CMC
2002-11-06	Information amendment: clinical
2002-12-09	Response to request for information: 26 wk. animal toxicity studies
2003-01-02	Rationale & study summary for additional long-term protocol
2003-01-13	Response to request for additional information regarding IND
2003-01-14	Response to request re safety monitoring plans for clinical trial
2003-02-07	Protocol amendment: new protocol
2003-03-05	IND 15-Day ADR Report
2003-03-11	Investigator notification of IND safety report for elevated liver function tests
2003-04-01	Duration of chronic toxicity study
2003-05-02	IND safety report: follow-up
2003-05-15	Type B meeting request
2003-05-15	Fax requesting End of Phase II meeting
2003-08-05	Information package for 27 August 2003 meeting
2003-08-27	End of Phase II meeting with FDA
2003-10-08	New Phase III protocols
2003-12-02	Change in clinical protocol
2003-12-18	Request for special protocol assessment 2-year mouse carcinogenicity protocol
2004-02-13	Information amendment
2004-03-17	Pharmacology-toxicology 2-Year rat and mouse final protocols

2004-03-25	Type C meeting request
2004-05-06	Protocol amendments
2004-05-27	Orphan drug application: amendment
2004-08-09	Type C meeting request to discuss proposed changes to the ambrisentan program
2004-08-27	Initial written report: 15-day safety alert report
2004-09-27	Type C meeting information package
2004-10-13	Meeting
2004-12-07	Information amendment: pharmacology/toxicology: 2-year rat and mouse carcinogenicity
2005-02-15	New protocol
2005-03-09	Information amendment: pharmacology/toxicology: 2-year rat and mouse carcinogenicity studies
2005-04-05	Response to request for information
2005-04-12	Protocol amendment
2005-05-24	Converting ARIES-2 study sites to ARIES-1
2005-08-04	Information amendment: Chemistry, Manufacturing and Controls
2005-08-22	Data analysis plan for FDA feedback
2005-08-22	Fax re 7 day safety report - initial manufacturer's report
2005-08-25	IND safety reports
2005-09-07	Request for FDA review of QT/QTc study proposal
2005-09-12	Type C meeting request: development plan for biopharmaceutics and clinical pharmacology
2005-10-04	Information amendment: Chemistry, Manufacturing, and Controls
2005-10-04	IND safety report: follow-up to a written report
2005-10-13	Meeting re PK and clinical pharmacology
2005-10-18	New protocol and new investigator
2005-10-19	Teleconference re data analysis plans
2005-11-04	New protocol and new investigator
2005-11-07	Response to FDA comments on QT/QTc study design
2005-11-11	Protocol amendment: change in protocol
2005-11-11	Information amendment: pharmacology/toxicology 2-year rat and mouse carcinogenicity studies
2005-11-29	Data analysis plans
2005-11-29	Information amendment: pharmacology/toxicology
2005-11-30	Data analysis plan for population pharmacokinetic modeling
2005-11-30	Protocol: new protocol and new investigator
2005-11-30	Data analysis plans

2005-12-15	Teleconference re PK/PD development plans
2005-12-19	IND safety report: initial written report
2005-12-19	Protocol amendment: new protocol and new investigators
2006-01-09	IND safety report: follow-up to a written report
2006-01-13	Protocol amendment: change in protocol
2006-01-16	IND safety report: follow-up to a written report
2006-01-23	Protocol amendment: change in protocol
2006-01-27	IND safety report: follow-up to a written report
2006-02-09	Request for fast track designation
2006-02-21	Response to IND correspondence
2006-03-02	IND safety report: follow-up to a written report
2006-03-08	Type B meeting request: Pre-NDA
2006-03-15	Requirements and format of NDA
2006-03-23	Information amendment: pharmacology/toxicology
2006-04-19	Information amendment: pharmacology/toxicology
2006-04-21	Pre-NDA briefing document
2006-04-27	IND safety report: initial written report
2006-05-04	Information amendment: pharmacology/toxicology
2006-05-08	Response to FDA comments
2006-05-17	Type B meeting request: pre-NDA CMC
2006-05-19	Pre-NDA meeting
2006-05-26	IND safety report: follow-up to a written report
2006-06-02	IND safety report: initial written report
2006-06-14	Request feedback on non-clinical NDA format and content
2006-06-15	Information amendment: clinical CSR's
2006-06-28	CMC pre-NDA information package
2006-07-06	IND safety report: initial and follow-up written safety report
2006-07-26	Pre-NDA CMC meeting
2006-10-06	CMC- proposed commercial dissolution method
2006-10-13	Proposal for 4-month safety update
2006-10-30	IND safety report: follow-up to a written report
2006-11-07	IND safety report: follow-up to a written report
2006-11-28	IND safety report: follow-up to a written report
2006-12-07	Transfer of sponsorship
2006-12-13	Submission of NDA No. 22-081
2006-12-18	Receipt of NDA No. 22-081
2007-01-09	Teleconference

2007-01-18	Response to letter re submission of complete CRF's and filing process
2007-01-19	Telephone call regarding inspections at clinical sites that conducted Phase 3 studies
2007-01-22	Email regarding revised protocol document-presence of sponsors
2007-02-09	Teleconference re protocols for capturing lab values
2007-02-13	Response to questions on the distribution of ambrisentan and RiskMAP
2007-02-15	IND safety report: follow-up to a written report
2007-03-03	Request for meeting to discuss status of review of NDA 22-081. Update on Amendments submitted to NDA
2007-03-07	Unformatted prescribing information; option to resolve formatting
2007-03-20	FDA site inspection
2007-03-20	Response regarding request for efficacy & safety datasets
2007-03-21	IND safety report: initial written report
2007-03-22	Protocol amendment: change to protocol
2007-03-29	90-day teleconference
2007-04-03	Request for Meeting to discuss dosing interval
2007-04-10	Protocol amendment: new protocol and new investigator
2007-04-16	Response to questions regarding dissolution profiles
2007-04-19	Population pharmacokinetic (PK) data analysis plan (DAP) amendment
2007-04-19	Response to questions regarding bioanalytical assay issues
2007-04-23	Response regarding randomization
2007-04-24	Protocol amendment: change to protocol
2007-04-30	IND safety report: follow up to a written safety report
2007-05-02	Protocol amendment. New protocol and new investigator
2007-05-04	DDMAC promotional materials. Request for perspective review and advisory comments for product launch materials
2007-05-08	Protocol amendment: change to protocol
2007-05-25	IND safety report: follow up to a written safety report
2007-05-25	Meeting
2007-05-31	Proposed pediatric study request
2007-05-31	IND safety report: follow-up to a written report
2007-06-07	Protocol amendment: new investigators
2007-06-07	IND safety report: follow-up to a written report
2007-06-15	Marketing approval letter for NDA 22-081



Back to Main TOC



Product	Department	Country	Document Date	Block Number	Document Type	Document Title	Doc ID	Keywords
Ambrisentan: Pulmonary Arterial Hypertension - IND 64,915								
1	Regulatory	US	7/20/2007	Temp 110	FDA Submission - IND	IND Safety Report. Initial Written Report. S-199	S-199	64,915
1	Regulatory	US	7/10/2007	Temp 110	FDA Submission - IND	IND Safety Report. Follow-up to a Written Report. S-198	S-198	64,915
1	Regulatory	US	6/28/2007	Temp 113	FDA Submission - IND	Annual Report. S-197	S-197	64,915
1	Regulatory	US	6/22/2007	Temp 110	FDA Submission - IND	IND Safety Report. Initial Written Report. S-196	S-196	64,915
1	Regulatory	US	6/18/2007	Temp 110	FDA Submission - IND	IND Safety Report. Follow-up to a Written Report. S-195	S-195	64,915
1	Regulatory	US	6/18/2007	Temp 110	FDA Submission - IND	IND Safety Report. Initial Written Report. S-194	S-194	64,915
1	Regulatory	US	6/7/2007	Temp 110	FDA Submission - IND	IND Safety Report. Follow-up to a Written Report. S-193	S-193	64,915
1	Regulatory	US	6/7/2007	Temp 110	FDA Submission - IND	Protocol Amendment. New Investigators. S-192	S-192	64,915
1	Regulatory	US	5/31/2007	Temp 110	FDA Submission - IND	IND Safety Report. Follow-up to a Written Report. S-191	S-191	64,915
1	Regulatory	US	5/31/2007	Temp 110	FDA Submission - IND	Other. Proposed Pediatric Study Request. S-190	S-190	64,915
1	Regulatory	US	5/29/2007	Temp 110	FDA Submission - IND	IND Safety Report. Follow-up to a Written Report. S-189	S-189	64,915
1	Regulatory	US	5/25/2007	Temp 110	FDA Submission - IND	IND Safety Report. Follow-up to a Written Report. S-188	S-188	64,915
1	Regulatory	US	5/18/2007	Temp 110	FDA Correspondence - Letter (Fax)	L. Tanner/N.Stockbridge - The 7 Day Safety Report	2007-05-18_64915_CORR_LETTER_FAX_LTANNE R_NSTOCKBRIDGE.pdf	64,915
1	Regulatory	US	5/18/2007	Temp 110	FDA Correspondence - Email	L. Tanner/D.Brum - Email with the 7-day Safety Report Documents attachment.	2007-05-18_64915_CORR_EMAIL_DBRUM_LTANNE ER.pdf	64,915
1	Regulatory	US	5/18/2007	Temp 110	FDA Submission - IND	IND Safety Report. Initial Written Report. S-187	S-187	64,915

1	Regulatory	US	5/14/2007	Temp 110	FDA Submission - IND	IND Safety Report. Initial Written Report. S-186	S-186	64,915
1	Regulatory	US	5/8/2007	Temp 112	FDA Submission - IND	Protocol Amendment. Change to Protocol: Addendum to Protocol(s) AMB-320/321-E, AMB-222 and AMB-220-E. S-185	S-185	64,915
1	Regulatory	US	5/2/2007	Temp 110	FDA Submission - IND	Protocol Amendment. New Protocol and New Investigator. S-184	S-184	64,915
1	Regulatory	US	4/30/2007	Temp 110	FDA Submission - IND	IND Safety Report. Follow-up to a Written Report. S-183	S-183	64,915
1	Regulatory	US	4/27/2007	Temp 110	FDA Submission - IND	IND Safety Report. Follow-up to a Written Report. S-182	S-182	64,915
1	Regulatory	US	4/26/2007	Book 109	FDA Submission - IND	Protocol Amendment. New Investigators. S-181	S-181	64,915
1	Regulatory	US	4/24/2007	Book 109	FDA Submission - IND	Protocol Amendment. Change to Protocol: Replacement of Amendment No. 1.0 to Protocol AMB-323. S-180	S-180	64,915
1	Regulatory	US	4/11/2007	Book 109	FDA Submission - IND	IND Safety Report - Initial Written Report. S-179	S-179	64,915
1	Regulatory	US	4/10/2007	Book 109	FDA Submission - IND	Protocol Amendment. New Protocol and New Investigator. S-178	S-178	64,915
1	Regulatory	US	4/4/2007	Book 109	FDA Submission - IND	IND Safety Report. Follow-up to a Written Report. S-177	S-177	64,915
1	Regulatory	US	3/22/2007	Temp 111	FDA Submission - IND	Protocol Amendment. Change to Protocol: Amendment No. 1 to Protocol AMB-323. S-176	S-176	64,915
1	Regulatory	US	3/21/2007	Book 109	FDA Submission - IND	IND Safety Report. Initial Written Report. S-175	S-175	64,915
1	Regulatory	US	2/23/2007	Book 109	FDA Submission - IND	Protocol Amendment. New Investigators. S-174	S-174	64,915
1	Regulatory	US	2/23/2007	Book 109	FDA Submission - IND	IND Safety Report. Follow-up to a Written Report. S-173	S-173	64,915
1	Regulatory	US	2/23/2007	Book 109	FDA Submission - IND	IND Safety Report. Initial Written Report. S-172	S-172	64,915
1	Regulatory	US	2/15/2007	Book 109	FDA Submission - IND	IND Safety Report. Follow-up to written Report. S-171	S-171	64,915

1	Regulatory	US	2/2/2007	Book 109	FDA Correspondence - Email	E.Smith/L.Tanner - Following on Transfer of Sponsorship from Myogen to Gilead, Sciences	2007-02-02_64915_CORR_EMAIL_ESMITH_LTAN_NER.pdf	64,915
1	Regulatory	US	1/30/2007	Book 109	FDA Submission - IND	IND Safety Report. Initial Written Report. S-170	S-170	64,915
1	Regulatory	US	1/30/2007	Book 109	FDA Submission - IND	Protocol Amendment. New Investigators. S-169	S-169	64,915
1	Regulatory	US	1/25/2007	Book 109	FDA Submission - IND	Protocol Amendment. New Investigator and New Investigator S-168	S-168	64,915
1	Regulatory	US	12/19/2006	Book 83	FDA Submission - IND	Protocol Amendment. New Investigators. S-167	S-167	64,915
1	Regulatory	US	12/15/2006	Book 83	FDA Correspondence - Letter	E.Fromm/L.Tanner. FDA Letter - Acknowledgment of the sponsor change.	2006-12-15_64915_CORR_LETTER_EFROMM_LTAN_NER.pdf	64,915
1	Regulatory	US	12/12/2006	Book 83	FDA Correspondence - Phone	L.Tanner/M.Robb. FDA contact report (phone call) - Clarify process for liaison with the Division during the review of NDA 022-081 and for submitting responses to reviewer questions.	2006-12-12_64915_CORR_PHONE_MROBB_LTAN_NER_.pdf	64,915
1	Regulatory	US	12/8/2006	Book 83	FDA Correspondence - Letter	N.Stockbridge/L.Tanner. FDA Letter indicates that Division does not recommend use of proprietary name LETAIRIS.	2006-12-08_64915_CORR_LETTER_NSTOCKBRIDGE_LTANNER.pdf	64,915
1	Regulatory	US	12/7/2006	Book 83	FDA Correspondence - Letter	N.Stockbridge/L.Tanner. FDA Letter - Clarification to Requirements 120-day Safety Update	2006-12-07_64915_CORR_LETTER_NSTOCKBRIDGE_LTANNER.pdf	64,915
1	Regulatory	US	12/7/2006	Book 83	FDA Submission - IND	Other. Transfer of Sponsorship. S-165	S-166	64,915
1	Regulatory	US	12/6/2006	Book 83	FDA Correspondence - Phone	L.Tanner/M.Robb - Confirm status of submission of NDA and transfer of sponsorship from Myogen to Gilead Sciences, Inc.	2006-12-06_64915_CORR_PHONE_MROBB_LTAN_NER_.pdf	64,915
1	Regulatory	US	11/28/2006	Book 83	FDA Submission - IND	IND Safety Report. Follow-up to a Written Safety Report. S-165	S-165	64,915
1	Regulatory	US	11/20/2006	Book 83	FDA Submission - IND	Protocol Amendment. New Investigators. S-164	S-164	64,915
1	Regulatory	US	11/20/2006	Book 83	FDA Submission - IND	IND Safety Report. Follow-up to a Written Safety Report. S-163	S-163	64,915

1	Regulatory	US	11/7/2006	Book 83	FDA Submission - IND	IND Safety Report. Follow-up to a Written Safety Report. S-162	S-162	64,915
1	Regulatory	US	10/30/2006	Book 83	FDA Submission - IND	IND Safety Report. Follow-up to a Written Safety Report. S-161	S-161	64,915
1	Regulatory	US	10/24/2006	Book 83	FDA Correspondence - Phone	L. Tanner/M. Robb - Confirm how RiskMAP materials are regulated and obtain status of review of trademark.	2006-10-24_64915_CORR_PHONE_LTANNER_MR_OBB_.pdf	64,915
1	Regulatory	US	10/20/2006	Book 83	FDA Submission - IND	Protocol Amendment. New Investigators. S-160	S-160	64,915
1	Regulatory	US	10/20/2006	Book 83	FDA Correspondence - Email	L. Tanner/M. Robb - FDA contact report (e-mail) - Proposal for 4-month Safety Update to NDA, S-159	2006-10-20_64915_CORR_EMAIL_LTANNER_MRO_BB_.pdf	64,915
1	Regulatory	US	10/16/2006	Book 83	FDA Correspondence - Email	L. Tanner/M. Robb - FDA contact report (e-mail) that confirms that the word version of the PI needs to be submitted in the two-column format.	2006-10-16_64915_CORR_EMAIL_LTANNER_MRO_BB_.pdf	64,915
1	Regulatory	US	10/13/2006	Book 83	FDA Submission - IND	Other: Proposal for 4-Month Safety Update. S-159	S-159	64,915
1	Regulatory	US	10/12/2006	Book 83	FDA Correspondence - Email	L. Tanner/M. Robb. Email with two attachments. Clarification on Format of PI; lvs. 2 Column Format for the PI; Ambrisentan.	2006-10-12_64915_CORR_EMAIL_LTANNER_MRO_BB_.pdf	64,915
1	Regulatory	US	10/10/2006	Book 83	FDA Correspondence - Email	Email from T. Marshall to S. Goldie with the attachment - electronic Desk Copy of AMB S-157. New Commercial Drug Product Dissolution Method.	2006-10-10_64915_CORR_EMAIL_TMARSHALL_S_GOLDIE_.pdf	64,915
1	Regulatory	US	10/9/2006	Book 83	FDA Submission - IND	IND Safety Report. Initial and Follow-up Written Report. S-158	S-158	64,915
1	Regulatory	US	10/6/2006	Book 83	FDA Submission - IND	Other: CMC - Proposed Commercial Dissolution Method. S-157	S-157	64,915
1	Regulatory	US	10/4/2006	Book 83	FDA Correspondence - Email	Email from M. Robb to L. Tanner. Subject: Pediatric exclusivity, Orphan Drugs; Ambrisentan - ND 22-081.	2006-10-04_64915_CORR_EMAIL_LTANNER_MRO_BB_.pdf	64,915

1	Regulatory	US	10/4/2006	Book 83	FDA Correspondence - Phone	M.Robb/L. Tanner. Purpose: Confirm location for providing the statement that ambisentan is exempt from the requirement for submitting pediatric data in the NDA.	2006-10-04_64915_CORR_PHONE_MROBB_LTAN_NER_.pdf	64,915
1	Regulatory	US	9/27/2006	Book 83	FDA Correspondence - Phone	M.Robb/L. Tanner. Purpose: Confirm timing for the submission of NDA.	2006-09-27_64915_CORR_PHONE_MROBB_LTAN_NER_.pdf	64,915
1	Regulatory	US	9/26/2006	Book 82	FDA Submission - IND	Protocol Amendment. New Investigators. S-156	S-156	64,915
1	Regulatory	US	9/12/2006	Book 82	FDA Submission - IND	IND Safety Report. Initial and Follow-up Written Report. S-155	S-155	64,915
1	Regulatory	US	9/6/2006	Book 82	FDA Submission - IND	Protocol Amendment AMB-323. New Investigators. S-154	S-154	64,915
1	Regulatory	US	8/23/2006	Book 82	FDA Correspondence - Letter - Meeting Minutes	Letter from S. Goldie/T. Marshall Meeting Minutes - Pre-NDA CMC meeting with FDA.	2006-08-23_64915_CORR_MEETING_MINUTES.pdf	64,915
1	Regulatory	US	8/21/2006	Book 82	FDA Correspondence - Email	Email from the FDA User Fee System	2006-08-21_64915_CORR_EMAIL_USERFEESFDA_HISOKOSKI_.pdf	64,915
1	Regulatory	US	8/8/2006	Book 82	FDA Correspondence - Phone	L. Tanner/M. Robb. Call at 2:30 PM. Purpose: Confirm Format of Annotating Prescribing Information.	2006-08-08_64915_CORR_PHONE_MROBB_LTAN_NER_2_.pdf	64,915
1	Regulatory	US	8/8/2006	Book 82	FDA Correspondence - Phone	L. Tanner/M. Robb. Call at 8:30AM Purpose: Confirm format of annotating the prescribing information based on the new requirements.	2006-08-08_64915_CORR_PHONE_MROBB_LTAN_NER_.pdf	64,915
1	Regulatory	US	7/26/2006	Book 82	FDA Correspondence - Meeting Minutes	T. Marshall. Myogen Pre-NDA CMC Meeting Minutes for July 26, 2006.	2006-07-26_64915_CORR_MEETING_MINUTES.pdf	64,915
1	Regulatory	US	7/25/2006	Book 82	FDA Submission - IND	Protocol Amendment. New Investigators. S-153	S-153	64,915
1	Regulatory	US	7/24/2006	Book 82	FDA Correspondence - Email	T. Marshall/S. Goldie. FDA Pre-meeting Responses to Myogen's Pre-NDA CMC Meeting Questions.	2006-07-24_64915_CORR_EMAIL_TMARSHALL_S_GOLDIE_1.pdf	64,915
1	Regulatory	US	7/24/2006	Book 82	FDA Correspondence - Email	T. Marshall/S. Goldie. Pre-NDA CMC Meeting - Additional Attendees.	2006-07-24_64915_CORR_EMAIL_TMARSHALL_S_GOLDIE.pdf	64,915
1	Regulatory	US	7/17/2006	Book 82	FDA Submission - IND	IND Safety Report. Follow-up to a Written Safety Report. S-152	S-152	64,915

1	Regulatory	US	7/13/2006	Book 82	FDA Correspondence - Phone	H.Isokoski/B.Friedman. NDA Number for Ambrisentan.	2006-07-12_64915_CORR_PHONE_HISOKOSKI_BF_RIEDMAN_.pdf	64,915
1	Regulatory	US	7/6/2006	Book 82	FDA Correspondence - Email	L.CURRAN/ESUB/FDA. To clarify issues to which there is no apparent guidance.	2006-07-06_64915_CORR_EMAIL_ESUB_LCURRA_N.pdf	64,915
1	Regulatory	US	7/6/2006	Book 82	FDA Submission - IND	IND Safety Report. Follow-up to a Written Safety Report. S-151	S-151	64,915
1	Regulatory	US	6/30/2006	Book 107-108	FDA Submission - IND	Annual Report. S-150	S-150	64,915
1	Regulatory	US	6/28/2006	Book 106	FDA Submission - IND	Other. CMC Pre-NDA Information Package S-149	S-149	64,915
1	Regulatory	US	6/20/2006	Book 82	FDA Submission - IND	Information Amendment. Update to Investigator 1572 Forms. S-148	S-148	64,915
1	Regulatory	US	6/20/2006	Book 82	FDA Correspondence - Phone	L.Tanner/M.Rabb. Feedback on proposed plan for submitting carcinogenicity data to the NDA (IND Serial No. 145).	2006-06-20_64915_CORR_PHONE_MROBB_LTAN_NER_.pdf	64,915
1	Regulatory	US	6/20/2006	Book 105	FDA Submission - IND	Information Amendment. New Protocol and New Investigator. S-147	S-147	64,915
1	Regulatory	US	6/15/2006	Book 100-104	FDA Submission - IND	Information Amendment -Clinical CSRs AMB-105 and AMB-106. S-146	S-146	64,915
1	Regulatory	US	6/14/2006	Book 82	FDA Correspondence - Phone	Phone. T.Marshall/S.Goldie regarding Pre-NDA CMC Meeting. Scheduling Submission of Pre-NDA CMC meeting information.	2006-06-14_64915_CORR_PHONE_SGOLDIE_TMARSHALL_.pdf	64,915
1	Regulatory	US	6/14/2006	Book 82	FDA Correspondence - Email	Email from L.Tanner/M.Robb - Request for feedback: IND64,915 S-145.	2006-06-14_64915_CORR_EMAIL_LTANNER_MROBB_.pdf	64,915
1	Regulatory	US	6/14/2006	Book 82	FDA Submission - IND	Other. Request Feedback on Nonclinical NDA Format and Content. S-145	S-145	64,915
1	Regulatory	US	6/12/2006	Book 82	FDA Submission - IND	IND Safety Report. Initial and Follow-up Written Report. S-144	S-144	64,915
1	Regulatory	US	6/2/2006	Book 82	FDA Submission - IND	IND Safety Report. Initial Written Report. S-143	S-143	64,915
1	Regulatory	US	6/1/2006	Book 82	FDA Submission - IND	Information Amendment. Update to Investigator 1572 Forms. S-142	S-142	64,915

1	Regulatory	US	5/26/2006	Book 82	FDA Correspondence - Letter	Letter from S.Goldie/T.Marshall regarding Pre-NDA CMC meeting with FDA.	2006-05-26_64915_CORR_LETTER_SGOLDIE_TM ARSHALL.pdf	64,915
1	Regulatory	US	5/26/2006	Book 82	FDA Correspondence - Fax	Fax from M.Robb/L.Tanner - Meeting Minutes from Pre-NDA meeting with FDA on May 19, 2006.	2006-05-26_64915_CORR_FAX_MROBB_LTANNER.pdf	64,915
1	Regulatory	US	5/26/2006	Book 82	FDA Submission - IND	IND Safety Report. Follow-up to a Written Report. S-141	S-141	64,915
1	Regulatory	US	5/25/2006	Book 82	FDA Correspondence - Email	S.Goldie/T.Marshall. Contract Information.	2006-05-25_64915_CORR_EMAIL_TMARSHALL_SGOLDIE.pdf	64,915
1	Regulatory	US	5/25/2006	Book 82	FDA Correspondence - Phone	Phone call - T.Marshall/S.Goldie regarding Pre-NDA CMC meeting request.	2006-05-25_64915_CORR_PHONE_SGOLDIE_TMARSHALL.pdf	64,915
1	Regulatory	US	5/19/2006	Book 82	FDA Correspondence - Phone	Phone call - T.Marshall/M.Robb regarding Pre-NDA CMC meeting request.	2006-05-19_64915_CORR_PHONE_MROBB_TMARSHALL.pdf	64,915
1	Regulatory	US	5/19/2006	Book 82	FDA Correspondence - Email	Email - T.Marshall/S.Goldie regarding Pre-NDA CMC meeting. IND Submission S-139 attached.	006-05-19_64915_CORR_EMAIL_TMARSHALL_SGOLDIE.pdf	64,915
1	Regulatory	US	5/18/2006	Book 82	FDA Submission - IND	IND Safety Report. Initial Written Report. S-140	S-140	64,915
1	Regulatory	US	5/17/2006	Book 82	FDA Correspondence - Email	Email - L.Tanner/M.Robb. To discuss comments and questions (pre-NDA meeting with FDA).	2006-05-17_64915_CORR_EMAIL_MROBB_LTANNER.pdf	64,915
1	Regulatory	US	5/17/2006	Book 82	FDA Submission - IND	Other. Type B Meeting Request: Pre-NDA CMC. S-139	S-139	64,915
1	Regulatory	US	5/8/2006	Book 82	FDA Correspondence - Email	L.Tanner/M.Robb - Response to FDA comment (SN#138) regarding scoop and content of NDA.	2006-05-08_64915_CORR_EMAIL_MROBB_LTANNER.pdf	64,915
1	Regulatory	US	5/8/2006	Book 82	FDA Submission - IND	Other: Response to FDA Comments. S-138	S-138	64,915
1	Regulatory	US	5/5/2006	Book 82	FDA Correspondence - Phone	Phone call - L.Tanner/M.Robb to discuss status of written comments to questions in pre-NDA briefing document (IND Serial No.134)	2006-05-05_64915_CORR_PHONE_MROBB_LTANNER_1.pdf	64,915

1	Regulatory	US	5/5/2006	Book 82	FDA Correspondence - Phone	Phone call - L. Tanner/M. Robb. Myogen response to Division comments on IND Serial No. 127, date of internal meeting; clarify FDA position on use of audio-visual aids.	2006-05- 05_64915_CORR_PHONE_MROBB_LTAN NER.pdf	64,915
1	Regulatory	US	5/4/2006	Book 97-99	FDA Submission - IND	Information Amendment. Pharmacology/Toxicology. S-137	S-137	64,915
1	Regulatory	US	4/27/2006	Book 82	FDA Submission - IND	Protocol Amendment. New Investigators Update. S-136	S-136	64,915
1	Regulatory	US	4/27/2006	Book 82	FDA Submission - IND	IND Safety Report. Initial Written Report. S-135	S-135	64,915
1	Regulatory	US	4/21/2006	Book 96	FDA Submission - IND	Other: Pre-NDA Briefing Document. S-134	S-134	64,915
1	Regulatory	US	4/21/2006	Book 82	FDA Correspondence - Multiple	Purpose: To test system upgrade and functionality in advance of actual Ambrisentan eCTD.	2006-04- 21_64915_CORR_MULTIPLE_LCURRAN_ CDER_ESUB.pdf	64,915
1	Regulatory	US	4/20/2006	Book 82	FDA Correspondence - Letter	The response to the questions regarding the NDA that was submitted in IND Serial No. 127	2006-04- 20_64915_CORR_LETTER_NSTOCKBRID GE_LTANNER.pdf	64,915
1	Regulatory	US	4/19/2006	Book 92-95	FDA Submission - IND	Information Amendment. Pharmacology/Toxicology. S-133	S-133	64,915
1	Regulatory	US	4/19/2006	Book 81	FDA Submission - IND	Other: Population Pharmacokinetic (PK) Data Analysis Plan (DAP) Amendment. S-132	S-132	64,915
1	Regulatory	US	4/17/2006	Book 81	FDA Correspondence - Phone	Phone call L. Tanner/M. Robb regarding status of FDA responses to questions relative to the NDA submitted in S-127	2006-04- 17_64915_CORR_PHONE_MROBB_LTAN NER.pdf	64,915
1	Regulatory	US	4/11/2006	Book 81	FDA Correspondence - Email	Email with the Word Attachment - L. Tanner/M. Robb regarding status of FDA responses to questions relative to the NDA submitted in S-127	2006-04- 11_64915_CORR_EMAIL_MROBB_LTANN ER.pdf	64,915
1	Regulatory	US	4/11/2006	Book 81	FDA Correspondence - Phone	Phone call L. Tanner/M. Robb regarding status of FDA responses to questions relative to the NDA submitted in S-127	2006-04- 11_64915_CORR_PHONE_MROBB_LTAN NER.pdf	64,915
1	Regulatory	US	4/5/2006	Book 81	FDA Correspondence - Phone	Phone call - L. Tanner/N. Beasley regarding analysis of pharmacokinetic parameters vs. QTc interval assessments.	2006-04- 05_64915_CORR_PHONE_LTANNER_NBE ASLEY.pdf	64,915

1	Regulatory	US	4/5/2006	Book 91	FDA Submission - IND	Information Amendment. Pharmacology/Toxicology. S-131	S-131	64,915
1	Regulatory	US	3/29/2006	Book 81	FDA Submission - IND	Protocol Amendment. New Investigators and Investigator Update. S-130	S-130	64,915
1	Regulatory	US	3/24/2006	Book 81	FDA Submission - IND	Information Amendment Pharmacology/Toxicology. S-129	S-129	64,915
1	Regulatory	US	3/23/2006	Book 81	FDA Correspondence - Phone	Phone call, L. Tanner/M. Robb - Clarification of FDA participants for pre-NDA meeting scheduled May 19, 2006.	2006-03- 23_64915_CORR_PHONE_MROBB_LTAN NER.pdf	64,915
1	Regulatory	US	3/23/2006	Book 89-90	FDA Submission - IND	Information Amendment. Pharmacology/Toxicology. S-128	S-128	64,915
1	Regulatory	US	3/23/2006	Book 81	FDA Correspondence - Email	E-mail from L. Tanner /M. Robb to obtain feedback from the statisticians on how to address their recommendations regarding the methodology used in the DAPs for the individual Phase 3 studies AMB-320 and AMB-321.	2006-03- 23_64915_CORR_EMAIL_LTANNER_MRO BB.pdf	64,915
1	Regulatory	US	3/21/2006	Book 81	FDA Correspondence - Phone	Phone call, L. Tanner/M. Robb - Clarification of FDA participants for pre-NDA meeting scheduled May 19, 2006.	2006-03- 21_64915_CORR_PHONE_MROBB_LTAN NER.pdf	64,915
1	Regulatory	US	3/20/2006	Book 81	FDA Correspondence - Fax	Fax from M. Robb/L. Tanner regarding Pre-NDA meeting conformation with FDA on May 19, 2006.	2006-03- 20_64915_CORR_FAX_MROBB_LTANNER .pdf	64,915
1	Regulatory	US	3/16/2006	Book 81	FDA Correspondence - Letter	Letter from N. Stockbridge/L. Tanner - Comments (Clinical Pharmacology and Biopharmaceutics) on AMB submission.	2006-03- 16_64915_CORR_LETTER_NSTOCKBRID GE_LTANNER.pdf	64,915
1	Regulatory	US	3/15/2006	Book 81	FDA Submission - IND	Other. Requirements and Format of NDA. S-127	S-127	64,915
1	Regulatory	US	3/15/2006	Book 81	FDA Correspondence - Email	L. Tanner/M. Robb - Email regarding IND 64,915; Serial No. 127; Requirements and Format of NDA.	2006-03- 15_64915_CORR_EMAIL_LTANNER_MRO BB.pdf	64,915
1	Regulatory	US	3/14/2006	Book 81	FDA Correspondence - Letter	Letter from N. Stockbridge/L. Tanner with the comments on AMB submission.	2006-03- 14_64915_CORR_LETTER_NSTOCKBRID GE_LTANNER.pdf	64,915
1	Regulatory	US	3/14/2006	Book 81	FDA Correspondence - Email	L. Curran/K. Edmunds - Email regarding Pilot Submission.	2006-03- 14_64915_CORR_EMAIL_LCURRAN_KED MUNDS.pdf	64,915

1	Regulatory	US	3/10/2006	Book 81	FDA Correspondence - Phone call	L. Tanner/M. Robb phone call regarding feedback on : submission of the rat carcinogenicity, acceptability of cross-reference to NDA in the IND Annual Report, notification of submission with questions on scope, format and date of pre-NDA meeting.	2006-03- 10_63412_CORR_PHONE_LTANNE R_MROBB_.pdf	64,915
1	Regulatory	US	3/8/2006	Book 81	FDA Submission - IND	Other: Type B Meeting Request: Pre-NDA. S-126	S-126	64,915
1	Regulatory	US	3/2/2006	Book 81	FDA Submission - IND	Protocol Amendment. New investigators and 1572 Update. S-125	S-125	64,915
1	Regulatory	US	3/2/2006	Book 81	FDA Submission - IND	IND Safety Report. Follow-up to a Fax Report: 52597. S-124	S-124	64,915
1	Regulatory	US	2/27/2006	Book 81	FDA Correspondence - Phone call/Fax	L. Curran called M. Robb to inform her that he would be faxing a 7-Day Safety Report. Faxed 7-Day Safety Report.	2006-02- 27_64915_CORR_PHONE_FAX_LC URRAN_MROBB.pdf	64,915
1	Regulatory	US	2/21/2006	Book 81	FDA Submission - IND	Other: Response to the IND correspondence. S-123	S-123	64,915
1	Regulatory	US	2/15/2006	Book 81	FDA Correspondence - Letter	Letter from N. Stockbridge to L. Tanner regarding FDA approval for fast track designation.	2006-02- 15_64915_CORR_LETTER_NSTOC KBRIDGE_LTANNER.pdf	64,915
1	Regulatory	US	2/9/2006	Book 88	FDA Submission - IND	Other. Request for Fast Track Designation. S-122	S-122	64,915
1	Regulatory	US	2/8/2006	Book 81	FDA Correspondence - Letter	Letter from N. Stockbridge to L. Tanner regarding Myogen request for additional clarification to a letter dated 22 December 2005 regarding the changes to the statistical analysis plans that was reflected in the protocol amendments to AMB-320 and AMB-321.	2006-02- 08_64915_CORR_LETTER_NSTOC KBRIDGE_LTANNER.pdf	64,915
1	Regulatory	US	2/8/2006	Book 81	FDA Correspondence - Phone call	Phone call L. Tanner/M. Robb. Confirm whether the popPK DAP has been reviewed and whether Division comments will be forthcoming.	2006-02- 08_63412_CORR_PHONE_LTANNE R_MROBB_.pdf	64,915
1	Regulatory	US	1/30/2006	Book 81	FDA Correspondence - Phone call	Phone call - L. Tanner/B.N. Beasley regarding status of Clinical QT/QTc Study AMB-104	2006-01- 30_64915_CORR_PHONE_LTANNE R_BNBEASLEY.pdf	64,915

1	Regulatory	US	1/27/2006	Book 81	FDA Submission - IND	IND Safety Report. Initial Written Report: 51629. Follow-Up to a Written Report: 52559. S-121	S-121	64,915
1	Regulatory	US	1/26/2006	Book 87	FDA Submission - IND	Protocol Amendment. Change in Protocol AMB-104. S-120	S-120	64,915
1	Regulatory	US	1/25/2006	Book 81	FDA Submission - IND	Protocol Amendment. New investigators and 1572 Update. S-119	S-119	64,915
1	Regulatory	US	1/24/2006	Book 86	FDA Submission - IND	Protocol Amendment. Change in Protocol AMB-222. S-118	S-118	64,915
1	Regulatory	US	1/23/2006	Book 81	FDA Correspondence - Phone call	Phone call L. Tanner/M. Robb. Feedback on submitting additional documentation to support changes in the revised Protocol AMB-222 that was submitted in Serial No. 115	2006-01-23_64915_CORR_PHONE_LTANNE_R_MROBB.pdf	64,915
1	Regulatory	US	1/23/2006	Book 85	FDA Submission - IND	Protocol Amendment. Change in Protocol AMB-107. S-117	S-117	64,915
1	Regulatory	US	1/19/2006	Book 81	FDA Correspondence - Phone call	Phone call - L. Tanner/L. Velazquez regarding feedback on Bioequivalence Protocol AMB-103 submitted on 12/19/2005 S-108.	2006-01-19_64915_CORR_PHONE_LTANNE_R_LVELAZQUEZ.pdf	64,915
1	Regulatory	US	1/16/2006	Book 81	FDA Submission - IND	IND Safety Report. Follow-up to a written Report: 52566. S-116	S-116	64,915
1	Regulatory	US	1/13/2006	Book 84	FDA Submission - IND	Protocol Amendment. Change in Protocol. S-115	S-115	64,915
1	Regulatory	US	1/10/2006	Book 81	FDA Correspondence - Phone call	Phone call L. Tanner/M. Robb. Follow-up on clarification on FDA statistical comments to protocol amendments for AMB-320 and AMB-321.	2006-01-10_64915_CORR_PHONE_LTANNE_R_MROBB.pdf	64,915
1	Regulatory	US	1/9/2006	Book 81	FDA Submission - IND	IND Safety Report. Follow-up to a written Report: 51627. S-114	S-114	64,915
1	Regulatory	US	1/5/2006	Book 81	FDA Correspondence - Email	Email - M. Robb/L. Tanner regarding IND 64,915 Letairis trade name - Response to Questions.	2006-01-05_64915_CORR_EMAIL_LTANNE_R_MROBB.pdf	64,915
1	Regulatory	US	1/4/2006	Book 81	FDA Submission - IND	IND Safety Report. Initial Written Report. S-113	S-113	64,915

	Regulatory	US	12/2005	Book #	FDA Correspondence - Lead	Email - M. Robb, Tanner (Classification of Statistical Comments: S-084 and S-088, p.3) 64,915	2005-01 02_64915 CORR_EMAIL_LTANNE R_MROBB.pdf	64,915
1	Regulatory	US	12/28/2005	Book 52	FDA Correspondence - Email	Email - M. Robb/L. Tanner regarding IND 64,915 Letairis trade name.	2005-12- 28_64915 CORR_EMAIL_LTANNE R_MROBB.pdf	64,915
1	Regulatory	US	12/27/2005	Book 52	FDA Correspondence - Fax	The FDA minutes for the Type C meeting scheduled as a teleconference on 15 December 2005 to discuss the PK/PD development plan. Attached are Internal (Myogen) Minutes for the same meeting.	2005-12- 27_64915 CORR_FAX_MTG_MINU TES_LTANNER_MROBB.pdf	64,915
1	Regulatory	US	12/22/2005	Book 52	FDA Correspondence - Letter	Letter from N. Stockbridge to L. Tanner regarding comments on ARIES-2 DAP.	2005-12- 22_64915 CORR_LETTER_NSTOC KBRIDGE_LTANNER.pdf	64,915
1	Regulatory	US	12/21/2005	Book 52	FDA Correspondence - Phone call	Phone call on 12-20-2005 and 12-21- 2005 L. Tanner/M. Robb. Intent to submit application for fast track designation.	2005-12- 21_64915 CORR_PHONE_LTANNE R_MROBB.pdf	64,915
1	Regulatory	US	12/21/2005	Book 52	FDA Submission - IND	IND Safety Report. Initial Written Report: 51627. S-112	S-112	64,915
1	Regulatory	US	12/21/2005	Book 52	FDA Submission - IND	IND Safety Report. Initial Written Report: 52559. S-111	S-111	64,915
1	Regulatory	US	12/20/2005	Book 80	FDA Submission - IND	Protocol Amendment. New Protocol (AMB-107) and New Investigator. S- 110	S-110	64,915
1	Regulatory	US	12/19/2005	Book 52	FDA Correspondence - Email	ECG measurements on Baseline and Treatment Days in Protocol AMB- 104.	2005-12- 19_64915 CORR_EMAIL_LTANNE R_MROBB.pdf	64,915
1	Regulatory	US	12/19/2005	Book 52	FDA Submission - IND	IND Safety Report. Initial Written Report: 52555. S-109	S-109	64,915
1	Regulatory	US	12/19/2005	Book 79	FDA Submission - IND	Protocol Amendment. New Protocol (AMB-103) and New Investigators. S-108	S-108	64,915
1	Regulatory	US	12/19/2005	Book 52	FDA Correspondence - Phone call	Phone call. T. Marshall/M. Robb. Feedback from Ambrisentan Chemistry Reviewer for Drug Substance and Drug Product IND Amendments.	2005-12- 19_64915 CORR_PHONE_TMARSH ALL_MROBB.pdf	64,915
1	Regulatory	US	12/16/2005	Book 52	FDA Correspondence - Phone call	Phone call. T. Marshall/M. Robb. Request Feedback from Ambrisentan Chemistry Reviewer for Drug Product Update.	2005-12- 16_64915 CORR_PHONE_TMARSH ALL_MROBB.pdf	64,915

1	Regulatory	US	12/15/2005	Book 52	FDA Correspondence - Email	Email - L. Tanner/M. Robb. Subject: List of Myogen Participants Type C Meeting 12/15/2005.	2005-12-15_64915_CORR_EMAIL_LTANNE_R_MROBB_1.pdf	64,915
1	Regulatory	US	12/15/2005	Book 52	FDA Correspondence - Email	Email - L. Tanner/M. Robb. Subject: Clarification on Medical Review Comments QT/QTc Protocol AMB-104.	2005-12-15_64915_CORR_EMAIL_LTANNE_R_MROBB.pdf	64,915
1	Regulatory	US	12/14/2005	Book 52	FDA Correspondence - Email	Email - L. Tanner/M. Robb. Subject: Slides Top Line Results Phase 3 Study AMB-321; IND 64,915 Ambriesentan.	2005-12-14_64915_CORR_EMAIL_LTANNE_R_MROBB.pdf	64,915
1	Regulatory	US	12/14/2005	Book 52	FDA Correspondence - Phone call	Phone call from L. Tanner to M. Robb. Subject: Type C teleconference meeting scheduled 12/15/05; QT/QTc Study (AMB-104)	2005-12-14_64915_CORR_PHONE_LTANNE_R_MROBB.pdf	64,915
1	Regulatory	US	12/13/2005	Book 52	FDA Correspondence - Email	Email - L. Tanner/M. Robb. Conformation of FDA Participants Teleconference - 12/15/2005.	2005-12-13_64915_CORR_EMAIL_LTANNE_R_MROBB.pdf	64,915
1	Regulatory	US	12/12/2005	Book 52	FDA Correspondence - Phone call	Phone call (on 12/09/05 and 12/12/05) from L. Tanner to M. Robb. Subject: Clarify FDA participations Type C teleconference meeting scheduled 12/15/2005.	2005-12-12_64915_CORR_PHONE_LTANNE_R_MROBB.pdf	64,915
1	Regulatory	US	12/6/2005	Book 52	FDA Correspondence - Email	Email - L. Tanner/M. Robb. Subject: Ambriesentan Type C Meeting: Myogen Participants and Teleconference Instruction.	2005-12-06_64915_CORR_EMAIL_LTANNE_R_MROBB.pdf	64,915
1	Regulatory	US	12/1/2005	Book 52	FDA Correspondence - Email	Email - L. Tanner/M. Robb. Subject: Electronic Copy of S-106 - Analysis Plan for Population Pharmacokinetic Modeling.	2005-12-01_64915_CORR_EMAIL_LTANNE_R_MROBB.pdf	64,915
1	Regulatory	US	12/1/2005	Book 73-78	FDA Submission - IND	Information Amendment. Clinical Study Report EE002. S-107	S-107	64,915
1	Regulatory	US	12/1/2005	Book 52	FDA Correspondence - Phone call	Phone call - L. Tanner/M. Robb. Purpose: To confirm receipt of desk copies of PK/PD briefing package for the teleconference meeting scheduled 15 December 2005 and update on IND submissions this week.	2005-12-01_64915_CORR_PHONE_LTANNE_R_MROBB.pdf	64,915
1	Regulatory	US	11/30/2005	Book 52	FDA Submission - IND	Other: Data Analysis Plan for Population Pharmacokinetic Modeling. S-106	S-106	64,915

1	Regulatory	US	11/30/2005	Book 72	FDA Submission - IND	Other: Briefing Document for Type c Meeting. S-105	S-105	64,915
1	Regulatory	US	11/30/2005	Book 71	FDA Submission - IND	Protocol. New Protocol and New Investigator. S-104	S-104	64,915
1	Regulatory	US	11/30/2005	Book 70	FDA Submission - IND	Other: Data Analysis Plans. S-103	S-103	64,915
1	Regulatory	US	11/29/2005	Book 69	FDA Submission - IND	Other: Data Analysis Plans. S-102	S-102	64,915
1	Regulatory	US	11/29/2005	Book 65-68	FDA Submission - IND	Information Amendment. Pharmacology/Toxicology. S-101	S-101	64,915
1	Regulatory	US	11/28/2005	Book 52	FDA Correspondence - Phone call	Phone call - L. Tanner/M. Robb. Myogen response to FDA comments on the QT/QTc study design (Serial No. 096)	2005-11-28_64915_CORR_PHONE_LTANNE_R_MROBB.pdf	64,915
1	Regulatory	US	11/28/2005	Book 64	FDA Submission - IND	Other: Data Analysis Plan. S-100	S-100	64,915
1	Regulatory	US	11/23/2005	Book 63	FDA Submission - IND	Protocol Amendment. New Investigators. S-099	S-099	64,915
1	Regulatory	US	11/16/2005	Book 52	FDA Correspondence - Phone call	Phone call - L. Tanner/M. Robb. Purpose: Instruction for shipping PK/PD package for the teleconference meeting scheduled 12/15/2005.	2005-11-16_64915_CORR_PHONE_LTANNE_R_MROBB.pdf	64,915
1	Regulatory	US	11/14/2005	Book 52	FDA Correspondence - Phone call	Phone call - L. Tanner/M. Robb. Purpose: To confirm timing of submitting the PK/PD briefing package for the teleconference meeting scheduled 15 December 2005.	2005-11-14_64915_CORR_PHONE_LTANNE_R_MROBB.pdf	64,915
1	Regulatory	US	11/11/2005	Book 62	FDA Submission - IND	Protocol Amendment. Change in Protocol. Information Amendment Clinical. S-098	S-098	64,915
1	Regulatory	US	11/11/2005	Book 52	FDA Submission - IND	Information Amendment. Pharmacology/Toxicology 2-Year Rat and Mouse Carcinogenicity Studies. S-097	S-097	64,915
1	Regulatory	US	11/10/2005	Book 52	FDA Correspondence - Phone call	Phone call - L. Tanner/W. Link on 11/10/05 and 11/09/05 regarding 2 year carcinogenicity (CAC) studies in mice and rats.	2005-11-10_64915_CORR_PHONE_LTANNE_R_WLINK.pdf	64,915

1	Regulatory	US	11/9/2005	Book 52	FDA Correspondence - Phone call	Phone call - L. Tanner/M. Robb on 11/08/05 and 11/09/05 regarding 2 year carcinogenicity (CAC) studies in mice and rats. Arrange teleconference with Dr. William Link to provide survival update on CAC studies.	2005-11-09_64915_CORR_PHONE_LTANNER_R_MROBB.pdf	64,915
1	Regulatory	US	11/7/2005	Book 52	FDA Submission - IND	Other: Response to FDA Comments on QT/QTc Study Design. S-096	S-096	64,915
1	Regulatory	US	11/4/2005	Book 61	FDA Submission - IND	Protocol. New Protocol and New Investigator. S-095	S-095	64,915
1	Regulatory	US	11/4/2005	Book 52	FDA Submission - IND	Other: Trademark Evaluation. S-094	S-094	64,915
1	Regulatory	US	10/24/2005	Book 52	FDA Correspondence - Email	Email from R. Fortney to L. Weissberger regarding minutes from October 19, 2005 teleconference.	2005-10-24_64915_CORR_EMAIL_RFORTNEY_LWEISSBERGER.pdf	64,915
1	Regulatory	US	10/21/2005	Book 60	FDA Submission - IND	Protocol Amendment: New Investigators. Other: Revisions to FDA Forms 1572. S-093	S-093	64,915
1	Regulatory	US	10/20/2005	Book 52	FDA Correspondence - Phone call	Phone call form L. Weissberger to M. Robb. Subject: QT/QTc study - comments on study design submitted for both darusentan (Serial No. 076) and ambrisentan (Serial No. 086)	2005-10-20_64915_CORR_PHONE_LWEISSBERGER_MROBB.pdf	64,915
1	Regulatory	US	10/19/2005	Book 52	FDA Correspondence - Letter	Letter from R. Fortney to L. Weissberger. Teleconference Minutes from FDA and Internal Minutes - October 19, 2005.	2005-10-19_64915_CORR_LETTER_RFORTNEY_LWEISSBERGER.pdf	64,915
1	Regulatory	US	10/19/2005	Book 52	FDA Correspondence - Email	Email from L. Tanner to R. Fortney regarding teleconference on October 19, 2005.	2005-10-19_64915_CORR_EMAIL_RFORTNEY_LTANNER.pdf	64,915
1	Regulatory	US	10/18/2005	Book 52	FDA Submission - IND	Protocol. New Protocol and New Investigator. S-092	S-092	64,915
1	Regulatory	US	10/13/2005	Book 52	FDA Correspondence - Email	Email from R. Fortney to L. Weissberger regarding FDA letter with comments on QT/QTc Study.	2005-10-13_64915_CORR_EMAIL_RFORTNEY_LWEISSBERGER.pdf	64,915
1	Regulatory	US	10/12/2005	Book 52	FDA Correspondence - Letter	Letter from N. Stockbridge to L. Weissberger. Comments on QT/QTc study proposal for Ambrisentan.	2005-10-12_64915_CORR_LETTER_NSTOCKBRIDGE_LWEISSBERGER.pdf	64,915

1	Regulatory	US	10/12/2005	Book 52	FDA Correspondence - Phone call	Phone call. L. Tanner/R. Fortney. Subject: Teleconference DAP; S-084	2005-10- 12_64915_CORR_PHONE_LTANNE R_RFORTNEY.pdf	64,915
1	Regulatory	US	10/12/2005	Book 52	FDA Correspondence - Email	Email from L. Tanner to R. Fortney regarding Teleconference on 10/19/2005, additional participant.	2005-10- 12_64915_CORR_EMAIL_RFORTN EY_LTANNER.pdf	64,915
1	Regulatory	US	10/11/2005	Book 52	FDA Correspondence - Phone call	Phone call. L. Tanner/R. Fortney. L. Tanner called R. Fortney on 10/06/05, 10/10/05 and 10/11/05. Subject: Teleconference DAP; S-084	2005-10- 11_64915_CORR_PHONE_LTANNE R_RFORTNEY.pdf	64,915
1	Regulatory	US	10/11/2005	Book 52	FDA Correspondence - Email	Email from R. Fortney to L. Weissberger regarding QT Study Comments.	2005-10- 11_64915_CORR_EMAIL_RFORTN EY_LWEISSBERGER.pdf	64,915
1	Regulatory	US	10/5/2005	Book 52	FDA Correspondence - Phone call	Phone call. L. Tanner/R. Fortney. Subject: Reschedule Type C Meeting; S-087	2005-10- 05_64915_CORR_PHONE_LTANNE R_RFORTNEY.pdf	64,915
1	Regulatory	US	10/4/2005	Book 59	FDA Submission - IND	Information Amendment. Chemistry, Manufacturing, and Controls. S-091	S-091	64,915
1	Regulatory	US	10/4/2005	Book 52	FDA Submission - IND	IND Safety Report: Follow-up to a Written Report. S-090	S-090	64,915
1	Regulatory	US	10/4/2005	Book 52	FDA Correspondence - Phone call	Phone call. L. Tanner/R. Fortney. Subject: Intention to Cancel or Re- schedule Type C Meeting, Serial No. 087	2005-10- 04_64915_CORR_PHONE_LTANNE R_RFORTNEY.pdf	64,915
1	Regulatory	US	9/28/2005	Book 52	FDA Correspondence - Letter	Letter from N. Stockbridge to L. Tanner regarding FDA Division comments on the Data Analysis Plan for AMB-321.	2005-09- 28_64915_CORR_LETTER_NSTOC KBRIDGE_LTANNER.pdf	64,915
1	Regulatory	US	9/26/2005	Book 58	FDA Submission - IND	Protocol Amendment: New Investigators: Gabbay, Channick, Frost, Waxman, Sulica, Taichman, Olschewski, Souza, Pulido, Rivera, Swisher, Booth, Ross, White. S-089	S-089	64,915
1	Regulatory	US	9/21/2005	Book 52	FDA Correspondence - Fax	Fax from M. Robb to L. Tanner. Subject: Conformation of 11/08/2005 Teleconference.	2005-09- 21_64915_CORR_FAX_MROBB_LT ANNER.pdf	64,915

1	Regulatory	US	9/20/2005	Book 52	FDA Correspondence - Phone call	Phone call L. Tanner/M. Robb. Finalize Date/Time of Type C Teleconference/Meeting. (Serial No.087); Status of DAP (Serial No. 084)	2005-09-20_64915_CORR_PHONE_LTANNE_R_ROBBM.pdf	64,915
1	Regulatory	US	9/19/2005	Book 52	FDA Correspondence - Phone call	Phone call T. Marshall/M. Robb. Subject: Follow-up to determine if Chemistry reviewer has any concerns regarding the drug substance IND update: IND 64,915, Serial No. 083, 4 Aug 05.	2005-09-19_64915_CORR_PHONE_TMARSHALL_MROBBB.pdf	64,915
1	Regulatory	US	9/19/2005	Book 52	FDA Correspondence - Phone call	Phone call L. Tanner/M. Robb. Finalize Date/Time of Type C Teleconference/Meeting. (Serial No.087); Status of DAP (Serial No. 084)	2005-09-19_64915_CORR_PHONE_LTANNE_R_ROBBM.pdf	64,915
1	Regulatory	US	9/15/2005	Book 52	FDA Correspondence - Letter	Letter from N. Stockbridge to L. Tanner. Confirmation that Food Effect Study Does not Need to be Repeated	2005-09-15_64915_CORR_LETTER_NSTOCKBRIDGE_LTANNER.pdf	64,915
1	Regulatory	US	9/15/2005	Book 52	FDA Submission - IND	Information Amendment. Pharmacology/Toxicology 2-year Rat and Mouse Carcinogenicity Studies. S-088	S-088	64,915
1	Regulatory	US	9/15/2005	Book 52	FDA Correspondence - Phone call	Phone called (1:30 p.m.) from L. Tanner to M. Robb regarding proposed Date for Type C Meeting PK/PD.	2005-09-15_64915_CORR_PHONE_LTANNE_R_ROBBM.pdf	64,915
1	Regulatory	US	9/15/2005	Book 52	FDA Correspondence - Phone call	Phone called (10:00 a.m.) from M. Robb to L. Tanner regarding proposed Date for Type C Meeting PK/PD.	2005-09-15_64915_CORR_PHONE_LTANNE_R_ROBBM_2.pdf	64,915
1	Regulatory	US	9/12/2005	Book 52	FDA Correspondence - Email	Email from L. Tanner to M. Robb regarding a Type C Meeting Request. S-087. Submission included.	2005-09-12_64915_CORR_EMAIL_LTANNE_R_MROBBB.pdf	64,915
1	Regulatory	US	9/12/2005	Book 52	FDA Submission - IND	Other: Type C Meeting Request, Development Plan for Biopharmaceutics and Clinical Pharmacology. S-087	S-087	64,915
1	Regulatory	US	9/7/2005	Book 52	FDA Submission - IND	Other: Request for FDA Review of QT/QTc Study Proposal. S-086	S-086	64,915

1	Regulatory	US	9/7/2005	Book 52	FDA Correspondence - Phone call	Phone call. L. Tanner/M. Robb. Subject: request to Submit QT/QTc Study Proposal to IND.	2005-09- 07_64915_CORR_PHONE_MROBB_ LTANNER.pdf	64,915
1	Regulatory	US	8/31/2005	Book 52	FDA Correspondence - Email	Email from L. Weissberger to M. Robb regarding a summary of the QT/QTc evaluation proposing for Ambrisentan (64,915) and Darusentan (59,669).	2005-08- 31_64915_CORR_EMAIL_WEISSBE RGERL_ROBBM.pdf	64,915
1	Regulatory	US	8/25/2005	Book 52	FDA Submission - IND	IND Safety Reports. S-085	S-085	64,915
1	Regulatory	US	8/24/2005	Book 52	FDA Correspondence - Phone call	Phone call. M. Robb/L. Tanner. Subject: FDA Decision that Food Effect Study Does not Need to Be Repeated	2005-08- 24_64915_CORR_PHONE_MROBB_ LTANNER.pdf	64,915
1	Regulatory	US	8/23/2005	Book 52	FDA Correspondence - Phone call	Phone call from M. Robb to L. Tanner. Subject: Clarify 7-day SAE Process for IND 63,412; Confirm FDA receipt of PDF file for Serial No. 084 (IND 64,915); Status of Serial No. 082 Food Effect (64, 915); Potential meeting PK/PD development plan (IND 64,915)	2005-08- 23_64915_CORR_PHONE_MROBB_ LTANNER.pdf	64,915
1	Regulatory	US	8/22/2005	Book 52	FDA Submission - IND	Other: Data Analysis Plan (AMB- 321) for FDA Feedback. S-084	S-084	64,915
1	Regulatory	US	8/22/2005	Book 52	FDA Correspondence - Phone call	Phone call from L. Tanner to M. Robb. Subject: Clarify 7-day SAE Process; Status of Serial No. 082 Food Effect; Notification of DAP Submission.	2005-08- 22_64915_CORR_PHONE_LTANNE R_MROBB.pdf	64,915
1	Regulatory	US	8/22/2005	Book 52	FDA Correspondence - Fax	Fax from L. Tanner to M. Robb. Subject: 7 Day Safety Report - Initial Manufacturer's Report No. 52505.	2005-08- 22_64915_CORR_FAX_LTANNER_ MROBB.pdf	64,915
1	Regulatory	US	8/19/2005	Book 52	FDA Correspondence - Phone call	Phone call. From M. Cooper to T. Marshall. Subject: Division feedback on ambrisentan starting materials (IND 64,915, Serial No. 083)	2005-08- 19_64915_CORR_PHONE_MCOOP ER_TMARSHALL.pdf	64,915
1	Regulatory	US	8/19/2005	Book 52	FDA Correspondence - Phone call	Phone call. From T. Marshall to M. Robb. On 8/18/2005 T. Marshall left voice message and on 8/19/2005 phoned M. Robb. Subject: Follow-up on requested feedback on starting materials from IND 64,915, Serial No. 083 dated 08/04/2005.	2005-08- 19_64915_CORR_PHONE_TMARSH ALL_MROBB.pdf	64,915

1	Regulatory	US	8/4/2005	Book 57	FDA Submission - IND	Information Amendment: Chemistry, Manufacturing and Controls. S-083	S-083	64,915
1	Regulatory	US	8/4/2005	Book 52	FDA Correspondence - Phone call	Phone call from L. Tanner to M.Robb. Subject: Confirm submission of S-082 Formulations Food/Effect.	2005-08-04_64915_CORR_PHONE_LTANNE_R_MROBB.pdf	64,915
1	Regulatory	US	8/4/2005	Book 52	FDA Correspondence - Phone call	Phone call from T. Marshall to M.Robb. Left phone message. Subject: Informed Project Manager of Drug Substance CMC Information Amendment and Requested Feedback on Starting Materials.	2005-08-04_64915_CORR_PHONE_TMARSH_ALL_MROBB.pdf	64,915
1	Regulatory	US	8/4/2005	Book 52	FDA Correspondence - Email	Email from L. Tanner to M.Robb regarding submission S-082. Submission included.	2005-08-04_64915_CORR_EMAIL_LTANNE_R_MROBB.pdf	64,915
1	Regulatory	US	8/3/2005	Book 52	FDA Submission - IND	Response To FDA Request For Information. S-082	S-082	64,915
1	Regulatory	US	7/26/2005	Book 56	FDA Submission - IND	Protocol Amendment. New Investigators.S-081 Keogh, Noordegraaf, Jennings, Murali, Schilz, Campos, Chatkin, Arakaki, Cardozo, Meyer, Kopisa, Hassoun, Feldman. S-081	S-081	64,915
1	Regulatory	US	6/30/2005	Book 51	FDA Submission - IND	Protocol Amendment. Annual Report. S-080	S-080	64,915
1	Regulatory	US	6/20/2005	Book 51	FDA Submission - IND	Protocol Amendment: New Investigators. Badesch, Foley, McGoon, Hassoun, Oudiz. Other: Revisions to FDA Form 1572. S-079	S-079	64,915
1	Regulatory	US	5/24/2005	Book 51	FDA Submission - IND	General Correspondence: Converting ARIES-2 Study Sites to ARIES-1. S-078	S-078	64,915
1	Regulatory	US	5/23/2005	Book 51	FDA Submission - IND	Protocol Amendment: New Investigators. Baratz, Barst, Fairman, Garcia, Mandel, Oudiz, Test. S-077	S-077	64,915
1	Regulatory	US	5/6/2005	Book 51	FDA Correspondence - Phone call	Phone call. L.Weissberger/M.Robb. Subject: Follow-up on requirement for food effects study.	2005-05-06_64915_CORR_PHONE_LWEISSBERGER_MROBB.pdf	64,915

1	Regulatory	US	5/3/2005	Book 51	FDA Correspondence - Phone call	Phone call. L. Weissberger/M. Robb. Subject: Clarify message from Dr. Velazquez.	2005-05-03_64915_CORR_PHONE_LWEISS BERGER_MROBB.pdf	64,915
1	Regulatory	US	5/7/2005	Book 51	FDA Correspondence - Phone call	Phone call. L. Weissberger/L. Velazquez. Subject: Protocol AMB-222.	2005-05-02_64915_CORR_PHONE_LWEISS BERGER_LVELAZQUEZ.pdf	64,915
1	Regulatory	US	4/29/2005	Book 51	FDA Correspondence - Email	Email/M. Robb/L. Weissberger - 2- Year Rat and Mouse Bioassays.	2005-04-29_64915_CORR_EMAIL_LTANNE R_MROBB.pdf	64,915
1	Regulatory	US	4/27/2005	Book 51	FDA Submission - IND	Protocol Amendment: New Investigators. S-076 Kilinger, Hurewitz, Feldman, Arfaei, Nikolaevich. S-076	S-076	64,915
1	Regulatory	US	4/25/2005	Book 51	FDA Correspondence - Phone call	Phone call. L. Weissberger/T. Link. FDA Response to our proposal for carcinogenicity studies.	2005-04-25_64915_CORR_PHONE_LWEISS BERGER_WLINK.pdf	64,915
1	Regulatory	US	4/22/2005	Book 51	FDA Correspondence - Phone call	Call to discuss 2-yr. Carcinogenicity studies.	2005-04-22_64915_CORR_PHONE_LWEISS	64,915
1	Regulatory	US	4/12/2005	Book 51	FDA Submission - IND	Protocol Amendment: Change in Protocol. S-075	S-075	64,915
1	Regulatory	US	4/5/2005	Book 53-55	FDA Submission - IND	Vol. 1 - 3 -Response to FDA Request for Information. S-074	S-074	64,915
1	Regulatory	US	4/1/2005	Book 51	FDA Correspondence - Email	Email/M. Robb/L. Weissberger - Response to FDA Request for Information	2005-04-01_64915_CORR_EMAIL_LTANNE R_MROBB.pdf	64,915
1	Regulatory	US	3/31/2005	Book 50	FDA Submission - IND	Protocol Amendment - L. Weissberger. New Investigator, Test, Noordgraaf, Kovalenko, Zagolin, Revisions to FDA Forms 1572. S-073	S-073	64,915
		US	3/28/2005	Book 50	FDA Correspondence - Fax	Response to a request from FDA, and follow-up	2005-03-28_64915_CORR_FAX_JFLIARD_N BEASLEY.pdf	64,915
1	Regulatory	US	3/24/2005	Book 50	FDA Submission - IND	Follow-up to a written Report. S- 072	S-072	64,915
1	Regulatory	US	3/16/2005	Book 50	FDA Correspondence - Letter	Stockbridge, N., Letter: Response to S 068 - Protocol Submission	2005-03-16_64915_CORR_LETTER_MROBB _LWEISSBERGER.pdf	64,915

1	Regulatory	US	3/9/2005	Book 50	FDA Submission - IND	L. Weissberger. Information Amendment. Pharmacology/Toxicology 2 year Rat and Mouse Carcinogenicity Studies. S-071	S-071	64,915
1	Regulatory	US	3/4/2005	Book 50	FDA Submission - IND	L. Weissberger. Protocol Amendment: New Investigators, Hassoun, Tereshchenko, Chakinala. S-070	S-070	64,915
1	Regulatory	US	2/18/2005	Book 50	FDA Submission - IND	L. Weissberger. General Correspondence. S-069	S-069	64,915
1	Regulatory	US	2/16/2005	Book 50	FDA Correspondence - Phone call	FDA Contact Report - Telephone. M. Robb/L. Weissberger. Subject: Existing "Food Effect" Study.	2005-02-16_64915_CORR_PHONE_LWEISSBERGER_MROBB.pdf	64,915
1	Regulatory	US	2/15/2005	Book 50	FDA Submission - IND	L. Weissberger. New Protocol: AMB-222. S-068	S-068	64,915
1	Regulatory	US	2/4/2005	Book 50	FDA Submission - IND	L. Weissberger. Protocol Amendment New Investigators, Colque, Noordegraaf, Chazova (AMB-321, AMB-320/321-E) S-067	S-067	64,915
1	Regulatory	US	1/5/2005	Book 50	FDA Submission - IND	L. Weissberger. Protocol Amendment. New Investigators (AMB-321, AMB-320/321-E, AMB-320/321-E, S-066)	S-066	64,915
1	Regulatory	US	12/22/2004	Book 50	FDA Submission - IND	L. Weissberger. Protocol Amendment: New Investigators, Taichman, Hurewitz, Gene, Kremer, Abrahamovych (AMB-320, AMB-321, AMB-320/321-E) S-065	S-065	64,915
1	Regulatory	US	12/17/2004	Book 50	FDA Correspondence - Phone call	FDA Contact Report - Telephone. L. Weissberger/W. Link. Subject: Executive CAC decision about lowering dose(s) for 2 year rat and mouse bioassays.	2004-12-17_64915_CORR_PHONE_WEISSBERGER_LINK.pdf	64,915
1	Regulatory	US	12/7/2004	Book 50	FDA Submission - IND	L. Weissberger-Information Amendment- Pharmacology/Toxicology. 2-year Rat and Mouse Carcinogenicity. S-064	S-064	64,915

1	Regulatory	US	11/12/2004	Book 50	FDA Submission - IND	L. Weissberger - Protocol Amendment: New Investigators: Kramer, M.R., Barst, R.J., Lawrence, E.C., Park, M.H., Schilz, R.J. (AMB-321, AMB-320/321-E) S-063	S-063	64,915
1	Regulatory	US	10/29/2004	Book 49	FDA Submission - IND	L. Weissberger - Protocol Amendment: New Investigators: Langleben, D., Carlson, R., Diez, F., Porcile, R., Ubaldini, J.E., Vico, M.L., Tereschenko, S., Semernin, E.N. (AMB-320, AMB-321, AMB-320/321-E) S-062	S-062	64,915
1	Regulatory	US	10/26/2004	Book 49	FDA Correspondence - Fax	FDA Correspondence - Fax - Meeting Minutes 10/13/04.	2004-10-26_64915_CORR_FAX_MTG_MINS_2004-10-13.pdf	64,915
1	Regulatory	US	10/22/2004	Book 49	FDA Submission - IND	L. Weissberger - Protocol Amendment-New Principal Investigators: Martinez, J.G., Vazquez, J., Chazova, Irina, Y., Kostenko, M.A., Czuriga, I., Landzberg, M.J., (AMB-320, AMB-321, AMB-320/321-E) S-061	S-061	64,915
1	Regulatory	US	10/5/2004	Book 49	FDA Submission - IND	L. Weissberger - Protocol Amendment. New Investigators. M. Amuchastegui, G. Bortman, E. Perna, K. Karlocai, O. Abrahamovych, G. Dzyak, N. Kopitsa, V. Kovalenko, S. Polyvoda, F. Kleber, P. Podolec, A. Torbicki, V. McLaughlin, A. Towlar (AMB-320, AMB-321, AMB-320/321-E) S-060	S-060	64,915
1	Regulatory	US	9/27/2004	Book 49	FDA Submission - IND	Lynn Weissberger - Type C Meeting Information Package. S-059	S-059	64,915

1	Regulatory	US	9/7/2004	Book 48	FDA Submission - IND	Lynne Weissberger - Protocol Amendment. New Investigators. R. Sulica, I. Czuriga, P. Podolec, A. Torbicki, I. Ben-Dov, R.P. Allen, R.J. Oudiz (AMB-320, AMB-321, AMB-320/321-E) S-058	S-058	64,915
1	Regulatory	US	8/31/2004	Book 48	FDA Submission - IND	Lynne Weissberger - Annual Report 07-03-2003 through 07-02-2004. S-057	S-057	64,915
1	Regulatory	US	8/27/2004	Book 48	FDA Submission - IND	Protocol Amendment - L. Weissberger - Initial Written Report. 15-Day Safety Alert Report. (AMB-320/321-E) S-056	S-056	64,915
1	Regulatory	US	8/11/2004	Book 48	FDA Correspondence - Fax	Fax from R. Fortney to L. Weissberger. Subject: Meeting confirmation with FDA for October 13, 2004.	2004-08-11_64915_CORR_FAX_RFORTNEY_LWEISSBERGER.pdf	64,915
1	Regulatory	US	8/10/2004	Book 48	FDA Submission - IND	L. Weissberger-Protocol Amendment New Investigators. R.Barst, M.L.Lamdzberg, M.A.G.Sanchez, J.A.Barbera, D.Badesch, R.Foley (AMB-320, AMB-320/321-E) S-055	S-055	64,915
1	Regulatory	US	8/9/2004	Book 48	FDA Submission - IND	L. Weissberger - Type C Meeting Request to discuss proposed changes to the ambrisentan program. S-054	S-054	64,915
1	Regulatory	US	7/20/2004	Book 48	FDA Correspondence - Phone call	FDA Contact Report - Call to Alisea Sermon. Subject: Schedule Type C Meeting.	2004-07-20_64915_CORR_PHONE_LWEISSBERGER_ASERMON.pdf	64,915
1	Regulatory	US	7/21/2004	Book 48	FDA Correspondence - Email	FDA Contact Report - Email to A. Sermon. Subject: Meeting Request with the Division of Cardio-Renal drug Products.	2004-07-21_64915_CORR_EMAIL_LWEISSBERGER_ASERMON.pdf	64,915
1	Regulatory	US	7/16/2004	Book 47	FDA Correspondence - Phone call	FDA Contact Report - Call to M. Robb. Subject: Type C Meeting Request.	2004-07-16_64915_CORR_PHONE_LWEISSBERGER_MROBB.pdf	64,915

1	Regulatory	US	7/15/2004	Book 47	FDA Correspondence - Email	FDA Contact Report - Email to M. Robb. Subject: Ambrisentan, Type C Meeting Request.	2004-07-15_64915_CORR_EMAIL_LWEISSBERGER_MROBB.pdf	64,915
1	Regulatory	US	7/14/2004	Book 47	FDA Submission - IND	L. Weissberger- Protocol Amendment- New Investigators- A. Frost, P. Galvez, H. Donoso, M. Delcroix, G. Simonneau, J. Behr, R. Fairman, A. Frost (AMB-320, AMB-321, AMB-320/321-E) S-053	S-053	64,915
1	Regulatory	US	7/7/2004	Book 47	FDA Submission - IND	L. Weissberger- Protocol Amendment- New Investigators- D. Baratz, J. Edelman, N. Hill, I. Robbins, M. Robbins, S. Shapiro, S. Bhorade (AMB-320/321-E) S-052	S-052	64,915
1	Regulatory	US	6/23/2004	Book 47	FDA Submission - IND	L. Weissberger-Protocol Amendment- New Investigators - A. Waxman, P. Corris, A. Peacock, J. Pepke-Zaba, J. Gossage, J. Klinger, K. Mubarak, S. Murali (AMB-320, AMB-321, AMB-320/321-E) S-051	S-051	64,915
1	Regulatory	US	5/27/2004	Book 47	FDA Correspondence - Letter	FDA Contact Report -AMB Orphan Drug Application - Amendment - Reference Number: 04-1836	2004-05-27_ODA_US_AMENDMENT.pdf	64,915
1	Regulatory	US	5/7/2004	Book 47	FDA Submission - IND	L. Weissberger- Protocol Amendment: New Investigators R. Allen, S. Murali, R. Oudiz, J. Wirth, J. Behr, J. Albert Barbera, C. Black, R. Channick, M. McGoon, F. Torres (AMB-320, AMB-321, AMB-320/321-E) S-050	S-050	64,915
1	Regulatory	US	5/6/2004	Book 46	FDA Submission - IND	L. Weissberger- Protocol Amendment: Change in Protocols: 320, 321, 320/321-E. S-049	S-049	64,915

1	Regulatory	US	5/3/2004	Book 46	FDA Correspondence - Phone call	FDA Contact Report - Call to Melissa Robb. Subject: To discuss darusentan submission & PK program for ambrisentan.	2004-05-03_64915_CORR_PHONE_LWEISS BERGER_MROBB.pdf	64,915
1	Regulatory	US	4/28/2004	Book 46	FDA Correspondence - Phone call	FDA Contact Report - Call to Brad Glasscock, Tan Nguyen. Subject: To clarify request for information from Brad Glasscock.	2004-04-28_64915_CORR_PHONE_LWEISS BERGER_GLASSCOCK.pdf	64,915
1	Regulatory	US	4/22/2004	Book 46	FDA Correspondence - Email	FDA Contact Report - Email. L. Weissberger/P. Marroum. Email with attached word document - Feedback on Proposed Changes to AMB-320/321-E.	2004-04-22_64915_CORR_EMAIL_LWEISS BERGER_PMARROUM.pdf	64,915
1	Regulatory	US	4/21/2004	Book 46	FDA Correspondence - Phone call	FDA Contact Report - Dr. Glasscock called to inquire as to the status of the requested amendment.	2004-04-21_64915_CORR_PHONE_BGLASSCOCK_LWEISSBERGER.pdf	64,915
1	Regulatory	US	4/12/2004	Book 46	FDA Submission - IND	Protocol Amendment - L. Weissberger- New Investigators J. Edelman, J. Mandel, M. Park, R. Schiltz, H. Olschewski (AMB-320, AMB-321, AMB-320/321-E) S-048	S-048	64,915
1	Regulatory	US	4/8/2004	Book 46	FDA Correspondence - Phone call	FDA Contact Report- Call to Jeffrey Fritsch to inquire the status of application - J. Fritsch was out of office and Mary Grice answered questions.	2004-04-08_64915_CORR_PHONE_LWEISS BERGER_BGLASSCOCK.pdf	64,915
1	Regulatory	US	4/7/2004	Book 46	FDA Correspondence - Phone call	FDA Contact Report- Comments on proposed changes to extension protocol - pop: K and PK sub study.	2004-04-07_64915_CORR_PHONE_LWEISS BERGER_MROBB.pdf	64,915
1	Regulatory	US	3/26/2004	Book 45	FDA Submission - IND	Protocol Amendment - L. Weissberger- New Investigators- N. Hill, C. Jennings, M. McGoon, D. Zwickel, S. Maruti Bhorade (AMB-320, AMB-321, AMB-320/321-E) S-047	S-047	64,915
1	Regulatory	US	3/25/2004	Book 45	FDA Submission - IND	L. Weissberger-Type C Meeting Request. S-046	S-046	64,915
1	Regulatory	US	3/17/2004	Book 45	FDA Submission - IND	L. Weissberger- Pharmacology/Toxicology 2-Year Rat and Mouse Final Protocols. S-045	S-045	64,915

1	Regulatory	US	3/5/2004	Book 45	FDA Submission - IND	Protocol Amendment - L. Weissberger- New Investigators- D. Badesch, R. Foley, E. Lawrence, I. Robbins, S. Shapiro (AMB-320) S-044	S-044	64,915
1	Regulatory	US	2/27/2004	Book 44	FDA Submission - IND	Protocol Amendment - L. Weissberger- New Investigators- R. Channick, K. Mubarak, F. Torres, R. Naeija, N. Galie, A. Keogh (AMB-320, AMB-321, AMB-320/321-E) S-043	S-043	64,915
		US	2/24/2004	Book 44	FDA Correspondence - Fax	Response to Carcinogenicity Protocol Assessment Request - Final CAC Report.	2004-02-24_64915_CORR_FAX_SEIFRIED_WALDO.pdf	64,915
1	Regulatory	US	2/24/2004	Book 44	FDA Correspondence - Letter	J. Fritsch- Acknowledge receipt of application for orphan designation submitted.	2004-02-24_ODA_US_CORR_LETTER_ASSI_GN_ODA_NUMBER.pdf	64,915
1	Regulatory	UK	2/20/2004	Book 44	Foreign Correspondence - MHRA	Clinical Trial Application UK - MHRA-Exemption from licenses.	2004-02-20_64915_MHRA_CORR_LETTER.pdf	64,915
1	Regulatory	US	2/16/2004	Book 44	FDA Submission - IND	Protocol Amendment - L. Weissberger- New Investigators- J. Gossage, M. Delcroix, G. Simonneau, F. Xavier Kleber, I. Ben-Dov, and P. Engel (AMB-320, AMB-321, AMB-320/321-E) S-042	S-042	64,915
1	Regulatory	US	2/13/2004	Book 44	FDA Submission - IND	L. Weissberger-Information Amendment- Updated IB.	S-041	64,915
1	Regulatory	US	1/30/2004	Book 44	FDA Submission - IND	L. Weissberger-Change in US Agent from Quintiles, Inc. to Myogen, Inc. S-040	S-040	64,915
1	Regulatory	US	1/28/2004	Book 44	FDA Correspondence - Fax	Fax - Response to Carcinogenicity Protocol Assessment Request - Final CAC Report.	2004-01-28_64915_CORR_FAX_FDA.pdf	64,915
1	Regulatory	US	1/16/2004	Book 44	FDA Correspondence - Fax	Z. McDonald- Receipt of request - Serial No. 036 for a special carcinogenicity protocol assessment.	2004-01-16_64915_CORR_FAX_FDA.pdf	64,915

1	Regulatory	US	1/15/2004	Book 44	FDA Submission - IND	Protocol Amendment - New Investigators-R. Fairman, M. Robbins, H. Garcia (AMB-320, AMB-320/321-E) S-039	Investigator's R. Fairman, M. Robbins, H. Garcia (AMB-320, AMB-320/321-E) S-039	S-039	64,915
1	Regulatory	US	1/14/2004	Book 44	FDA Correspondence - Email	Special assessment for 2-year mouse carcinogenicity protocol.	14_64915_CORR_EMAIL_CWALDO_MROBB.pdf	2004-01-14_64915_CORR_EMAIL_CWALDO_MROBB.pdf	64,915
1	Regulatory	US	1/12/2004	Book 44	FDA Submission - IND	Courtesy copy of Orphan Drug Application (Cover Letter) S-038	Courtesy copy of Orphan Drug Application (Cover Letter) S-038	S-038	64,915
1	Regulatory	US	1/6/2004	Book 44	FDA Submission - IND	Protocol Amendment - New Investigators- Keogh, Baratz, Engel, Garcia, Klinger (AMB-320-E) S-037	Protocol Amendment - New Investigators- Keogh, Baratz, Engel, Garcia, Klinger (AMB-320-E) S-037	S-037	64,915
1	Regulatory	US	1/5/2004	Book 44	FDA Correspondence - Letter	Letter from - M. Gerber to Dr. Haffner about transfer of responsibility as US Agent and Authorized Representative effective Dec. 12, 2003, quintiles, Inc. assumes the responsibility from Myogen, Inc. as the US Agent to interact with the office of Orphan Products Development	Letter from - M. Gerber to Dr. Haffner about transfer of responsibility as US Agent and Authorized Representative effective Dec. 12, 2003, quintiles, Inc. assumes the responsibility from Myogen, Inc. as the US Agent to interact with the office of Orphan Products Development	2004-01-05_64915_CORR_LETTER_HAFNER_WALDO.pdf	64,915
1	Regulatory	US	1/5/2004	Book 44	FDA Correspondence - Letter	Letter from - C. Waldo to Dr. Haffner regarding application for Orphan Drug designation	Letter from - C. Waldo to Dr. Haffner regarding application for Orphan Drug designation	2004-01-05_64915_CORR_LETTER_HAFNER_WALDO.pdf	64,915
1	Regulatory	US	12/18/2003	Book 43	FDA Submission - IND	Request for Special Protocol Assessment 2-Year Mouse Carcinogenicity Protocol. S-036	Request for Special Protocol Assessment 2-Year Mouse Carcinogenicity Protocol. S-036	S-036	64,915
1	Regulatory	US	12/2/2003	Book 43	FDA Submission - IND	Change in Protocol: 220-E. S-035	Change in Protocol: 220-E. S-035	S-035	64,915
1	Regulatory	US	11/24/2003	Book 43	FDA Correspondence - Fax	FDA Contact Report. Fax. Subject: Response to Carcinogenicity Protocol Assessment Request - Final CAC	FDA Contact Report. Fax. Subject: Response to Carcinogenicity Protocol Assessment Request - Final CAC	2003-11-24_64915_CORR_FAX_SEIFRIED_WALDO.pdf	64,915
1	Regulatory	US	10/20/2003	Book 43	FDA Correspondence - Letter	Report - IND 64,915 FDA Contact Report-Z. McDonald-Acknowledgement of receipt from Oct. 13, 2003, request for a special carcinogenicity protocol assessment.	Report - IND 64,915 FDA Contact Report-Z. McDonald-Acknowledgement of receipt from Oct. 13, 2003, request for a special carcinogenicity protocol assessment.	2003-10-20_64915_CORR_LETTER_ZMCDONALD_MGERBER.pdf	64,915
1	Regulatory	US	10/13/2003	Book 43	FDA Submission - IND	Request for special protocol assessment 2-Year Rat Carcinogenicity Protocol. S-034	Request for special protocol assessment 2-Year Rat Carcinogenicity Protocol. S-034	S-034	64,915

1	Regulatory	US	10/9/2003	Book 42	FDA Correspondence - Phone call	FDA Contact Report- Response to questions.	2003-10-09_64915_CORR_PHONE_CWALDO_MROBB.pdf	64,915
1	Regulatory	US	10/8/2003	Book 42	FDA Correspondence - Email	C. Waldo-Response to Carcinogenicity Protocol Assessment Request.	2003-10-08_64915_CORR_EMAIL_CWALDO_MROBB.pdf	64,915
1	Regulatory	US	10/8/2003	Book 42	FDA Submission - IND	New Phase III Protocols: 320, 321, 320/321-E Response Requested. S-033	S-033	64,915
1	Regulatory	US	10/7/2003	Book 42	FDA Correspondence - Email	FDA Contact Report- Email - Phase III Protocols. C. Waldo.	2003-10-07_64915_CORR_EMAIL_CWALDO_MROBB.pdf	64,915
1	Regulatory	US	10/7/2003	Book 42	FDA Correspondence - Phone call	FDA Contact Report- Regarding request for feedback.	2003-10-07_64915_CORR_PHONE_WALDO_ROBB.pdf	64,915
1	Regulatory	US	10/7/2003	Book 42	FDA Correspondence - Phone call	FDA Contact Report- Phone call - Left v-mail regarding request for feedback.	2003-10-07A_64915_CORR_PHONE_ROBB_WALDO.pdf	64,915
1	Regulatory	US	9/9/2003	Book 42	FDA Correspondence - Fax	FDA Correspondence - Fax - 8/27/03 Meeting Minutes.	2003-09-09_64915_CORR_FAX_ROBB_WALDO.pdf	64,915
1	Regulatory	US	9/9/2003	Book 42	FDA Correspondence - Phone call	FDA Contact Report- Confirm receipt of fax containing the meeting minutes from the 8/27/2003 meeting with the division.	2003-09-09_64915_CORR_PHONE_ROBB_WALDO.pdf	64,915
1	Regulatory	US	9/9/2003	Book 42	FDA Submission - IND	Protocol Amendment: New investigators: D. Badesch, M. McGoon, S. Rich, M. Landzberg, R. Barst (AMB-220-E) S-032	S-032	64,915
1	Regulatory	US	9/4/2003	Book 42	FDA Correspondence - Phone call	FDA Contact Report-Special Protocol Assessment.	2003-09-04_64915_CORR_PHONE_CWALDO_MROBB.pdf	64,915
1	Regulatory	US	9/3/2003	Book 42	FDA Submission - IND	IND Annual Report. S-031	S-031	64,915
1	Regulatory	US	8/27/2003	Book 41	FDA Correspondence - Phone call	FDA Contact Report- Verify FDA meeting attendees.	2003-08-27_64915_CORR_PHONE_CWALDO_MROBB.pdf	64,915
1	Regulatory	US	8/27/2003	Book 41	FDA Correspondence - Meeting	Meeting Minutes from - August 27, 2003 meeting with FDA.	2003-08-27_64915_CORR_MEETING_CWALDO_MROBB.pdf	64,915

1	Regulatory	US	8/22/2003	Book 41	FDA Correspondence - Phone call	FDA Contact Report- End of Phase II Meeting.	2003-08-22_64915_CORR_PHONE_CWALD_O_MROBB.pdf	64,915
1	Regulatory	US	8/8/2003	Book 41	FDA Correspondence - Phone call	FDA Contact Report- Copies for August 27 Meeting.	2003-08-08_64915_CORR_PHONE_CWALD_O_MROBB.pdf	64,915
1	Regulatory	US	8/8/2003	Book 41	FDA Correspondence - Letter	FDA Correspondence - Letter - 4 Additional copies of the info. Package for 8/27/03 meeting.	2003-08-08_64915_CORR_LETTER_INFO_PKG_COPIES.pdf	64,915
1	Regulatory	US	8/7/2003	Book 41	FDA Correspondence - Phone call	FDA Contact Report- Confirm FDA receipt of Briefing Document for August 27 Meeting.	2003-08-07_64915_CORR_PHONE_CWALD_O_MROBB.pdf	64,915
1	Regulatory	US	8/5/2003	Book 41	FDA Correspondence - Phone call	FDA Contact Report- End of Phase II briefing package.	2003-08-05_64915_CORR_PHONE_MROBB_CWALDO.pdf	64,915
1	Regulatory	US	8/5/2003	Book 41	FDA Submission - IND	Information Package for August 27, 2003 Meeting. S-030	S-030	64,915
1	Regulatory	US	7/25/2003	Book 41	FDA Submission - IND	Protocol Amendment: New Investigators: Teresa De Marco (AMB-220-E) S-029	S-029	64,915
1	Regulatory	US	7/10/2003	Book 41	FDA Submission - IND	FDA - General Correspondence - Contact Information. S-028	S-028	64,915
1	Regulatory	US	7/8/2003	Book 41	FDA Correspondence - Fax	FDA Contact Report - Confirmation of Meeting g. August 27, 2003	2003-07-08_64915_CORR_FAX_MROBB_MENLOW.pdf	64,915
1	Regulatory	US	7/7/2003	Book 41	FDA Submission - IND	Protocol Amendment: New Investigators-L Robbins, S. Shapiro, AMB-220-E. S-027	S-027	64,915
1	Regulatory	US	7/2/2003	Book 41	FDA Submission - IND	Meeting Request: Type B. Request for Re-Scheduling. S-026	S-026	64,915
1	Regulatory	US	7/2/2003	Book 41	FDA Correspondence - Phone call	FDA Contact Report- M. Robb requested that we resubmit the request to reschedule the end of phase II meeting for IND 64,915	2003-07-02_64915_CORR_PHONE_MROBB_MENLOW.pdf	64,915
1	Regulatory	US	6/26/2003	Book 41	FDA Correspondence - Phone call	FDA Contact Report-R. Fortney checked on request to re-schedule the end-of Phase II meeting with Melissa Robb.	2003-06-26_64915_CORR_PHONE_RFORTNEY_MENLOW.pdf	64,915

		US	6/24/2003	Book 41	FDA Submission - IND	IND - Meeting Request - Type B Request for Re-Scheduling. S-025	S-025	64,915
1	Regulatory	US	6/23/2003	Book 41	FDA Correspondence - Phone call	FDA Contact Report- M.Robb requested that the end of Phase II meeting originally scheduled for July 11, 2003 be re-scheduled.	2003-06-23_64915_CORR_PHONE_MENLO W_MROBB.pdf	64,915
1	Regulatory	US	6/13/2003	Book 41	FDA Submission - IND	Protocol Amendment: New Investigators and Revision to FDA form 1572 (AMB-220-E) S-024	S-024	64,915
1	Regulatory	US	5/23/2003	Book 40	FDA Correspondence - Fax	FDA Contact Report-Fax - Confirmation of 7/1/03.	2003-05-23_64915_CORR_FAX_MROBB_ME NLOW.pdf	64,915
1	Regulatory	US	5/23/2003	Book 40	FDA Correspondence - Phone call	FDA Contact Report-M. Robb called Project Manager to confirm receipt of fax	2003-05-23_64915_CORR_PHONE_ATANNE R_MROBB.pdf	64,915
1	Regulatory	US	5/15/2003	Book 40	FDA Correspondence - Fax	FDA Correspondence - Fax - Formal meeting request for an End of Phase II meeting.	2003-05-15_64915_CORR_FAX_MENLOW_ MROBB.pdf	64,915
1	Regulatory	US	5/15/2003	Book 40	FDA Submission - IND	Meeting Request : Type B. S-023	S-023	64,915
1	Regulatory	US	5/6/2003	Book 40	FDA Submission - IND	Protocol Amendment- New Investigators. S-022	S-022	64,915
1	Regulatory	US	5/2/2003	Book 40	FDA Submission - IND	IND Safety Report - Follow-up IND Safety Report Mfg. Rpt. No. 29404 (Follow-up 1) S-021	S-021	64,915
1	Regulatory	US	4/22/2003	Book 40	FDA Submission - IND	General Correspondence - Transfer of Regulatory Obligations. S-020	S-020	64,915
1	Regulatory	US	4/1/2003	Book 40	FDA Submission - IND	General Correspondence - Duration of Chronic Toxicity Study. M. Enlow/D. Throckmorton. S-019	S-019	64,915
1	Regulatory	US	3/20/2003	Book 40	FDA Correspondence - Phone call	FDA Contact Report: Inquire about letter of intent for submission of Special Carcinogenicity Protocol submission.	2003-03-20_64915_CORR_PHONE_MENLO W_MROBB.pdf	64,915

1	Regulatory	US	3/19/2003	Book 40	FDA Submission - IND	General Correspondence - Copy of letter to investigators regarding two deaths (unrelated) and consent form changes. M.Enlow/D.Throckmorton. S-018	S-018	64,915
1	Regulatory	US	3/11/2003	Book 40	FDA Submission - IND	General Correspondence - Copy of Investigator Notification of IND Safety Report for elevated Liver Function Tests. M.Enlow/D.Throckmorton. S-017	S-017	64,915
1	Regulatory	US	3/10/2003	Book 40	FDA Correspondence - Phone call	FDA Contact Report: Express concern that report of elevated LFTs to greater than 8 times upper limit of normal was not initially considered a SAE and suggest the sponsors remind investigators of potential for hepatotoxicity and need for SAE reporting of such event. JPelayo, MD/M.Enlow.	2003-03-10_64915_CORR_PHONE_JPELAYO_MENLOW.pdf	64,915
1	Regulatory	US	3/7/2003	Book 40	FDA Correspondence - Phone call	FDA Contact Report: Project Manager communicates FDA decision on extension protocol AMB-220-E. L.Tanner/M.Robb.	2003-03-07_64915_CORR_PHONE_MROBB_ATANNER.pdf	64,915
1	Regulatory	US	3/5/2003	Book 40	FDA Submission - IND	IND 15-Day ADR Report. M.Enlow/FDA. S-016	S-016	64,915
1	Regulatory	US	3/5/2003	Book 40	FDA Correspondence - Fax	FDA Correspondence - Fax - Fax of submission dated 3/5/03 S-016.	2003-03-05_64915_CORR_FAX_MENLOW_MROBB.pdf	64,915
1	Regulatory	US	2/28/2003	Book 40	FDA Correspondence - Phone call	FDA Contact Report: Discuss case of increased liver function tests reported in study AMB-220.	2003-02-28_64915_CORR_PHONE_MENLOW_MROBB.pdf	64,915
1	Regulatory	US	2/27/2003	Book 40	FDA Correspondence - Phone call	FDA Contact Report: Check status of Division's review of extension Protocol, AMB-220-E. M. Enlow/M. Robb	2003-02-27_64915_CORR_PHONE_MENLOW_MROBB.pdf	64,915
1	Regulatory	US	2/11/2003	Book 40	FDA Correspondence - Phone call	FDA Contact Report: Discuss Typo's of year submitted on Protocol AMB220-E.	2003-02-11_64915_CORR_PHONE_MENLOW_MROBB.pdf	64,915
1	Regulatory	US	2/7/2003	Book 40	FDA Submission - IND	Protocol Amendment: New Protocol AMB 220-E. S-015	S-015	64,915

1	Regulatory	US	2/5/2003	Book 40	FDA Submission - IND	Protocol Amendment: New Investigators -McGoan, Landzberg, Marro, S-014	S-014	64,915
1	Regulatory	US	1/27/2003	Book 40	FDA Correspondence - Phone call	FDA Contact Report: Inform sponsors the Division is still discussing internally the open-label extension study, protocol AMB-222, and timing relative to the non-rodent chronic toxicity study.	2003-01-27_64915_CORR_PHONE_MROBB_MENLOW.pdf	64,915
1	Regulatory	US	1/24/2003	Book 40	FDA Correspondence - Phone call	FDA Contact Report: Discuss open-label extension study, protocol AMB-222, and timing relative to non-rodent chronic toxicity study. M. Robb & M. Enlow	2003-01-24_64915_CORR_PHONE_MROBB_MENLOW.pdf	64,915
1	Regulatory	US	1/20/2003	Book 40	FDA Correspondence - Phone call	FDA Contact Report: Message left-update on feedback request for proposal to provide open-label treatment beyond 24 wks.	2003-01-20_64915_CORR_PHONE_MENLOW_MROBB.pdf	64,915
1	Regulatory	US	1/14/2003	Book 40	FDA Submission - IND	Response to FDA Request - submitting safety monitoring plans for 12-wk Open-label Extension Period for AMB 220 and draft safety monitoring plans for AMB 222. S-013	S-013	64,915
1	Regulatory	US	1/14/2003	Book 40	FDA Correspondence - Phone call	FDA Contact Report - Confirm 12-wk extension period in Protocol AMB-220 could proceed.	2003-01-14_64915_CORR_PHONE_MROBB_MENLOW.pdf	64,915
1	Regulatory	US	1/13/2003	Book 40	FDA Correspondence - Phone call	FDA Contact Report - FDA Project Manager called to request additional IND 64,915 information. M. Robb and A. Tanner	2003-01-13_64915_CORR_PHONE_MROBB_ATANNER.pdf	64,915
1	Regulatory	US	1/13/2003	Book 40	FDA Correspondence - Fax	FDA Contact Report - Fax - Response to FDA Request for additional information regarding IND 64,915.	2003-01-13_64915_CORR_FAX_TANNER_MROBB.pdf	64,915
1	Regulatory	US	1/10/2003	Book 40	FDA Correspondence - Phone call	FDA Contact Report - Discuss causes of death in some animals in 26-wk rat toxicity study. M. Enlow & W. Link.	64915_CORR_PHONE_MENLOW_MROBB.pdf	64,915
1	Regulatory	US	1/10/2003	Book 40	FDA Correspondence - Phone call	FDA Contact Report - Inquire whether Melissa could provide update on Division's position on the explanation given for mortality in 26 wk rat toxicity study and moving into the extension phase of the clinical study.	2003-01-10A_64915_CORR_PHONE_MENLOW_MROBB.pdf	64,915

1	Regulatory	US	1/9/2003	Book 40	FDA Correspondence - Phone call	FDA Contact Report - Clarify their internal mtg. to discuss 26-wk toxicity studies & open-label extensions to the clinical study.	2003-01-09_64915_CORR_PHONE_MROBB_MENLOW.pdf	64,915
1	Regulatory	US	1/9/2003	Book 40	FDA Submission - IND	Protocol Amendment - New Investigators: AMB-220 Simonneau, France; McLaughlin, Robbins, & Shapiro, United States. S-012	S-012	64,915
1	Regulatory	US	1/9/2003	Book 40	FDA Correspondence - Phone call	FDA Contact Report - Arrange time for phone conference to discuss questions about the 26-wk toxicity study. W_Link, M. Enlow.	2003-01-09_64915_CORR_PHONE_MENLO_W_WLINK.pdf	64,915
1	Regulatory	US	1/8/2003	Book 40	FDA Correspondence - Phone call	FDA Contact Report - To clarify the date of their internal meeting to discuss the 26-week toxicity studies and the open-label extensions to the clinical study.	2003-01-08_64915_CORR_PHONE_MENLO_W_MROBB.pdf	64,915
1	Regulatory	US	1/2/2003	Book 40	FDA Submission - IND	General Correspondence - Rationale & Study Summary for additional long-term protocol. From Quintiles to Dr. Throckmorton. S-011	S-011	64,915
1	Regulatory	US	1/2/2003	Book 40	FDA Correspondence - Phone call	FDA Contact Report - Informed Melissa Robb that faxed copy of submission w- Rationale & Study Summary for Protocol AMB-222 sent.	2003-01-02_64915_CORR_PHONE_MENLO_W_MROBB.pdf	64,915
1	Regulatory	US	1/2/2003	Book 40	FDA Correspondence - Fax	FDA Contact Report - Fax - Copy of submission with rationale and summary to Dr. S-011.	2003-01-02_64915_CORR_PHONE_MENLOW_W_MROBB.pdf	64,915
1	Regulatory	US	12/30/2002	Book 2	FDA Correspondence - Phone call	FDA Contact Report - Follow-up regarding extension of treatment beyond 6 months.	2002-12-30_64915_CORR_PHONE_ENLOW_ROBB.pdf	64,915
1	Regulatory	US	12/24/2002	Book 2	FDA Correspondence - Phone call	FDA Contact Report - Follow-up regarding extension of treatment beyond 6 months.	2002-12-24_64915_CORR_PHONE_MROBB_MENLOW.pdf	64,915
1	Regulatory	US	12/23/2002	Book 2	FDA Correspondence - Phone call	FDA Contact Report - Inquire about date of Division's Internal mtg. To discuss 26 wk toxicity studies and whether Division would consider clinical extension protocol for treatment beyond 6 months.	2002-12-23_64915_CORR_PHONE_MENLO_W_MROBB.pdf	64,915

1	Regulatory	US	12/12/2002	Book 2	FDA Correspondence - Phone call	FDA Contact Report – Informed Quintiles that the Division scheduled an internal mtg. In January 2003 to discuss 26 wk toxicology studies.	2002-12- 12_64915_CORR_PHONE_MROBB_ MENLOW.pdf	64,915
1	Regulatory	US	12/11/2002	Book 2	FDA Correspondence - Phone call	FDA Contact Report – Informed Melissa Robb, new FDA project mgr. That the 26 wk toxicity study submitted and receipt confirmed.	2002-12- 11_64915_CORR_PHONE_MENLO W_MROBB.pdf	64,915
1	Regulatory	US	12/10/2002	Book 2	FDA Correspondence - Phone call	FDA Contact Report – Informed Zelda that 26 wk toxicology draft study report submitted. Zelda to provide name & phone # of new FDA project mgr for IND.	2002-12- 10_64915_CORR_PHONE_MENLO W_ZMCDONALD.pdf	64,915
1	Regulatory	US	12/9/2002	Book 34-39	FDA Submission - IND	Vol. 1 - 6 - Response to FDA Request for Information – 26 wk. Toxicity Studies (Draft Reports: Dog and Rat) S-010	S-010	64,915
1	Regulatory	US	11/8/2002	Book 2	FDA Submission - IND	Protocol Amendment - New Investigators – Olschewski, Schilz, Germany and United States (AMB- 220) S-009	S-009	64,915
1	Regulatory	US	11/6/2002	Book 2	FDA Submission - IND	Information Amendment: Clinical. S-008	S-008	64,915
1	Regulatory	US	10/29/2002	Book 1	FDA Submission - IND	Response to FDA Request for Information – Chemistry, Manufacturing & Controls. S-007	S-007	64,915
1	Regulatory	US	10/18/2002	Book 1	FDA Submission - IND	New Investigators – Keogh, Naeije, Hooper, Galie, Rubin, Frost, Zwicke, Australia, Belgium, Germany, Italy and United States (AMB-220) S-006	S-006	64,915
1	Regulatory	US	9/25/2002	Book 1	FDA Submission - IND	Protocol Amendment – New Investigators – DBadesch and Rdoyle (AMB-220) S-005	S-005	64,915
1	Regulatory	US	9/20/2002	Book 1	FDA Correspondence - Letter	FDA Contact Report – FDA completed chemistry review of 7-17- 2002 (S-002) submission & provided comments-requests. Dthrockmorton- JMFreytag-Myogen Menlow.	2002-09- 20_64915_CORR_LETTER_DTHRO CKMORTON_WFREYTAG.pdf	64,915
1	Regulatory	US	9/10/2002	Book 1	FDA Submission - IND	Protocol Amendment – New Investigators US: Roudiz 004 (AMB-220) - S-004	S-004	64,915

1	Regulatory	US	8/30/2002	Book 1	FDA Submission - IND	Protocol Amendment – Submitted Amendment 1, dated 7-26-2002 for Protocol No. AMB-220 (No Suggestions) - S-003	S-003	64,915
1	Regulatory	US	7/31/2002	Book 1	FDA Correspondence - Letter	FDA Contact Report – Letter from FDA with regard to Clinical Trials Data Bank, asking for review of protocol submitted with S-000 to determine if it is a trial for a serious disease or condition and if it is a trial to test effectiveness.	2002-07-31_64915_CORR_LETTER_JWOOD COCK_CKIRK.pdf	64,915
1	Regulatory	US	7/17/2002	Book 33	FDA Submission - IND	Information Amendment: Amendment to provide updated info for drug substance and drug product. (CHEMISTRY) - S-002	S-002	64,915
1	Regulatory	US	6/28/2002	Book 1	FDA Submission - IND	Information Amendment: Clinical Revised Informed Consent Form - S-001	S-001	64,915
1	Regulatory	US	6/28/2002	Book 1	FDA Correspondence - Fax	FDA Contact Report – Inform Zelda a revised Informed Consent form for Protocol AMB-220 was being sent to her as requested by Dr. Stockbridge.	2002-06-28_64915_CORR_FAX_MENLOW_Z_MCDONALD.pdf	
1	Regulatory	US	6/28/2002	Book 1	FDA Correspondence - Phone call	FDA Contact Report – Inform Zelda a revised Informed Consent form for Protocol AMB-220 was being sent to her as requested by Dr. Stockbridge.	2002-06-28_64915_CORR_PHONE_MENLOW_W_ZMCDONALD.pdf	64,915
1	Regulatory	US	6/25/2002	Book 1	FDA Correspondence - Phone call	FDA Contact Report – Request Chg to Informed Consent document & discuss Pharm-Tox required for supporting open-label extension study.	2002-06-25_64915_CORR_PHONE_NSTOCK BRIDGE_MENLOW.pdf	64,915
1	Regulatory	US	6/25/2002	Book 1	FDA Correspondence - Phone call	FDA Contact Report – Called Monica Cooper to discuss questions about stability data for the drug product.	2002-06-25_64915_CORR_PHONE_MENLOW_W_MCOOPER.pdf	64,915
1	Regulatory	US	6/24/2002	Book 1	FDA Correspondence - Phone call	FDA Contact Report – Monica Cooper call Marguerite - asked a few questions about the stability data for the drug product.	2002-06-24_64915_CORR_PHONE_MCOOPER_MENLOW.pdf	64,915
1	Regulatory	US	6/10/2002	Book 1	FDA Correspondence - Letter	FDA Correspondence - Letter - Acknowledgement of receipt of IND Application submitted.	2002-06-10_64915_CORR_LETTER_ZMCDONALD_WFREYTAG.pdf	

1	Regulatory	US	6/6/2002	Book 1	FDA Correspondence - Phone call	FDA Contact Report - To check- confirm receipt by Zelda of IND Submission.	2002-06- 06_64915_CORR_PHONE_ZMCDO NALD_MENLOW.pdf	64,915
1	Regulatory	US	6/3/2002	Book 1	FDA Correspondence - Phone call	FDA Contact Report - Inform Zelda BSF 208075 IND for PAH was shipped to FDA on June 3, 2002.	2002-06- 03_64915_CORR_PHONE_MENLO W_ZMCDONALD.pdf	64,915
	Regulatory	US	6/5/2002	Book 1	FDA Submission - IND	Vol 1 - 30 - Initial Submission BSF 208075 IND - 6/4/2002 Zelda's Approval Required 6/13/2002 \$-000	\$-000	64,915

Back to Section TOC

Back to Main TOC

Product	Department	Country	Document Date	Book Number	Document Type	Document Title	File Copy	Keywords
Ambrisentan: Pulmonary Arterial Hypertension - NDA 22-081 - CORRESPONDENCE								
LINK TO NDA AMENDMENTS								
1	Regulatory	US	7/20/2007	Temp 6	FDA Correspondence - Phone	H. Isokoski/D. Brum - phone call. Subject: Spanish translations of the RiskMAP tools. New reminder tools for LEAP. Correct address for waiver request for MedWatch forms for non-serious and labeled adverse events (Aes)	20_22081_CORR_PHONE_HISOKOSKI_D BRUM.pdf	22-081
1	Regulatory	US	7/20/2007	Temp 6	FDA Correspondence - Email	D. Brum - 7/20/2007 on foreign language translation.	2007-07-20_22081_CORR_EMAIL_HISOKOSKI_DB RUM.pdf	22-081
1	Regulatory	US	7/16/2007	Temp 6	FDA Correspondence - Email	D. Brum/H. Isokoski - Postmarketing Study Commitment Correspondence and Patent Information. NDA 22-081	2007-07-16_22081_CORR_EMAIL_HISOKOSKI_DB RUM.pdf	22-081
1	Regulatory	US	7/13/2007	Temp 6	FDA Correspondence - Email	D. Brum/H. Isokoski - Postmarketing Study Commitment Correspondence and Patent Information. NDA 22-081	2007-07-13_22081_CORR_EMAIL_HISOKOSKI_DB RUM.pdf	22-081
1	Regulatory	US	7/11/2007	Temp 6	FDA Correspondence - Phone	D. Brum/H. Isokoski - Letairis RiskMAP. To update the Division on the status of the submission and seek their advice on correct process.	2007-07-11_22081_CORR_PHONE_HISOKOSKI_D BRUM.pdf	22-081
1	Regulatory	US	7/11/2007	Temp 6	FDA Correspondence - Email	D. Brum/H. Isokoski - Letairis RiskMAP.	2007-07-11_22081_CORR_EMAIL_HISOKOSKI_DB RUM.pdf	22-081
1	Regulatory	US	7/9/2007	Temp 6	FDA Correspondence - Phone	T. Marshall/T. Bouie - Phone calls on June 21, June 29 and July 9, 2007. Subject: Post-Approval Supplement for Change to RPM in Dissolution Method. NDA 22-081	2007-07-09_22081_CORR_PHONE_TBOUIE_TMAR SHALL.pdf	22-081

1	Regulatory	US	7/9/2007	Temp 6	FDA Correspondence - Email	T.Marshall/T.Bouie - Teleconference (July 10) information with the list of attendees from Gilead and FDA attendees. NDA 22-081 for Letairis Tablets-Proposal for CBE-30 Post Approval Supplement-Increase in Dissolution Method Paddle Speed.	09_22081_CORR_EMAIL_TMARSHALL_TBOUIE.pdf	22-081
1	Regulatory	US	7/6/2007	Temp 6	FDA Correspondence - Email	L.Tanner/D.Brum - Notification of Last Day at Gilead.	06_22081_CORR_EMAIL_LTANNER_DBRUM.pdf	22-081
1	Regulatory	US	7/3/2007	Temp 6	FDA Correspondence - Email	L.Tanner/D.Brum - Respond from D.Brum to the questions regarding the Revising RiskMAP and Materials to Reflect "Prescriber"	03_22081_CORR_EMAIL_LTANNER_DBRUM.pdf	22-081
1	Regulatory	US	7/2/2007	Temp 6	FDA Correspondence - Phone	L.Tanner/D.Brum - Subject: Pediatric Plan. Revisions to RiskMAP and educational materials.	02_22081_CORR_PHONE_LTANNER_DBRUM.pdf	22-081
1	Regulatory	US	7/2/2007	Temp 6	FDA Correspondence - Email	L.Tanner/D.Brum - Proposed Plan for Revising RiskMAP and Materials to Reflect "Prescriber"	02_22081_CORR_EMAIL_LTANNER_DBRUM.pdf	22-081
1	Regulatory	US	6/22/2007	Temp 6	FDA Correspondence - Email	T.Marshall/T.Bouie - Proposal for CBE-30 Post Approval Supplement-Increase in Dissolution Method Paddle Speed. NDA 22-081	22_22081_CORR_EMAIL_TBOUIE_TMARSHALL.pdf	22-081
1	Regulatory	US	6/21/2007	Temp 6	FDA Correspondence - Phone	T.Marshall/S.Goldie - Post-Approval Supplement for Change to RPM in Dissolution Method. NDA 22-081	21_22081_CORR_PHONE_TMARSHALL_SGOLDIE.pdf	22-081
1	Regulatory	US	6/19/2007	Temp 6	FDA Correspondence - Phone	L.Tanner/D.Brum - Subject: Administrative process for post-approval submissions of PI to the NDA	19_22081_CORR_PHONE_LTANNER_DBRUM.pdf	22-081
1	Regulatory	US	6/15/2007	Temp 6	FDA Correspondence - Phone	L.Tanner/D.Brum - Subject: Final processes for approval. NDA 22-081	15_22081_CORR_PHONE_LTANNER_DBRUM.pdf	22-081
1	Regulatory	US	6/15/2007	Temp 6	FDA Correspondence - Letter	R.Temple/L.Tanner - The NDA 22-081 - Letairis, Approval Letter from FDA. PI attached.	15_22081_CORR_LETTER_RTEMPLE_LTANNER.pdf	22-081
1	Regulatory	US	6/15/2007	Temp 6	Internal Correspondence - Labeling Approval	ABS - GS22-081-000: LETAIRIS (ambrisentan) 5 and 10 mg tablets - RAAN CMC - Approved in the US on June 15, 2007	15_22081_CORR_RAAN_NOTIFICATION.pdf	22-081

1	Regulatory	US	6/14/2007	Temp 6	FDA Correspondence - Phone	L. Tanner/D. Brum, T. Marciniak, J. Hung - Resolve remaining issues with PI.	14_22081_CORR_PHONE_LTANNER_DBR UM.pdf	2007-06-	22-081
1	Regulatory	US	6/13/2007	Temp 6	FDA Correspondence - Phone	L. Tanner/D. Brum - Issues with opening files during Label Negotiation. Cancellation of teleconference between Gilead and FDA.	13_22081_CORR_PHONE_LTANNER_DBR UM.pdf	2007-06-	22-081
1	Regulatory	US	6/12/2007	Temp 6	FDA Correspondence - Phone	L. Tanner/D. Brum, J. Weaver, S. Berkman - Remaining issues with the RiskMAP	12_22081_CORR_PHONE_LTANNER_DBR UM_2.pdf	2007-06-	22-081
1	Regulatory	US	6/12/2007	Temp 6	FDA Correspondence - Phone	L. Tanner/D. Brum - Final inspection report for Site #207 (Nazareno Galie) Italy. Next steps for submitting Gilead comments for PI. Teleconference with FDA on Wednesday, 13 June 2007. Teleconference to discuss cyclosporine contraindication.	12_22081_CORR_PHONE_LTANNER_DBR UM.pdf	2007-06-	22-081
1	Regulatory	US	6/11/2007	Temp 6	FDA Correspondence - Phone	L. Tanner/T. Marciniak - Feedback regarding FDA comments to PI.	11_22081_CORR_PHONE_LTANNER_TM ARCINIACK.pdf	2007-06-	22-081
1	Regulatory	US	6/11/2007	Temp 6	FDA Correspondence - Phone	L. Tanner/R. Fortney - The phone calls (6/8/2007 & 6-11-2007) to proactively schedule teleconference to resolve any remaining NDA issues, particularly with the PI.	11_22081_CORR_PHONE_LTANNER_RFO RTNEY.pdf	2007-06-	22-081
1	Regulatory	US	6/11/2007	Temp 6	FDA Correspondence - Email	T. Marshall/G. Scott - Attachment NDA 22-081 Amend 019. Summary of CMC Agreements Reached During June 8, 2007 CMC Teleconference	11_22081_CORR_EMAIL_SGOLDIE_TMA RSHALL.pdf	2007-06-	22-081
1	Regulatory	US	6/11/2007	Temp 6	FDA Correspondence - Email	T. Marshall/G. Scott - Update on Gilead's ABS NDA 22-081 Amend 019. Summary of CMC Agreements Reached During June 8, 2007 CMC Teleconference	11_22081_CORR_EMAIL_SGOLDIE_TMA RSHALL_1.pdf	2007-06-	22-081
1	Regulatory	US	6/8/2007	Temp 6	FDA Correspondence - Phone	L. Tanner/T. Marciniak - Feedback regarding FDA comments to PI.	08_22081_CORR_PHONE_LTANNER_TM ARCINIACK.pdf	2007-06-	22-081
1	Regulatory	US	6/8/2007	Temp 6	FDA Correspondence - Email	T. Marshall/G. Scott - T Con participants.	08_22081_CORR_EMAIL_SGOLDIE_TMA RSHALL_1.pdf	2007-06-	22-081

1	Regulatory	US	6/7/2007	Temp 6	FDA Correspondence - Email	D. Brum/L. Tanner - Notifications about comments on PI	07_22081_CORR_EMAIL_LTANNER_DBR UM_2.pdf	22-081
1	Regulatory	US	6/7/2007	Temp 6	FDA Correspondence - Phone	L. Tanner/D. Brum. The phone calls on 06/06/07 and 06/07/07. Process and Timing for Receiving FDA Comments to PI. Process for submitting revised RiskMAP and associated Materials.	07_22081_CORR_PHONE_LTANNER_DBR UM.pdf	22-081
1	Regulatory	US	6/7/2007	Temp 6	FDA Correspondence - Email	L. Tanner/D. Brum. NDA 22-081: Tracleer Label	07_22081_CORR_EMAIL_LTANNER_DBR UM_1.pdf	22-081
1	Regulatory	US	6/7/2007	Temp 6	FDA Correspondence - Email	L. Tanner/D. Brum. NDA 22-081: Comments on Proposed RiskMAP	07_22081_CORR_EMAIL_LTANNER_DBR UM.pdf	22-081
1	Regulatory	US	6/7/2007	Temp 6	FDA Correspondence - Phone	L. Tanner/M. Gordon - Subject: Processes and Timing for Receiving FDA Comments to PI. Processes for submitting revised RiskMAP and associated Materials.	07_22081_CORR_PHONE_LTANNER_DBR UM_2.pdf	22-081
1	Regulatory	US	6/7/2007	Temp 6	FDA Correspondence - Phone	L. Tanner/M. Gordon - The phone calls to confirm that CRF pages for subject 2050/248-001 present and that there are no further outstanding issues regarding input into the PI.	07_22081_CORR_EMAIL_LTANNER_MG ORDON.pdf	22-081
1	Regulatory	US	6/6/2007	Book 5	FDA Correspondence - Email	M. Gordon/L. Tanner - &-day report; Subject 2050/248-001 (updated forms). The CRF's forms attached.	06_22081_CORR_EMAIL_LTANNER_MG ORDON_1.pdf	22-081
1	Regulatory	US	6/6/2007	Book 5	FDA Correspondence - Email	M. Gordon/L. Tanner - Message email from May 29, 2007 has been lacked.	06_22081_CORR_EMAIL_LTANNER_MG ORDON.pdf	22-081
1	Regulatory	US	6/6/2007	Book 5	FDA Correspondence - Email	L. Tanner/D. Brum. NDA 22-081: Reformatted MedGuide for LETAIRIS™ (ambrisentan)	06_22081_CORR_EMAIL_LTANNER_DBR UM.pdf	22-081
1	Regulatory	US	6/5/2007	Book 5	FDA Correspondence - Email	T. Marshall/G. Scott - The FDA participants - May 23, 2007 teleconference regarding NDA 22-081	05_22081_CORR_EMAIL_SGOLDIE_TMA RSHALL.pdf	22-081
1	Regulatory	US	6/5/2007	Book 5	FDA Correspondence - Phone	L. Tanner/D. Brum. Two phone calls on 06/04/07 and 06/05/07. Process for finalizing Medication Guide, PI, and RiskMAP	05_22081_CORR_PHONE_LTANNER_DBR UM.pdf	22-081

1	Regulatory	US	6/4/2007	Book 5	FDA Correspondence - Email	L.Tanner/D Brum. RiskMAP revised proposal.	04_22081_CORR_EMAIL_LTANNER_DBRUM.pdf	2007-06-22-081
1	Regulatory	US	6/2/2007	Book 5	FDA Correspondence - Email	D Brum/L. Tanner - MedGuide and PI	02_22081_CORR_EMAIL_DBRUM_LTANN.ER.pdf	2007-06-22-081
1	Regulatory	US	6/1/2007	Book 5	FDA Correspondence - Email	T. Marshall/S. Goldie. The response to CMC specification changes discussed during May 23, 2007 CMC teleconference. NDA 22-081 Amendment 0017 attached.	01_22081_CORR_EMAIL_SGOLDIE_TMARSHALL.pdf	2007-06-22-081
1	Regulatory	US	6/1/2007	Book 5	FDA Correspondence - Email	L.Tanner/D Brum. E-mail from Dan Brum, FDA Project Manager, who has requested that Gilead resend the Medication Guide for ambrisentan that "looks" like Tracleer. Attached are the Medication Guides for Tracleer and Letairis.	01_22081_CORR_EMAIL_DBRUM_LTANN.ER_1.pdf	2007-06-22-081
1	Regulatory	US	6/1/2007	Book 5	FDA Correspondence - Phone	L.Tanner/D Brum. Subject: Process for resolving PI Issues. FDA Minutes from 25 May 2007 Teleconference. Company Audit Details Dr. Galie.	01_22081_CORR_PHONE_LTANNER_DBRUM.pdf	2007-06-22-081
1	Regulatory	US	6/1/2007	Book 5	FDA Correspondence - Email	L.Tanner/D Brum. Email with two attachments. Subject: The Gilead details of the audit at Dr. Galie's site.	01_22081_CORR_EMAIL_DBRUM_LTANN.ER.pdf	2007-06-22-081
1	Regulatory	US	6/1/2007	Book 5	FDA Correspondence - Email	D Brum/L. Tanner. Email with the FDA Meeting Minutes from May 25, 2007.	01_22081_CORR_EMAIL_DBRUM_LTANN.ER_2.pdf	2007-06-22-081
1	Regulatory	US	5/31/2007	Book 5	FDA Correspondence - Phone	L.Tanner/D Brum - Phone contacts, May 18 - May 31, 2007. Subjects: Response to preliminary RiskMAP comments and finalization of RiskMAP. FDA comments to PI.	31_22081_CORR_PHONE_LTANNER_DBRUM.pdf	2007-05-22-081
1	Regulatory	US	5/31/2007	Book 5	FDA (DDMAC) Correspondence - Fax	J.Acbay/L.M.Hubbard. Fax regarding NDA 22-081 Letairis MACMIS ID # 15246. Comments from the DDMAC on the first submission.	31_22081_CORR_DDMAC_FAX.pdf	2007-05-22-081
1	Regulatory	US	5/30/2007	Book 5	FDA Correspondence - Email	L.Tanner/D Brum. Response to FDA Comments to RiskMAP. Cover Letter (Amendment No. 16 to NDA 22-081) attached.	30_22081_CORR_EMAIL_LTANNER_DBRUM.pdf	2007-05-22-081

1	Regulatory	US	5/25/2007	Book 5	FDA Correspondence - Email	L.Tanner/M.Gordon. 7 day report; CRF 248-001-2020	25_22081_CORR_EMAIL_LTANNER_MG ORDON.pdf	2007-05-	22-081
1	Regulatory	US	5/24/2007	Book 5	FDA Correspondence - Email	L.Tanner/D.Brum. Confirm Teleconference Time (2:30 EDT) and addition of Jennifer Stewart as a Participant.	24_22081_CORR_EMAIL_DBRUM_LTANN ER_3.pdf	2007-05-	22-081
1	Regulatory	US	5/24/2007	Book 5	FDA Correspondence - Email	L.Tanner/D.Brum. Acceptability of Revised Labeling (Primary and Secondary Packaging). NDA 22-081.	24_22081_CORR_EMAIL_DBRUM_LTANN ER_2.pdf	2007-05-	22-081
1	Regulatory	US	5/24/2007	Book 5	FDA Correspondence - Email	L.Tanner/D.Brum. RiskMAP Questions	24_22081_CORR_EMAIL_DBRUM_LTANN ER_1.pdf	2007-05-	22-081
1	Regulatory	US	5/24/2007	Book 5	FDA Correspondence - Email	L.Tanner/D.Brum. FDA comments to Packaging	24_22081_CORR_EMAIL_DBRUM_LTANN ER.pdf	2007-05-	22-081
1	Regulatory	US	5/23/2007	Book 5	FDA Correspondence - Email	T.Marshall/S.Goldie. Ambrisenian Registration Tablets Dissolutions Data.	23_22081_CORR_EMAIL_SGOLDIE_TMA RSHALL.pdf	2007-05-	22-081
1	Regulatory	US	5/22/2007	Book 5	FDA Correspondence - Email	L.Tanner/D.Brum. Confirmation of Participants and Call-in Number for FDA-Gilead Teleconference 05/25/2007.	22_22081_CORR_EMAIL_DBRUM_LTANN ER_1.pdf	2007-05-	22-081
1	Regulatory	US	5/21/2007	Book 5	FDA Correspondence - Email	L.Tanner/D.Brum. Clarification for Processes in Reviewing the RiskMAP; Including attachment of Meeting Minutes from March 29, 2007 teleconference with FDA.	21_22081_CORR_EMAIL_DBRUM_LTANN ER_1.pdf	2007-05-	22-081
1	Regulatory	US	5/21/2007	Book 5	FDA Correspondence - Email	L.Tanner/D.Brum. Acceptability of Revised Labeling (Primary and Secondary Packaging). NDA 22-081.	21_22081_CORR_EMAIL_DBRUM_LTANN ER.pdf	2007-05-	22-081
1	Regulatory	US	5/17/2007	Book 5	FDA Correspondence - Letter	E.Fromm/L.Tanner. Discipline Review Letter. The comments on the RiskMAP portion of NDA 22-081 from the Office of Surveillance and Epidemiology.	17_22081_CORR_LETTER_EFROMM_LTANNER.pdf	2007-05-	22-081
1	Regulatory	US	5/14/2007	Book 5	FDA Correspondence - Phone	T.Marshall/S.Goldie (Calles made on 4/30/07, 05/02/07, 05/03/07, 05/08/07, 05/14/07) - CMC Information Request, NDA Amendment 13: Updating List of Establishments and Pre-Approval Inspections. NDA 22-081.	14_22081_CORR_PHONE_SGOLDIE_TMA RSHALL.pdf	2007-05-	22-081

1	Regulatory	US	5/11/2007	Book 5	FDA Correspondence - Letter	L. Tanner/D. Brum. Desk Copies. 022081 - Amendment No. 14. Briefing Document for 25 May 2007	14_22081_CORR_EMAIL_DBRUM_LTANN ER.pdf	2007-05-	22-081
1	Regulatory	US	5/9/2007	Book 5	FDA Correspondence - Email	T. Marshall/S. Goldie - Response to the 8 comments/questions letter from 04/30/2007. NDA 22-081	09_22081_CORR_EMAIL_SGOLDIE_TMA RSHALL.pdf	2007-05-	22-081
1	Regulatory	US	5/7/2007	Book 5	FDA Correspondence - Phone	L. Tanner/M. Robb. Three calls on 5/03/07, 5/04/07 and 05/07/07 - Subject: Processing during labeling	07_22081_CORR_PHONE_LTANNER_MR OBB.pdf	2007-05-	22-081
1	Regulatory	US	5/7/2007	Book 5	FDA Correspondence - Email	L. Tanner/M. Robb - Subject: FedEx Shipment Notification from M. Robb (FDA).	07_22081_CORR_EMAIL_LTANNER_MRO BB.pdf	2007-05-	22-081
1	Regulatory	US	5/4/2007	Temp 7	FDA (DDMAC) Submission NDA 22-081	DDMAC Promotional Materials for NDA 22-081. Request for Perspective Review and Advisory Comments for Product Launch Materials for NDA 22-081 Latairis™ (ambrisentan 5 mg and 10 mg tablets) GSI Ref. No.000.	04_22081_CORR_DDMAC_PROMO_MATE RIALS.pdf	2007-05-	22-081
1	Regulatory	US	5/3/2007	Book 4	FDA Correspondence - Email	L. Tanner/M. Robb - Subject: Response to DMETS, including revised labeling.	03_22081_CORR_EMAIL_LTANNER_MRO BB.pdf	2007-05-	22-081
1	Regulatory	US	5/1/2007	Book 4	FDA Correspondence - Email	L. Tanner/M. Gordon - Subject: Response to Clinical Questions. NDA 22-081	01_22081_CORR_EMAIL_LTANNER_MG ORDON.pdf	2007-05-	22-081
1	Regulatory	US	5/1/2007	Book 4	FDA Correspondence - Email	L. Tanner/M. Robb - Subject: Updated PI Incorporating DMETS Recommendations (Version 1).	01_22081_CORR_EMAIL_LTANNER_MRO BB.pdf	2007-05-	22-081
1	Regulatory	US	4/30/2007	Book 4	FDA Correspondence - Letter	R. Sood/T. Marshall. Information request letter from FDA (review and comments of CMC section for NDA 22-081).	30_22081_CORR_LETTER_RSOOD_TMAR SHALL.pdf	2007-04-	22-081
1	Regulatory	US	4/30/2007	Book 4	FDA Correspondence - Phone	L. Tanner/M. Robb. Two phone calls on 4/27/07 and 4/30/07. Subject: Briefing document for May 25 teleconference to discuss proposal to measure 6MWD at trough and peak. NDA 22-081.	30_22081_CORR_PHONE_LTANNER_MR OBB.pdf	2007-04-	22-081
1	Regulatory	US	4/30/2007	Book 4	FDA Correspondence - Fax	S. Goldie/T. Marshall. Information Request Letter included. NDA 22-081.	30_22081_CORR_FAX_SGOLDIE_TMARS HALL.pdf	2007-04-	22-081

1	Regulatory	US	4/26/2007	Book 4	FDA Correspondence - Phone	L. Tanner/M. Robb - Three phone calls on 4/20/07, 4/24/07, 4/26/07. Subject: Plan Promotional Materials; DMETS Comments; Process Labeling Revisions NDA 22-081	2007-04-26_22081_CORR_PHONE_LTANNER_MR OBB.pdf	22-081
1	Regulatory	US	4/26/2007	Book 4	FDA Correspondence - Email	L. Tanner/M. Robb - Subject: Proposed plan for submitting promotional materials for use with the first 120 days post-approval.. NDA 22-081	2007-04-26_22081_CORR_EMAIL_LTANNER_MRO BB.pdf	22-081
1	Regulatory	US	4/24/2007	Book 4	FDA Correspondence - Email	L. Tanner/M. Robb - Regarding proposed plan for submitting promotional materials for use with the first 120 days post-approval.. NDA 22-081	2007-04-24_22081_CORR_EMAIL_LTANNER_MRO BB.pdf	22-081
1	Regulatory	US	4/23/2007	Book 4	FDA Correspondence - Letter	E. Fromm/L. Tanner -Discipline Review Letter from FDA, Office of Surveillance and Epidemiology's DMETS. NDA 22-081	2007-04-23_22081_CORR_Letter_LTANNER_EFRO MM.pdf	22-081
1	Regulatory	US	4/23/2007	Book 4	FDA Correspondence - Email	L. Tanner/M. Robb - Response regarding randomization. NDA 22-081	2007-04-23_22081_CORR_EMAIL_LTANNER_MRO BB.pdf	22-081
1	Regulatory	US	4/19/2007	Book 4	FDA Correspondence - Email	L. Tanner/P. Hinderling - Response to Questions Regarding Bioanalytical Assay Issues; NDA 22-081	2007-04-19_22081_CORR_EMAIL_LTANNER_PHI NDERLING_2.pdf	22-081
1	Regulatory	US	4/19/2007	Book 4	FDA Correspondence - Email	L. Tanner/P. Hinderling - Response to additional request Multimedia Dissolution Profiles; NDA 22-081	2007-04-19_22081_CORR_EMAIL_LTANNER_PHI NDERLING_1.pdf	22-081
1	Regulatory	US	4/19/2007	Book 4	FDA Correspondence - Email	L. Tanner/M. Robb - NDA 22-081; Follow-up information to Clinical Review Question 4 from e-mail dated 09 March 2007.	2007-04-19_22081_CORR_EMAIL_LTANNER_MRO BB.pdf	22-081
1	Regulatory	US	4/17/2007	Book 4	FDA Correspondence - Phone	T. Marshall/S. Goldie - Three phone calls on 04/09/07, 04/16/07 and 04/17/07 Subject: Proposed "CMC" Amendment to Ambrisentan NDA to revise listed establishments/functions and to provide corrections to typos/minor errors. NDA 22-081	2007-04-17_22081_CORR_PHONE_TMARSHALL_S GOLDIE.pdf	22-081
1	Regulatory	US	4/17/2007	Book 4	FDA Correspondence - Email	L. Tanner/M. Robb - Request for Meeting to discuss Dosing Interval; Follow-up to March 29 Meeting. NDA 22-081	2007-04-17_22081_CORR_EMAIL_LTANNER_MRO BB.pdf	22-081

1	Regulatory	US	4/16/2007	Book 4	FDA Correspondence - Fax	M.Robb/L.Tanner - The FDA Teleconference Meeting Minutes (March 29, 2007). NDA 22-081.	2007-04-16_22081_CORR_FAX_LTANNER_MROBB_MEETING_MINUTES.pdf	22-081
1	Regulatory	US	4/16/2007	Book 4	FDA Correspondence - Email	L.Tanner/P.Hinderling - Follow-up email to request validation dilution.	2007-04-16_22081_CORR_EMAIL_LTANNER_PHI_NDERLING.pdf	22-081
1	Regulatory	US	4/16/2007	Book 4	FDA Correspondence - Phone	L.Tanner/M.Robb - Confirm the date and time for teleconference (Amendment to AMB-323). Confirm name of new Project Manager. NDA 22-081	2007-04-16_22081_CORR_PHONE_LTANNER_MROBB.pdf	22-081
1	Regulatory	US	4/16/2007	Book 4	FDA Correspondence - Email	L.Tanner/P.Hinderling - Response to Questions Regarding Dissolution Profiles; NDA 22-081	2007-04-16_22081_CORR_EMAIL_LTANNER_PHI_NDERLING_1.pdf	22-081
1	Regulatory	US	4/13/2007	Book 4	FDA Correspondence - Email	L.Tanner/M.Robb - Request for Teleconference: Advice Clinical Inspection.	2007-04-13_22081_CORR_EMAIL_LTANNER_MROBB.pdf	22-081
1	Regulatory	US	4/13/2007	Book 4	FDA Correspondence - Phone	L.Tanner/M.Robb - Phone calls on 04/12/07 and 04/13/07 - Clinical Inspection for Site #207 (Nazzareno)	2007-04-13_22081_CORR_PHONE_LTANNER_MROBB.pdf	22-081
1	Regulatory	US	4/12/2007	Book 4	FDA Correspondence - Email	L.Tanner/M.Robb - Email to M. Robb indicating that Gilead acknowledged and understood the Clinical Pharmacology issues that P. Hinderling addressed in his written comments (03/29/07 - FDA teleconference). NDA 22-081	2007-04-12_22081_CORR_EMAIL_LTANNER_MROBB.pdf	22-081
1	Regulatory	US	4/12/2007	Book 4	FDA Correspondence - Email	L.Tanner/P.Hinderling - Response to Questions Regarding Dissolution Profiles; NDA 22-081	2007-04-12_22081_CORR_EMAIL_LTANNER_PHI_NDERLING.pdf	22-081
1	Regulatory	US	4/9/2007	Book 4	FDA Correspondence - Phone	L.Tanner/M.Robb. Subject: Status of scheduling teleconference regarding plan to support once-daily dosing. Submission of promotional materials.	2007-04-09_22081_CORR_PHONE_LTANNER_MROBB.pdf	22-081
1	Regulatory	US	4/5/2007	Book 4	FDA Correspondence - Email	L.Tanner/P.Hinderling - Request from P. Hinderling requesting F2 tests of respective dissolution profiles are various pHs for clinical and commercial products.	2007-04-05_22081_CORR_EMAIL_LTANNER_PHI_NDERLING.pdf	22-081

1	Regulatory	US	4/4/2007	Book 4	FDA Correspondence - Phone	L. Curran/V. Ventura - Clarification of submission format. NDA 22-081	04_22081_CORR_PHONE_LCURRAN_VVE NTURA.pdf	22-081
1	Regulatory	US	4/3/2007	Book 4	FDA Correspondence - Email	L. Tanner/M. Robb - Request for Meeting to discuss Dosing Interval; Follow-up to March 29 Meeting. NDA 22-081	03_22081_CORR_EMAIL_LTANNER_MRO BB.pdf	22-081
1	Regulatory	US	3/28/2007	Book 3	FDA Correspondence - Phone	L. Tanner/M. Robb. Three phone calls on 03/26/07, 03/27/07 and 03/28/07. Subjects: Preparation for March 29, 2007 90-Day Teleconference (NDA review status). Amendment No. 8. Issues with e-mails sent to Melissa Robb. NDA 22-081.	2007-03- 28_22081_CORR_PHONE_LTANNER_MR OBB.pdf	22-081
1	Regulatory	US	3/28/2007	Book 3	FDA Correspondence - Email	L. Tanner/M. Robb - Summary of Amendments submitted or will be submitted to NDA 22-081.	2007-03- 28_22081_CORR_EMAIL_LTANNER_MRO BB_1.pdf	22-081
1	Regulatory	US	3/28/2007	Book 3	FDA Correspondence - Email	L. Tanner/M. Robb - Plan for submitting electronic datasets are acceptable.	2007-03- 28_22081_CORR_EMAIL_LTANNER_MRO BB.pdf	22-081
1	Regulatory	US	3/27/2007	Book 3	FDA Correspondence - Fax	L. Tanner/M. Robb - Pre-Meeting Comments NDA 22-081	2007-03- 27_22081_CORR_FAX_LTANNER_MROBB .pdf	22-081
1	Regulatory	US	3/27/2007	Book 3	FDA Correspondence - Email	L. Tanner/M. Robb - Revised List of Gilead Participants and Call-in Number. NDA 22-081	2007-03- 27_22081_CORR_EMAIL_LTANNER_MRO BB_2.pdf	22-081
1	Regulatory	US	3/27/2007	Book 3	FDA Correspondence - Email	L. Tanner/M. Robb - List of Gilead Participants and Call-in Number. NDA 22-081	2007-03- 27_22081_CORR_EMAIL_LTANNER_MRO BB.pdf	22-081
1	Regulatory	US	3/26/2007	Book 3	FDA Correspondence - Email	L. Tanner/M. Robb - Response to questions in e-mail dated 9/03/07; Amendment No. 8; NDA 22-081	2007-03- 26_22081_CORR_EMAIL_LTANNER_MRO BB_1.pdf	22-081
1	Regulatory	US	3/26/2007	Book 3	FDA Correspondence - Email	L. Tanner/M. Robb - Word questions submitted in meeting request (Amendment No. 5). NDA 22-081	2007-03- 26_22081_CORR_EMAIL_LTANNER_MRO BB.pdf	22-081
1	Regulatory	US	3/22/2007	Book 3	FDA Correspondence - Phone	M. Plamondon/E. Smith - Mr. Smith was following up on Gilead Colorado's registration as a manufacturer.	2007-03- 22_22081_CORR_PHONE_MPLAMONDON _ESMITH.pdf	22-081

1	Regulatory	US	3/20/2007	Book 3	FDA Correspondence - Phone	L. Tanner/S. Gershon - FDA Inspection for Site # 207 (Nazzareno Galie) Italy. NDA 22-081	20_22081_CORR_PHONE_LTANNER_SGE RSHON.pdf	22-081
1	Regulatory	US	3/20/2007	Book 3	FDA Correspondence - Email	L. Tanner/M. Robb - Gilead Response to FDA regarding the request for Efficacy and Safety Datasets AMB-220, AMB-222, PK/PD PopPK. NDA 22-081	20_22081_CORR_EMAIL_LTANNER_MRO BB.pdf	22-081
1	Regulatory	US	3/19/2007	Book 3	FDA Correspondence - Email	L. Tanner/M. Robb - Request for Efficacy and Safety Datasets AMB-220, AMB-222, PK/PD PopPK. NDA 22-081	19_22081_CORR_EMAIL_LTANNER_MRO BB.pdf	22-081
1	Regulatory	US	3/13/2007	Book 3	FDA Correspondence - Email	L. Tanner/M. Robb - The PDF file of Amendment No. 6. NDA 22-081.	13_22081_CORR_EMAIL_LTANNER_MRO BB.pdf	22-081
1	Regulatory	US	3/13/2007	Book 3	FDA Correspondence - Phone	L. Tanner/M. Robb (Phone calls on 03/05/07, 03/06/07, 03/08/07 & 03/13/07) - Status feedback Letairis; Meeting request. NDA 22-081	13_22081_CORR_PHONE_LTANNER_MR OBB.pdf	22-081
1	Regulatory	US	3/9/2007	Book 3	FDA Correspondence - Phone	L. Tanner/S. Gershon - The official contact report with Sharon Gershon regarding the status of the inspection of Dr. Galie (Italy)	09_22081_CORR_EMAIL_LTANNER_SGE RSHON.pdf	22-081
1	Regulatory	US	3/9/2007	Book 3	FDA Correspondence - Email	L. Tanner/P. Hinderling - Formatting Changes and Instructions for PI. NDA 22-081	09_22081_CORR_EMAIL_LTANNER_PHI NDERLING.pdf	22-081
1	Regulatory	US	3/9/2007	Book 3	FDA Correspondence - Email	L. Tanner/M. Robb - Ambrisenan Questions. NDA 22-081.	09_22081_CORR_EMAIL_MROBB_LTANN ER.pdf	22-081
1	Regulatory	US	3/8/2007	Book 3	FDA Correspondence - Email	L. Tanner/M. Robb - The e-mail sent to Melissa Robb inquiring about the status of the proprietary name of LETAIRIS. (Note: This question was answered in a teleconference report dated 3-13-07 to Melissa Robb). NDA 22-081	08_22081_CORR_EMAIL_LTANNER_MRO BB.pdf	22-081
1	Regulatory	US	3/8/2007	Book 3	FDA Correspondence - Email	L. Tanner/P. Hinderling - Formatting Changes and Instructions for PI. NDA 22-081	08_22081_CORR_EMAIL_LTANNER_PHI NDERLING.pdf	22-081
1	Regulatory	US	3/8/2007	Book 3	FDA Correspondence - Fax	M. Robb/L. Tanner - Teleconference meeting conformation - March 29, 2007. NDA 22-081.	08_22081_CORR_FAX_MROBB_LTANNER .pdf	22-081

1	Regulatory	US	3/7/2007	Book 3	FDA Correspondence - Email	L. Tanner/P. Hinderling - Unformatted PI for Ambrisentan; NDA 22-081; Option to resolve formatting PI.	2007-03-07_22081_CORR_EMAIL_LTANNER_PHI_NDERLING.pdf	22-081
1	Regulatory	US	3/6/2007	Book 3	FDA Correspondence - Email	L. Tanner/M. Gordon - Formal Response on Clinically Significant Abnormal ECGs. NDA 22-081.	2007-03-06_22081_CORR_EMAIL_LTANNER_MG_ORDON.pdf	22-081
1	Regulatory	US	3/6/2007	Book 3	FDA Correspondence - Email	L. Tanner/M. Robb - Unformatted PI for Ambrisentan - No need to submit to the NDA. 22-081.	2007-03-06_22081_CORR_EMAIL_LTANNER_MRO_BB.pdf	22-081
1	Regulatory	US	3/5/2007	Book 3	FDA Correspondence - Email	L. Tanner/M. Robb/P. Hinderling - Unformatted PI for Ambrisentan; NDA 22-081.	2007-03-05_22081_CORR_EMAIL_LTANNER_MRO_BB.pdf	22-081
1	Regulatory	US	3/3/2007	Book 3	FDA Correspondence - Email	L. Tanner/M. Robb - request for the meeting to discuss status of review of NDA 22-081. Update on Amendments submitted to NDA. Amendment 5 attached.	2007-03-03_22081_CORR_EMAIL_LTANNER_MRO_BB.pdf	22-081
1	Regulatory	US	3/2/2007	Book 3	FDA Correspondence - Phone	L. Tanner/P. Hinderling - Request for unformatted PI for internal edits. NDA 22-081	2007-03-02_22081_CORR_PHONE_LTANNER_PHI_NDERLING.pdf	22-081
1	Regulatory	US	2/27/2007	Book 2	FDA Correspondence - Email	L. Tanner/M. Gordon - The initial response regarding clinically significant abnormal ECGs which was submitted to Mary Gordon on 02/27/07. NDA 22-081	2007-02-27_22081_CORR_EMAIL_LTANNER_MG_ORDON.pdf	22-081
1	Regulatory	US	2/22/2007	Book 2	FDA Correspondence - CD-ROM	Desk Copy Request for Phase I CRF's. NDA 22-081	Request_for_Phase_I_CRFS-Desk_Copy	22-081
1	Regulatory	US	2/21/2007	Book 2	FDA Correspondence - Phone	L. Tanner/M. Robb - Response to Filing Communication; Process for Submitting Completed Nonclinical Study not previously submitted in the NDA; Process for requesting meeting to discuss status of NDA. 22-081.	2007-02-21_22081_CORR_PHONE_LTANNER_MR_OBB.pdf	22-081
1	Regulatory	US	2/21/2007	Book 2	FDA Correspondence - Email	L. Tanner/M. Gordon. The FDA e-mail contact report that provides the plan to provide Maryann Gordon the CRFs that were not previously submitted for subjects who discontinued from Phase I studies. NDA 22-081.	2007-02-21_22081_CORR_EMAIL_LTANNER_MG_ORDON.pdf	22-081

1	Regulatory	US	2/20/2007	Book 2	FDA Correspondence - Email	The E-mail with Maryann Gordon regarding our intention to provide the CRF for Subject 38 in Study EE-001. NDA 22-081	2007-02-20_22081_CORR_EMAIL_LTANNER_MG ORDON.pdf	22-081
1	Regulatory	US	2/16/2007	Book 2	FDA Correspondence - Letter	N Stockbridge/M Gerber - Filling Communication. Filling accepted and priority filling granted. NDA 22-081.	2007-02-16_22081_CORR_LETTER_NSTOCKBRIDGE_MGERBER.pdf	22-081
1	Regulatory	US	2/16/2007	Book 2	FDA Correspondence - Phone	L. Tanner/M. Robb - Phone on 02/13/07, 02/14/07, 02/16/07 to confirm status of NDA filing letter and process for formally submitting responses that have already been emailed to reviewers. NDA 22-081	2007-02-16_22081_CORR_PHONE_LTANNER_MROBB.pdf	22-081
1	Regulatory	US	2/16/2007	Book 2	FDA Correspondence - Email	L. Tanner/M. Robb - RE: NDA 22-081; Status of Feedback Regarding Acceptability of Trade name LETAIRIS (Amendment No. 1)	2007-02-16_22081_CORR_EMAIL_MROBB_LTANNER_ER.pdf	22-081
1	Regulatory	US	2/16/2007	Book 2	FDA Correspondence - Email	L. Tanner/M. Robb - E-mail response to Melissa Robb regarding how refills would be handled in the RiskMAP.	2007-02-16_22081_CORR_EMAIL_LTANNER_MROBB.pdf	22-081
1	Regulatory	US	2/15/2007	Book 2	FDA Correspondence - Email	L. Tanner/P. Hinderling - Summary of PT and INR Methodology. Prottime Summary Information doc. Attached.	2007-02-15_22081_CORR_EMAIL_LTANNER_PHINDERLING.pdf	22-081
1	Regulatory	US	2/14/2007	Book 2	FDA Correspondence - Phone	Phone - Nikolas Bulew (Regulus Pharmaceutical) called Nancy Schmidt (FDA-Denver District) to establish registration for Gilead Colorado.	2007-02-14_22081_CORR_PHONE_NBURLEW_NSCHMIDT.pdf	22-081
1	Regulatory	US	2/14/2007	Book 2	FDA Correspondence - Email	M. Robb/L. Tanner/ - Email from M. Robb with additional question. (Ambrisentan and RiskMAP). NDA 22-081	2007-02-14_22081_CORR_EMAIL_LTANNER_MROBB.pdf	22-081
1	Regulatory	US	2/14/2007	Book 2	FDA Correspondence - Email	L. Tanner/P. Hinderling - Email indicating that Gilead is continuing to work with our vendor to obtain the PT and INR methodology for AMB-106. NDA 22-081	2007-02-14_22081_CORR_EMAIL_LTANNER_PHINDERLING.pdf	22-081
1	Regulatory	US	2/13/2007	Book 2	FDA Correspondence - Phone	L. Tanner/M. Robb - Confirm for handling requests directly from reviewer. E-mail dated 2/13/07 regarding RiskMAP and distribution. Filling Letter.	2007-02-13_22081_CORR_PHONE_LTANNER_MROBB.pdf	22-081

1	Regulatory	US	2/13/2007	Book 2	FDA Correspondence - Email	L. Tanner/M. Robb - Gilead response to the questions from FDA on the distribution of Ambrisentan and RiskMAP. The patient enrollment form attached. NDA 22-081	2007-02-13_22081_CORR_EMAIL_LTANNER_MRO_BB.pdf	22-081
1	Regulatory	US	2/12/2007	Book 2	FDA Correspondence - Phone	M. Gordon/H. Isokoski. Maryann Gordon called and request to talk to L. Tanner. NDA 22-081	2007-02-12_22081_CORR_PHONE_MGORDON_HISOKOSKI.pdf	22-081
1	Regulatory	US	2/12/2007	Book 2	FDA Correspondence - Email	M. Gordon/L. Tanner - Another E-mail from Maryann Gordon asking that we submit all clinical information sent to her formally to the NDA.	2007-02-12_22081_CORR_EMAIL_MGORDON_LTANNER.pdf	22-081
1	Regulatory	US	2/12/2007	Book 2	FDA Correspondence - Email	M. Gordon/L. Tanner - E-mail contact report with Maryann Gordon regarding regenerating a table for LFTs from AMB-222 for archival in the database.	2007-02-12_22081_CORR_EMAIL_LTANNER_MGORDON.pdf	22-081
1	Regulatory	US	2/12/2007	Book 2	FDA Correspondence - Email	L. Tanner/M. Robb - FDA questions on the distribution of Ambrisentan and RiskMAP.	2007-02-12_22081_CORR_EMAIL_LTANNER_MRO_BB.pdf	22-081
1	Regulatory	US	2/9/2007	Book 2	FDA Correspondence - Phone	L. Tanner/M. Gordon - Confirm the requirements for clinical information requested in emails dated 02/07/07 & 02/09/07.	2007-02-09_22081_CORR_PHONE_LTANNER_MGORDON.pdf	22-081
1	Regulatory	US	2/9/2007	Book 2	FDA Correspondence - Email	L. Tanner/M. Gordon - email sent to M. Gordon regarding her request for additional clinical information. The email contains all of the attachments. NDA 22-081.	2007-02-09_22081_CORR_EMAIL_LTANNER_MGORDON.pdf	22-081
1	Regulatory	US	2/9/2007	Book 2	FDA Correspondence - Email	E-mail from Peter Hinderling confirming that he received the replacement pages for EE-002	2007-02-09_22081_CORR_EMAIL_LTANNER_PHIINDERLING.pdf	22-081
1	Regulatory	US	2/8/2007	Book 2	FDA Correspondence - Email	E-mail that was submitted to Peter Hinderling, Clinical Pharmacology Reviewer, which contains the replacement pages with figures that are easier to read from EE-002 at his request.	2007-02-08_22081_CORR_EMAIL_LTANNER_PHIINDERLING.pdf	22-081
1	Regulatory	US	2/8/2007	Book 2	FDA Correspondence - Email	L. Tanner/M. Gordon - Conformation of Teleconference on Friday, February 9, 10:00 a.m. EST	2007-02-08_22081_CORR_EMAIL_LTANNER_MGORDON.pdf	22-081

1	Regulatory	US	2/8/2007	Book 2	FDA Correspondence - Phone	M.Gordon/L. Tanner - Schedule time for teleconference to discuss process for capturing lab values.	08_22081_CORR_PHONE_MGORDON_LT - ANNER.pdf	2007-02-	22-081
1	Regulatory	US	2/6/2007	Book 2	FDA Correspondence - Phone	H.Isokoski/P.Hinderling - The Methodology to determine Prothrombin Time (PT) and International Normalized Ratio (INR) in AMB-106 and Legible Figures for the report EE-002.	06_22081_CORR_PHONE_PHINDERLING_HISOKOSKI.pdf	2007-02-	22-081
1	Regulatory	US	2/5/2007	Book 2	FDA Correspondence - Email	L.Tanner/M.Robb - E-mail correspondence; Request for Location QTC documentation; Clinical Pharmacology Summary Table. The FDA Response, 2006 Clin. Final IB and FDA Notification App. Attached.	05_22081_CORR_EMAIL_LTANNER_MRO BB_.pdf	2007-02-	22-081
1	Regulatory	US	2/2/2007	Book 1	FDA Correspondence - Email	L.Tanner/S.Gershon - Confirm that CD's were sent with information for Clinical Inspections. Attached to the email is the cover letter.	02_22081_CORR_EMAIL_LTANNER_SGE RSHON.pdf	2007-02-	22-081
1	Regulatory	US	2/2/2007	Book 1	FDA Correspondence - Phone	L.Tanner/M.Gordon - Confirm that Maryann Gordon was able to retrieve the CRF for Subject 109-002.	02_22081_CORR_PHONE_MGORDON_LT ANNER.pdf	2007-02-	22-081
1	Regulatory	US	2/2/2007	Book 1	FDA Correspondence - CD-ROM	Desk Copy Request for Site Specific Information. NDA 22-081	Clinical_Inspection_Request-Desk_Copy	2007-02-	22-081
1	Regulatory	US	2/1/2007	Book 1	FDA Correspondence - Phone	E.Smith/L. Tanner & M.Plamondon - E.Smith of the Denver District Office of the FDA called regarding the ambrisentan NDA.	01_22081_CORR_PHONE_ESMITH_LTAN NER_MPLAMONDON_.pdf	2007-02-	22-081
1	Regulatory	US	2/1/2007	Book 1	FDA Correspondence - Phone	L.Tanner/M.Gordon - Clarify whether CRF for Subject 109-002 was submitted in NDA	01_22081_CORR_PHONE_LTANNER_MG ORDON.pdf	2007-02-	22-081
1	Regulatory	US	2/1/2007	Book 1	FDA Correspondence - Email	S.Gershon/L.Tanner - Confirm Information to be provided on CD's; Clinical Inspections NDA 22-081.	01_22081_CORR_EMAIL_SGERSHON_LT ANNER.pdf	2007-02-	22-081
1	Regulatory	US	1/31/2007	Book 1	FDA Correspondence - Email	L.Tanner/M.Robb - Confirmation that CRF's for subject 156-007 and 126-008 was received at FDA.	31_22081_CORR_EMAIL_LTANNER_MRO BB_156-007.pdf	2007-01-	22-081

1	Regulatory	US	1/30/2007	Book 1	FDA Correspondence - Phone	L. Tanner/S. Gershon - Confirm acceptability of listings that will be included in the information package on the CD's that will be submitted to her for use during the FDA clinical inspections.	2007-01- 30_22081_CORR_PHONE_LTANNER_SGE RSHON.pdf	22-081
1	Regulatory	US	1/30/2007	Book 1	FDA Correspondence - Phone	L. Tanner/M. Robb - Confirm that Amendment #2 was received at FDA on January 30, 2007. NDA 22-081.	2007-01- 30_22081_CORR_PHONE_LTANNER_MR OBB_156-007.pdf	22-081
1	Regulatory	US	1/30/2007	Book 1	FDA Correspondence - Phone	L. Tanner/M. Gordon - Death of female subject (221-003) enrolled in the extension study (AMB-32/321-3). NDA 22-081	2007-01- 30_22081_CORR_PHONE_LTANNER_MG ORDON.pdf	22-081
1	Regulatory	US	1/26/2007	Book 1	FDA Correspondence - Email	L. Tanner/M. Robb - CRF for Subject 156-007 requested by Dr. Marciniak; NDA 22-081. (156-007.zip attached)	2007-01- 26_22081_CORR_EMAIL_LTANNER_MRO BB_156-007.pdf	22-081
1	Regulatory	US	1/26/2007	Book 1	FDA Correspondence - Email	L. Tanner/M. Robb - CRF for subject 126-008 requested by Dr. Marciniak; NDA 22-081. (126-008.zip attached)	2007-01- 26_22081_CORR_EMAIL_LTANNER_MRO BB_126-008.pdf	22-081
1	Regulatory	US	1/26/2007	Book 1	FDA Correspondence - Email	L. Tanner/S. Gershon - Confirm information to be provided on CD's; Clinical Inspections NDA 22-081	2007-01- 26_22081_CORR_EMAIL_LTANNER_SGE RSHON.pdf	22-081
1	Regulatory	US	1/25/2007	Book 1	FDA Correspondence - Phone	L. Tanner/S. Gershon - Reminder for non-USA contact information for Site #207 (Nazzareno Galie, Italy) NDA 22-08.	2007-01- 25_22081_CORR_PHONE_LTANNER_SGE RSHON.pdf	22-081
1	Regulatory	US	1/25/2007	Book 1	FDA Correspondence - Email	L. Tanner/S. Gershon - Contact Information Italian Inspector; NDA 22- 081 (ambrosiantan)	2007-01- 25_22081_CORR_EMAIL_LTANNER_SGE RSHON.pdf	22-081
1	Regulatory	US	1/25/2007	Book 1	FDA Correspondence - Email	S. Gershon/L. Tanner - Contact Person in Italy.	2007-01- 25_22081_CORR_EMAIL_SGERSHON_LT ANNER.pdf	22-081
1	Regulatory	US	1/23/2007	Book 1	FDA Correspondence - Email	M. Robb/L. Tanner - Email - Response from FDA to the letter dated 1/11/07. Re: Submission of complete CRF's; NDA 022-081.	2007-01- 23_22081_CORR_EMAIL_MROBB_LTANN ER.pdf	22-081
1	Regulatory	US	1/22/2007	Book 1	FDA Correspondence - Email	S. Gershon/L. Tanner - Email regarding Revised Protocol Document - Presence of Sponsors Clinical Investigations.	2007-01- 22_22081_CORR_EMAIL_SGERSHON_LT ANNER.pdf	22-081

1	Regulatory	US	1/19/2007	Book 1	FDA Correspondence - Phone	S. Gershon/L. Tanner - Phone regarding FDA inspections at clinical sites that conducted Phase 3 studies AMB-320 or AMB-321.	19_22081_CORR_PHONE_SGERSHON_LT ANNER_.pdf	2007-01-	22-081
1	Regulatory	US	1/19/2007	Book 1	FDA Correspondence - Email	L. Tanner/S. Gershon. Email regarding revised protocol documents. AMB-321 & AMB 320 protocols attached.	19_22081_CORR_EMAIL_LTANNER_SGE RSHON_.pdf	2007-01-	22-081
1	Regulatory	US	1/19/2007	Book 1	FDA Correspondence - Email	S. Gershon/L. Tanner - Email regarding NDA 22-081 Letairis. Respond from CDER about DSI inspections.	19_22081_CORR_EMAIL_SGERSHON_LT ANNER_.pdf	2007-01-	22-081
1	Regulatory	US	1/18/2007	Book 1	FDA Correspondence - Email	L. Tanner/M. Robb - Response to FDA Letter Dated 1/11/07 Re: Submission of Complete CRF's, NDA 022-081	18_22081_CORR_EMAIL_MROBB_LTANN ER_.pdf	2007-01-	22-081
1	Regulatory	US	1/16/2007	Book 1	FDA Correspondence - Phone	L. Tanner/M. Robb - Follow-up on response to Division regarding re-submission of CRF's and filing process.	16_22081_CORR_PHONE_MROBB_LTAN NER_.pdf	2007-01-	22-081
1	Regulatory	US	1/16/2007	Book 1	FDA Correspondence - Email	L. Tanner/M. Robb - Clarification on the requested presented during the teleconference on 1/9/07. The Response to Division regarding re-submission of CRF's and filing.	16_22081_CORR_EMAIL_MROBB_LTANN ER_.pdf	2007-01-	22-081
1	Regulatory	US	1/11/2007	Book 1	FDA Correspondence - Letter	Letter from E. Fromm/M. Gerber. Discipline Review Letter - CRF's Forms in the NDA 20-081	11_22081_CORR_LETTER_EFROMM_MG ERBER.pdf	2007-01-	22-081
1	Regulatory	US	1/11/2007	Book 1	FDA Correspondence - Email	Email from M. Robb to H. Isokoski with the discipline review letter from FDA.	11_22081_CORR_EMAIL_MROBB_HISOK OSKI_1.pdf	2007-01-	22-081
1	Regulatory	US	1/11/2007	Book 1	FDA Correspondence - Email	H. Isokoski/M. Robb - Email. Clarification on the requested, presented during the teleconference on 01/09/07.	11_22081_CORR_EMAIL_MROBB_HISOK OSKI_.pdf	2007-01-	22-081
1	Regulatory	US	1/11/2007	Book 1	FDA Correspondence - Phone	H. Isokoski/M. Robb - Three phone calls. Clarification on the teleconference held on 01/09/07.	11_22081_CORR_PHONE_HISOKOSKI_M ROBB.pdf	2007-01-	22-081
1	Regulatory	US	1/10/2007	Book 1	FDA Correspondence - Letter	E. Fromm/L. Tanner - FDA letter that acknowledges that the date of receipt of NDA 22-081 was December 18, 2006. The official filing data will be February 16, 2007	10_22081_CORR_LETTER_EFROMM_LTA NNER.pdf	2007-01-	22-081

1	Regulatory	US	1/9/2007	Book 1	FDA Correspondence - Phone	Gilead Teleconference Meeting Minutes with FDA - T. Marciniak.	2007-01- 09_22081_CORR_PHONE_MEETING_MIN UTES_TMARCINIAK_HISOKOSKI.pdf	22-081
1	Regulatory	US	1/5/2007	Book 1	FDA Correspondence - Email	L. Tanner/M. Robb - Email. Confirmation of teleconference scheduled for Tuesday, January 9, 2007 with the FDA.	2007-01- 05_22081_CORR_EMAIL_MROBB_LTANN ER_.pdf	22-081
1	Regulatory	US	1/5/2007	Book 1	FDA Correspondence - Phone	L. Tanner/M. Robb - Phone. No confirmation of time and date for teleconference with FDA.	2007-01- 05_22081_CORR_PHONE_MROBB_LTANN NER_.pdf	22-081
1	Regulatory	US	12/19/2006	Book 1	FDA Correspondence - Phone	L. Tanner/M. Robb - Feedback from M. Robb regarding the process for regarding the Division of DMETS LETAIRIS. Attached FDA contact report from 12/18/2006 per L. Tanner.	2006-12- 19_22081_CORR_PHONE_MROBB_LTAN NER_.pdf	22-081
1	Regulatory	US	12/19/2006	Book 1	FDA Correspondence - Email	L. Tanner/M. Robb - Confirmation from M. Robb that the submission NDA 22-081 was received at document room.	2006-12- 19_22081_CORR_EMAIL_MROBB_LTANN ER_.pdf	22-081
1	Regulatory	US	12/18/2006	Book 1	FDA Correspondence - Email	L. Tanner/M. Robb - Confirmation that NDA 22-081 was received at FDA Mail Room.	2006-12- 18_22081_CORR_EMAIL_MROBB_LTANN ER_.pdf	22-081

EXHIBIT L

U.S. PATENT NO. 7,109,205

CALCULATION OF LENGTH OF PATENT TERM EXTENSION FOR A HUMAN DRUG PRODUCT			
1. Enter the number of days for the testing phase as defined in 37 CFR 1.775(c)(1)			1629
2. Enter the number of days for the approval phase as defined in 37 CFR 1.775(c)(2)			180
3. Add line 1 and line 2 and enter the total here		1809	
4. Enter the number of days of the period of line 2 which occurred prior to the issue date of the patent			0
5. Enter the number of days the period of line 2 during which the applicant failed to act with due diligence as defined in 37 CFR 1.775(d)(1)(ii)			0
6. Add line 4 and line 5 and enter the total here		0	
7. Subtract line 6 from line 3 and enter the difference here (if less than zero enter 0)		1809	
8. Enter the number of days of the period of line 1 which occurred prior to the issue date of the patent			1539
9. Enter the number of days of the period of line 1 during which the applicant failed to act with due diligence as defined in 37 CFR 1.775(d)(1)(ii)			0
10. Add line 8 and line 9 and enter the total here		1539	
11. Subtract line 10 from line 7 and enter the difference here		270	
12. Enter the number of days from line 1			1629
13. Enter the number of days from line 10			1539
14. Subtract line 13 from line 12 and enter the difference here (if less than zero enter 0)			90
15. Multiply line 14 by 0.5 (one half) and enter the amount here		45	
16. Subtract line 15 from line 11 and enter the difference here (if less than zero enter 0)		225	
17. Enter the original expiration date of the patent			10.07.15
18. Enter the expiration date of the patent if extended by the number of days on line 16			05.19.16
19. Enter the date of the FDA (Food and Drug Administration) final approval			06.15.07
20. Limitation set forth in 37 CFR 1.775(d)(3)			14 years
21. Add the number of years on line 20 to the date on line 19 and enter the revised date here			06.15.21
22. Enter the earlier date appearing on line 18 or line 21		05.19.16	
23. Enter the original expiration date of the patent (from line 17)			10.07.15
24. Check one of the following three boxes and enter the listed time period here			5 years
<input checked="" type="checkbox"/> The patent issued after 24/9/84	5 Years	X	
<input type="checkbox"/> The patent issued prior to 24/9/84 and no request for exemption as defined in 37 CFR 1.775(d)(6)(i) was filed prior to 24/9/84	5 Years		
<input type="checkbox"/> The patent issued prior to 24/9/84 and an exemption as defined in 37 CFR 1.775(d)(6)(ii) was filed prior to 24/9/84	2 Years		
25. Add the number of years on line 24 to the date on line 23 and enter the revised date here			10.07.20
26. Enter the earlier date appearing on line 22 or line 25		05.19.16	
27. Enter the original expiration date of the patent (from line 17)		10.07.15	
28. Enter the number of days by which line 26 and line 27 differ here This is the length of patent term extension		225	

INFORMATION OBTAINED FROM THE U.S. PATENT AND TRADEMARK OFFICE